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Thesis summary 
 
Since the discovery of cell-free fetal DNA in the circulation of pregnant women 
fetal-specific DNA biomarkers for non-invasive prenatal diagnosis of fetal 
aneuploidy have been sought.  A model system assessing the DNA methylation of 
placental DNA and adult peripheral leukocyte DNA has been developed previously 
to represent fetal and maternal plasma DNA. 
 
To use DNA methylation to detect specific DNA molecules it is desirable that cell-
free plasma DNA maintains the methylation profile of its tissue source.  Using the 
imprinted gene GNAS1, a test has been developed to assess, for the first time the 
relative abundance of methylated and unmethylated DNA circulating in plasma.  
Methylated and unmethylated DNA sequences were found in equal abundance.  If 
this finding is applicable to all plasma DNA sequences, we conclude that the steady-
state concentration of DNA in methylated and unmethylated form is a reliable 
indicator of its input into the circulation. 
 
We have also investigated whether the abundances of different single copy gene 
sequences in cell-free plasma DNA are equal.  Using real-time PCR, the relative 
abundances of six unique genomic DNA sequences in plasma were assessed.  We 
find that plasma DNA from different sequences is not present in equal abundance in 
normal healthy individuals.  The relative abundance of sequences tested differed by 
as much as 12.3 fold. 
 
We present a panel of novel candidate epigenetic biomarkers which have been 
identified using the model system.  Of 366 DNA regions tested 3% were found to be 
differential.  Further characterisation of these candidate epigenetic biomarkers has 
revealed limitations of the model system. 
 
In view of these results, future epigenetic biomarker development should be 
achieved by a direct assessment of first trimester plasma DNA. 
 
 
 
 
 
 
 
 
 
Introduction  
 
 
 
Chapter 1 
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1.1 Overview of meiosis  
1.1.1 Fetal aneuploidy risk factors 
 
When assessing risk factors for fetal aneuploidy there are several important 
questions which must be addressed: 1) What are the underlying mechanisms of fetal 
aneuploidy? 2) What is the parental origin of the additional copy of the 
chromosome?  3)  What are the health risks associated with aneuploid births to the 
infants born? (Hassold et al, 2007).  No fewer than 5% of all pregnancies are 
aneuploid pregnancies, either trisomic or monosomic for a specific chromosome; 
most of which terminate in utero and are thought to be the leading cause of 
miscarriages (Hassold and Hunt, 2001).  However, some aneuploidies are not 
sufficiently deleterious as to cause termination of the fetus in utero and may be 
carried to term.  Trisomy 21 is one such aneuploidy, making fetal aneuploidy the 
leading cause of congenital birth defects (Hassold et al, 2007), with an incidence of 
1-2/1000 births (Hook and Cross, 1983). For this reason the main focus of this 
research project has been on Chromosome 21 trisomy, however the strategic 
approaches of the work presented are applicable to other aneuploidies such as 
trisomy of Chromosome 18 Edwards syndrome, and trisomy of Chromosome 13 
Patau Syndrome. 
1.1.2 Meiotic errors in fetal aneuploidy 
 
Errors during meiosis can cause aneuploidies, causing some gametes to gain an extra 
chromosome, and become trisomic.  Meiosis is a specialised cell division process, 
which is essential for the propagation of all sexually reproducing organisms.  During 
meiosis a diploid germ cell divides to generate daughter cells.  Meiosis differs from 
mitosis in that the germ cell divides twice after a single DNA replication event.  
During meiosis I homologous chromosomes are separated into two daughter cells; 
the cells then proceed to meiosis II without an additional replication event.  During 
meiosis II sister chromatids are separated into two daughter cells creating a total of 
four haploid gametes in males; and generating a single haploid gamete in females (in 
meiosis I half of the chromosomal material is packaged into a separate cellular 
structure known as a polar body, the same process occurs during meiosis II, giving a 
total of two polar bodies per oocyte created) (Morelli and Cohen, 2005). 
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Meiosis I is divided into four stages: prophase, metaphase, anaphase and telophase.  
Most of the events which define meiosis occur during prophase I.  During prophase I 
a proteinaceous meiosis-specific structure called the synaptonemal complex (SC) 
forms (figure 1.1).  The SC is composed of two lateral elements which form along 
the entire length of each sister chromatid and one central element which joins both 
lateral elements and binds them to the two homologous chromosomes (Morelli and 
Cohen, 2005). 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Chromosome synapsis during the different stages of meiotic 
prophase I 
A single bivalent is shown.  The pachytene stage is defined as the period during 
which the synaptonemal complex is fully formed.  As meiosis progresses, the two 
homologs become tightly connected by proteins that form the central region of the 
synaptonemal complex; which is composed of a central element (blue), transverse 
filaments (thin black lines) and lateral elements (red) that anchor the chromatin 
loops.  (Taken from Alberts, 2002, 4th Edn). 
 
The SC facilitates recombination and enables chiasma to form between homologous 
chromatids.  The formation of chiasma during prophase I is important as it increases 
genetic diversity by enabling recombination and also creates tension between the 
homologous chromosomes which is necessary for successful cell division during 
meiosis I (Carpenter, 1994).  This is an important factor in preventing the generation 
of aneuploid gametes. 
1.1.3 Nondisjunction during maternal meiosis I  
 
90% of all cases of Chromosome 21 nondisjunction (ND) are due to meiotic errors, 
the majority of which occur during meiosis I (Freeman et al, 2007) ND is 
characterised as an error in cell division where the chromosomes fail to disjoin.  
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Meiosis is initiated at about 11-12 weeks of gestation, and after pairing, synapsis and 
recombination events, cells arrest until just prior to ovulation.  This means that 
homologous chromosomes are arrested at prophase I for approximately 10-50 years, 
during a period which is termed dictyate arrest (Oliver et al, 2008).  The formation 
of chiasma during prophase I (in addition to a role in recombination) functions to 
stabilise paired homologous chromosomes and enables their correct orientation on 
the meiotic spindle (Carpenter, 1994). 
 
One cause of ND at meiosis I is a lack of chiasma formation between homologous 
chromosomes, this is termed achiasmate ND.  Without the formation of chiasma to 
generate tension and ensure correct alignment on the meiotic spindle, chromosomes 
may segregate incorrectly during anaphase I.  Another cause of ND at meiosis I 
occurs when chiasmata are formed during prophase I, this is termed chiasmate ND.  
Incorrect segregation in the case of chiasmate ND is not fully understood, but it is 
thought that either meiotic spindle error may be the cause, or that the position of the 
cross-over event may be important (Oliver et al, 2008).  Research has shown that the 
number of observed aneuploidies increased in the oocytes of women under the age of 
29, when the chiasmata are formed in the most distal 3.8 Mb of the long arm of 
Chromosome 21 (Oliver et al, 2008), confirming telomeric recombination as a risk 
factor for ND.  Although ND during meiosis I is the largest risk factor for generation 
of aneuploid gametes, ND at meiosis II creates an additional barrier to successful 
gametogenesis (Oliver et al, 2008). 
1.1.3.1 Precocious separation at meiosis I 
 
Another form of meiotic error which occurs early during prophase I, is caused by the 
precocious separation of the centromere allowing the sister chromatids to separated 
prematurely (Angell et al, 1997).  One study demonstrated that MI aneuploidies were 
commonly due to the addition or loss of a single chromatid rather than an entire 
chromosome (Angell et al, 1997).  Another study of mouse oocytes demonstrated 
that at anaphase I sister chromatids (univalents) lying far from the equator are still 
included with bivalents and pass to one or other poles, before cell division (Hunt et 
al, 1995).  MI metaphase chromosomes from the oocytes of young women are long 
and extended, but with increasing age can become contracted, it may be that the 
 5 
failure of condensation proteins such as condensin, due to age related structural 
damage, may reduce the capacity for chromosomes to condense into a stable bivalent 
prior to division (Angell, 1997).  Other potential factors, which may lead to 
precocious separation of sister chromatids could be age related structural damage of 
cohesins at the centromere, or even possibly the early action of the enzyme separase, 
which cleaves cohesins at the centromere (see section 1.1.5 page 6). 
 
1.1.4 Nondisjunction during maternal meiosis II  
 
ND events can also occur in meiosis II, these events can arise from defects in 
prophase II, where there is a failure to resolve chromosome crossovers before 
segregation into daughter cells. These events can be distinguished from meiosis I 
meiotic errors by detection of recombination-specific markers.  In meiosis I the 
presence of a meiotic cross-over event occurring in the telomeric region of 
Chromosome 21 increases the risk of ND.  However, during meiosis II the presence 
of a single meiotic cross-over event occurring closer to the pericentromeric region 
increases the risk of a ND event (Oliver et al, 2008).  This may be due to the fact that 
during prophase II it is the sister chromatids which separate and the formation of 
crossovers closer to the centromere may impede this separation (figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  Ideogram of 
Chromosome 21q, with location of 
meiotic nondisjunction events 
During MI most meiotic ND events 
occur in sub-telomeric and telomeric 
regions with an average of 41% of MI 
ND events occurring within interval 5 
in all age groups and 41% of MI ND 
events occurring within interval 6 in 
women under the age of 29.  During 
MII ND events occur predominantly 
in the centromeric region of 
Chromosome 21. In the combined 
group of women over the age of 29 the 
average rate of ND events occurring 
within interval 1 is 37.5%.  (Adapted 
from Oliver et al, 2008).
 
Centromeric 
nondisjunction M II
Sub-telomeric 
nondisjunction M I
Telomeric 
nondisjunction M I
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One risk factor of fetal aneuploidy which has been identified is maternal age, which 
is part of the criteria used to determine which women should undergo prenatal 
screening during pregnancy. 
1.1.5 Maternal age effect 
 
There are multivariate factors which mean that with increasing maternal age there is 
an increased risk of fetal aneuploidy.  Some of the risk factors and cellular events 
have been characterised, however there is still much unknown about all of the factors 
which contribute to the maternal age effect. 
 
Degradation of meiotic proteins Bub1 and MAD2 is correlated with maternal age 
(Baker et al, 2004; Steuerwald et al, 2001).  These proteins are part of the spindle 
assembly checkpoint pathway, which interacts with the kinetochore in order to delay 
anaphase by inhibition of the anaphase promoting complex (APC) in order to ensure 
correct chromosome segregation.  With increasing maternal age, the probability of a 
single crossover occurring within the pericentromeric region in meiosis II also 
increases, which also increases the risk of ND (Oliver et al, 2008). 
 
The chance of a ND event leading to a trisomy 21 birth increases with maternal age, 
or more accurately by increase in oocyte age.  The likelihood that a woman under 30 
who becomes pregnant with a Down syndrome (DS) fetus is less than 1 in 1,000.  
However, the chance increases to 1 in 400 for women who become pregnant at age 
35. The likelihood of DS continues to increase as a woman ages, so that by age 42, 
the chance of a DS birth is 1 in 60 and by age 49, the chance is 1 in 12 
(http://www.bgcdownsyndrome.org/about.cfm). 
1.1.6 Paternal-specific nondisjunction  
 
Meiosis in males in much more closely regulated than meiosis in females.  During 
spermatogenesis there is no prolonged arrest during meiosis I, which reduces the risk 
of ND.  However, ND in meiosis does occur and it is an additional paternal copy of 
Chromosome 21, which is responsible for 5-10% of trisomy 21 conceptions (Muller 
et al, 2000; Hook et al, 1995; Sherman et al, 1991; Yoon et al, 1996).  Other factors 
which have also been suggested to play a role in the successful completion of 
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meiosis in males include: the lower temperature of the testicular environment (in 
relation to the rest of the body) and the presence of spermatogenic specific versions 
of heat shock proteins, which act as chaperones during spermatogenesis (Allen et al, 
1996). 
1.1.7 Trisomy 21 and congenital birth defects 
 
Down syndrome (DS) was first described by Langdon Down in 1866 and linked to 
trisomy 21 in 1959 by Lejeune and Jacobs.  It is the most common chromosomal 
abnormality causing learning difficulties and mental defects.  There is no racial 
predilection, males and females are affected in the almost the same ratios (Byard et 
al, 2007).  Mortality ratios provide evidence of excessive risk of leukaemia as well 
as other haematopoietic malignancies, as well as congenital defects resulting in heart 
failure.  In addition, respiratory tract infections and pneumonia were also shown to 
be higher in the DS population compared to the general population (Scholl et al, 
1982). 
 
In a population-based study of 2,814 individuals with DS the overall incidence of 
cancer was comparable to that of the general population, but showed a different 
distribution of tumour types and malignancies.  The incidence of solid tumours was 
less in all age groups by approximately half, whereas leukaemia occurred 10–20 
times more frequently in individuals with DS (Hasel et al, 2000).  The largest 
relative risk is observed in young children (under the age of 5 years), in whom acute 
myeloid leukaemia (AML) is 153 fold more frequent in children with DS compared 
with the general population and the incidence of acute megakaryoblastic leukaemia 
is 500 fold higher in children with DS than in the general population (Hasle et al, 
2000; Hitzler, 2007; Zipursky et al, 1992). 
 
It has also been shown that there is a 40-50% risk for congenital heart defects 
(CHDs) among children born with DS, whereas the risk to the population in general 
is about 1% (Frid et al, 1999).  When offering diagnosis of DS it is important to 
remember that DS is also a potential indicator of these other conditions, which can 
be associated with a Downs birth.  
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1.2 Current prenatal diagnosis 
 
Current prenatal diagnosis relies on a combination of techniques, which fall in to two 
broad categories: prenatal screening tests, which are non-invasive and are designed 
to detect those cases which have a higher probability of fetal abnormality, and 
prenatal diagnostic techniques, which are more accurate but usually more invasive.  
There are many forms of prenatal diagnosis, which are currently in use (see pages 8-
12). 
 
Amniocentesis is an invasive diagnostic technique and is the most widely accepted 
method for obtaining fetal cells for genetic analysis.  After amniocentesis, chorionic 
villus sampling (CVS) is the most common form of invasive prenatal diagnosis.  
Both of these techniques are invasive and carry an associated risk of approximately 
1% fetal loss (Brambati and Tului, 2005). 
 
Non-invasive techniques are used as screening tools and lack the predictive power to 
form diagnostic tests individually.  Ultrasound examinations are routinely used to 
diagnose congenital defects such as DS, and specific characteristics such as nuchal 
translucency can be measured to indicate risk.  Second trimester serum screening is 
another non-invasive technique, which uses the measurement of fetal-specific 
proteins as an indicator for trisomy 21. 
 
1.2.1 Invasive methods for prenatal diagnosis:  amniocentesis and 
chorionic villus sampling 
 
Women choose to have invasive prenatal diagnosis for a number of reasons 
including; having a child previously affected with a congenital defect, or aneuploidy, 
or the presence of markers for aneuploidy as indicated by an ultrasound test.  On 
average approximately 5-10% of pregnant women in the U.K opt for some form of 
invasive prenatal diagnostic testing (Eddleman et al, 2006; Mujezinovic et al, 2007; 
Nicolaides et al, 2005 a).  The most common invasive prenatal diagnostic techniques 
are amniocentesis and chorionic villus sampling (CVS).  Amniocentesis is the 
drainage of amniotic fluid from the amniotic sac, in order to obtain fetal cells which 
are predominantly extravasted from the fetus itself, this is achieved by insertion of a 
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needle crossing the maternal abdomen and penetrating the amniotic sac (Wapner et 
al, 2005). 
 
CVS is the collection of fetal cells from multiple tissue types which form the 
chorionic villus.  Cell types within the chorionic villus include villus cells, 
syncytiotrophoblasts and mesodermal cells which make up fetal capillaries (Wapner 
et al, 2005). 
 
Amniocentesis is regarded as the ‘gold standard’ of second trimester testing, 
however it can only be safely performed after 14 weeks of gestation, first trimester 
testing with amniocentesis has been linked with increased risk of fetal loss, amniotic 
sac fluid leakage and limb reduction defects (LRDs) such as talipe equinovarus 
(Wapner et al, 2005). 
 
CVS can be used in the first trimester (approximately 10-12 weeks), and has been 
used clinically since the 1980s.  However, similarly to amniocentesis, earlier testing 
has been linked to LRDs and increased risk of fetal loss (Wapner et al, 2005). 
Additional difficulties with CVS include the diagnostic errors caused by maternal 
cell contamination and confined placental mosaicism (CPM).  Chorionic villus 
samples typically contain a mixture of fetal and maternal cells, although samples are 
thoroughly cleaned and separated under the microscope, some maternal cells may 
occasionally remain and grow in the subsequent cell culture.  In some cases this may 
lead to the development of two cell lines, and in rare circumstances the maternal cell 
line may out-grow the fetal cell line (Boehm et al, 1993; Ledbetter et al, 1992; 
Wapner et al, 2005; Williams et al, 1987). 
 
CPM is one source of potential diagnostic error for CVS.  CPM can develop in either 
of two ways.  One mechanism by which CPM occurs is when an aneuploid 
embryonic cell undergoes ‘mitotic rescue’, whereby the additional chromosome is 
expelled from the cell during mitosis. The other mechanism by which CPM occurs is 
known as post zygotic error.  During the 32-64 cell stage of embryogenesis only 3-4 
cells make up the inner cell mass (ICM) of the embryo, the rest of the cells become 
precursors for extra-embryonic tissues.  If one of these precursors somehow becomes 
aneuploid by way of post zygotic error this can lead to CPM (Wolstenholme et al, 
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1996).  Another form of CPM can occur when an embryonic cell undergoes ‘mitotic 
rescue’ and by chance expels the wrong copy of a trisomic chromosome, the cell can 
be left with two chromosomes from the same parent; this is known as uniparental 
disomy (Cassidy et al, 1992). 
 
In one trial where the CVS test was performed on pregnancies between 8 to 9 weeks 
after conception, severe LRDs were reported in 5/289 cases (Firth et al, 1991).  In 
another clinical trial, CVS and amniocentesis were performed during the first 
trimester.  The associated risk of fetal loss was 7.6% for CVS and 7.0% for 
amniocentesis (Mujezinovic et al, 2007).  A systematic review of all clinical trials 
conducted in relation to CVS and amniocentesis has established that with optimal 
conditions for each test; including experienced medical teams and laboratory staff as 
well as testing at the ideal gestational age during the second trimester; the associated 
risk of fetal loss was between 0.7-2.0% for CVS and 0.6-1.9% for amniocentesis 
(Mujezinovic et al, 2007). 
 
The slightly higher risk in CVS is due to the slightly different gestational ages, with 
CVS testing being slightly earlier than amniocentesis.  Overall the data suggests that 
these tests are optimal for late first trimester to second trimester testing, as earlier 
testing results in a greatly increased risk of fetal loss, which is unacceptable. 
 
1.2.2 Non-Invasive methods for prenatal diagnosis 
 
Current non-invasive methods of prenatal diagnosis involve the use of screening 
technologies and procedures in order to assess risk of fetal aneuploidy (usually 
trisomy 21).  The judicious application of non-invasive techniques such as those 
based on ultrasound and the detection of serum biomarkers, greatly reduces the 
number of pregnancies which are subjected to testing by invasive methods. 
 
1.2.2.1 Nuchal translucency 
 
Nuchal translucency (NT) is an ultrasound technique, which is used to measure the 
fluid behind the neck of the fetus; the translucency is measured from the skin of the 
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fetus to the soft tissue overlying the cervical spine. NT changes throughout gestation 
and the optimal period for NT measurement is between 11 and 13 weeks (Nicolaides, 
2005). 
 
NT can only be measured if the fetus is within the normal size range; this is 
measured as fetal crown to rump length, with the acceptable range being between 
45mm and 84mm.  The lower limit is due to the technical aspects of sonography and 
deals with issues of image resolution, and the upper limit is in place to offer women 
earlier and safer forms of termination (Nicolaides, 2005).  NT can be measured 
either by transabdominal or transvaginal sonography and the results achieved are 
similar (Nicolaides, 2005).  One potential barrier to correct NT measurement occurs 
when the umbilical cord wraps around the neck of the fetus; this occurs in 5-10 % of 
all cases and can increase NT measurements by 0.8mm (Nicolaides et al, 2004). 
 
Using NT measurements combined with maternal age, successful detection of 
trisomy 21 can be as high as 75-80% with a false positive rate of 5% (Avgidou et al, 
2005; Nicolaides, 2004; Nicolaides et al, 2005 b).  Another test based on 
ultrasonography is the measurement of fetal nasal bone, which is also measured in 
relation to the fetal crown to rump length.  Although, nasal bone measurement alone 
is not an absolute marker for chromosomal abnormalities, as 2.2% of all Caucasian, 
9.0% of all Afro-Caribbean and 5.0% of all Asian fetuses have no nasal bone but are 
chromosomally normal (Cicero et al, 2004).  However, using the measurement of 
nasal bone in addition to other measurements such as NT can reduce the overall false 
positive rate of a screen (Filkins and Koos, 2005).   
 
1.2.2.2 Maternal serum screening 
 
Maternal serum screening for fetal biomarkers is another non-invasive method for 
prenatal diagnosis.  Screening for Down syndrome (DS) by means of maternal serum 
analytes in the second trimester was first described in 1988 (Wald et al, 1988).  This 
first small study included 17 cases of DS and 74 unaffected cases, in the DS 
population (65%) were found to have a human gonadotropin (hCG) level greater 
than 20IU/ml, whereas only 1 of the unaffected population (1.4%) exhibited the 
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same level (Wald et al, 1988).  As serum testing continued to develop another 
marker was discovered which, was termed pregnancy-associated plasma protein A 
(PAPP-A) and the measurement of human gonadotropin was refined to detect the β 
subunit of human gonadotropin (βhCG).  Optimal times for gestational testing have 
since been established, and it has been shown that measurement of PAPP-A is 
optimal between 8-11 weeks (Cuckle and Van Lith, 1999). 
 
1.2.2.3 Combined non-invasive testing 
 
Combining NT measurement and serum biochemical testing has often been used as a 
way of increasing trisomy detection rates, whilst also reducing the false positive rate.  
One strategy described (Wright et al, 2006) has been successfully developed to give 
a high detection rate of 90% for trisomy 21 and a low false positive rate of 2.0%.  
This strategy is called the three stage contingent test.  The first stage of the test is 
biochemical testing of PAPP-A and βhCG at 10 weeks.  Cut off values for PAPP-A 
and βhCG levels determine if women need to proceed to the next stage which is NT 
measurement.  NT measurement is offered to women at 12 weeks but only if the cut-
off levels are exceeded for the first stage test, or if there is an additional risk factor 
such as higher maternal age.  Only women who exceed the cut-off value for NT 
testing proceed to the third and final test.  The third stage is quadruple serum 
biomarker testing; markers included are α-fetoprotein, βhCG, unconjugated estriol 
and inhibin-A.  Information on maternal age and the three tests are combined to 
assess risk (figure 1.3) (Wright et al, 2006). 
 
This test is regarded as being one of the best, and has a high detection rate for the 
low false positive rate of 2%.  However, this means that potentially women are 
subjected to three assessments before a diagnosis can be made, and even after these 
tests women may still be referred for invasive prenatal testing such as amniocentesis 
and CVS.  A more efficient method for non-invasive prenatal diagnosis is sought, 
such a test would need to provide a much more direct method of fetal assessment and 
also eliminate the requirement for invasive prenatal testing. 
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Figure 1.3:  Schematic showing the three stage contingency policy 
At stage one PAPP-A and β-hCG are measured at approximately 10 weeks, the first 
stage risk cut off 1/b determines the proportions of pregnancies that go on to have 
nuchal translucency (NT) measurements in the second stage.  NT is measured at 
approximately 11 weeks.  The cut off value 1/c1 determines the early detection and 
early false positive rate, while the lower cut off value 1/c2 determines the proportion 
of women who continue to the third stage, and undergo second trimester-testing with 
biochemical biomarkers.  The quadruple biochemical biomarker test measures 
amounts of: α-fetoprotein, β-hCG, unconjugated estriol and inhibin-A.  On the basis 
of this risk, the pregnancy is screened as negative or positive according to the final 
cut off value 1/d.  (Taken from Wright et al, 2006). 
 
1.3 Fetal cells 
 
The first paper to document the description of feto-maternal cellular trafficking, was 
published in 1893 by Georg Schmorl, the title of the paper translates as 'Pathological 
and anatomical examinations of puerperal-eclampsia' (Schmorl G, 1893).  Schmorl 
described the results obtained from the examination of 17 deceased pregnant women, 
in relation to the liver as this was the original focus of his work.  In autopsied lungs 
Schmorl observed liver cells which make up part of the thrombi and other peculiar 
cells, which were observed in the capillaries of the lung (Lapaire et al, 2007). 
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The cells were described as ‘giant’ and contained between 6-15 nuclei with rounded 
nucleoli.  These cells either originated from the bone marrow or the placenta; and 
since none of the cases exhibited internal bleeding, it seemed unlikely that the cells 
originated from bone marrow (Lapaire et al, 2007).  Schmorl postulated that these 
multinuclear cells were originally from the surface of the villi, and several 
observations supported his hypothesis: 
 
1) The morphological pattern corresponded to that of placental giant cells 
2) In all of the cases the giant cells were detectable in all parts of the body, 
including the uterine veins 
3) In one case cubic cells with the same morphological features as villi were 
found in association with the ‘giant’ cells 
 
Schmorl was the first physician to describe the presence of fetal cells in the maternal 
body, and since that discovery the placenta has been studied by scientists around the 
world.  The presence of fetal cells in the maternal circulation offers a prime 
opportunity for the development of non-invasive prenatal diagnosis, if it is possible 
to isolate these cells from the maternal blood. 
 
1.3.1   Placental development 
 
Development of mammals depends on the formation of a placenta, this process 
involves uterine attachment and acquisition of the maternal blood supply.  This 
connection to the mother allows gaseous exchange, supply of nutrients to the fetus 
and the removal of fetal waste products. 
 
Cytotrophoblasts (CTBs) are specialised epithelial cells, which function to 
aggressively invade maternal tissues (Fisher et al, 1989; Librach et al, 1991; Weier 
et al, 2005).  During early pregnancy CTBs invade the maternal uterine wall and 
associated arterial network, this process takes place during the first trimester and is 
completed rapidly thereafter.  CTBs have been found to express several gelatine 
degrading proteinases, the activities of which are inhibited by the use of tissue 
inhibitor of metalloproteinases (TIMPs).  This evidence suggests that CTBs are 
 15 
specifically regulated to produce metalloproteinases in order to aid trophoblast 
invasion of the uterus (Fisher et al, 1989).  CTBs have also been shown to invade 
and migrate through extracellular matrix (ECM) in vitro (Glass et al, 1983).   
 
Many elements of trophoblast invasion are similar to events which occur during 
tumour cell invasion.  After a brief adherent stage CTBs penetrate the basement 
membrane of uterine epithelial cells and invade the stroma and its associated 
arterioles.  However, unlike tumour invasion, CTB invasion is regulated and 
confined spatially and temporally, to placental development in early pregnancy 
(Librach et al, 1991).  CTBs up-regulate the production of type IV collagenase 
during the first trimester, indicating a role in maternal invasion (Fisher et al, 1989; 
Librach et al, 1991). 
 
CTBs arise by differentiation of a progenitor population that is anchored to the 
trophoblast basement membrane surrounding the mesochymal cores of the chorionic 
villi.  CTBs at the anchoring chorionic villi leave the trophoblast basement 
membrane and form columns of non-polarised cells, which attach to and penetrate 
the uterine wall (figure 1.4).  As well as allowing the development of the essential 
route for nutrient and gaseous exchange, the formation of the placenta also allows 
fetal cells to enter the maternal circulation (Weier et al, 2005). 
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Figure 1.4:  Placenta invasion at the fetal-maternal interface at approximately 
10 weeks of gestation 
The anchoring villi, which function as a bridge between the fetal and maternal 
compartments, form cell columns that give rise to the subpopulation of 
cytotrophoblasts (CTBs) that invade the uterine interstitium and maternal vasculature, 
thereby anchoring the fetus to the mother and accessing the maternal circulation.  
(Taken from Weier et al, 2005). 
 
1.3.2 Fetal cells in the mother 
 
Transfusion of cells from the fetus to the mother may be the cause of some ‘auto-
immune diseases’; most notably systemic sclerosis (SSc).  Cells determined to be of 
fetal origin by fluorescent in situ hybridisation (FISH) analysis, by the detection of a 
Y chromosome, have been observed in the tissue of women with SSc in at least 
tissue type (Johnson et al, 2001).  Fetal cells are predominantly found in the spleen, 
as it filters the contents of the peripheral blood (Johnson et al, 2001).  The detection 
of fetal cells in the spleen indicates the presence of fetal cells in the maternal 
circulation, and highlights their potential use in non-invasive prenatal diagnosis 
(NIPD). 
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Many other studies have also documented cases of SSc, not only in cases of 
pregnancy, SSc can also been linked with blood transfusion, with cells detected in 
the skin, lungs, and lymph nodes.  The observation of fetal nucleated red blood cells 
(FNRBCs) in skin lesions in pregnant women with SSc indicates that fetal cells are 
able to migrate and survive in the maternal circulation (Arlett et al, 1998). 
  
1.3.2.1  Fetal nucleated red blood cells 
 
In addition to cytotrophoblasts, FNRBCs are also present in the maternal circulation 
(Bianchi et al, 1990; Chen et al, 2004; Elias et al, 1996; Krabchi et al, 2006; Wachi 
and Kitagawa 2004; and many others). FNRBCs were first detected in the maternal 
circulation in 1990 (Bianchi et al, 1990).  
 
Using a monoclonal antibody for the CD71 cell surface receptor, transferrin (TfR), 
candidate fetal cells were identified from the peripheral blood of pregnant women.  
Y chromosome specific sequences were then detected by PCR, this was followed 
with karyotyping analysis.  In 7/19 cases fetal cells were detected in the blood of 
pregnant women, with cells from 6/7 cases being confirmed as fetal by Y 
chromosome sequence detection (Bianchi et al, 1990). 
 
One issue with the use of FNRBCs for NIPD is the paucity of these cells in the 
maternal circulation; on average there are approximately 1.9-6 cells detectable per 
ml of maternal blood, depending on which study is observed (Bianchi et al, 1990; 
Chen et al, 2004; Kolvraa et al, 2005; Krabchi et al, 2001; Guetta et al, 2003). 
1.3.2.1.1  Fetal cell enrichment techniques 
 
The isolation and enrichment of fetal cells in the maternal circulation is a goal that 
has been pursued by many research groups for many years, for the development of 
non-invasive prenatal diagnosis (NIPD).  If sufficient cells can be isolated and 
recovered from the maternal blood they could be used directly in tests for fetal 
aneuploidy disorders or other genetically inherited diseases.  FNRBCs are an 
attractive candidate for enrichment, as 10% of fetal blood cells are nucleated red 
blood cells and these cells are rare in adults (Elias et al, 1996). 
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Developing markers for the enrichment of FNRBCs has long been a goal in NIPD, 
the first such marker was the transferrin receptor (Bianchi et al, 1990; Elias et al, 
1996).  Another technique developed relied on slides stained with linked α galactose 
residues, to bind to lectin receptors on fetal cells.  This enabled the enrichment of 
fetal blood cells before further sorting by filtration.  The enrichment achieved was 
4.7-10.9 FNRBCs per ml of maternal blood (Wachi and Kitagawa 2004).  
 
Other techniques have not been so efficient.  The use of CD34+ progenitor cells was 
also targeted as a candidate for fetal cell enrichment (Guetta et al, 2003).  Under the 
correct conditions CD34+ cells proliferate in culture and are more abundant in the 
fetal circulation than the maternal circulation (Guetta et al, 2003).  However this 
technique yielded on average 1 fetal cell/ml of maternal blood, and so did not give 
the level of enrichment required for NIPD. 
 
Another study reported the utility of an erythroblast scoring system, as a method for 
the detection of FNRBCs and their use in detecting fetal aneuploidies.  FNRBCs 
were isolated by density gradient separation, followed by CD15 and CD45 depletion, 
and γ haemoglobin positive selection. 
 
Each cell was then designated a score ranging from 0-12, with cells scoring 5 or less 
deemed to be of maternal origin (94.3% accurate) and cells scoring 9 or more 
deemed to be of fetal origin (86.8% accurate).  The method did not improve the 
enrichment of fetal cells, but used blood samples of ample volume so as to give 
enough cells for analysis (Cha et al, 2005).  Overall the technique was labour 
intensive and costly, requiring the use of expensive cell sorting equipment.  In 
addition this method offered no additional benefits for prenatal diagnosis above that 
of the three stage contingency testing currently available (Wright et al, 2006). 
 
In addition to the difficulties of obtaining sufficient FNRBCs from the maternal 
circulation, some studies have suggested that FNRBCs are not the optimal targets for 
use in NIPD (Kolvraa et al, 2005).  A large multi-centre collaborative study funded 
by the National Institute of Child Health and Human development (NICHD) has 
concluded; and results from the first part of the study have been published (Bianchi 
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et al, 2002).  The study was named NIFTY and the objectives were to identify 
optimal methods for fetal cell enrichment from maternal blood and to demonstrate 
the utility of these cells for the determination of fetal sex and fetal aneuploidy, in 
comparison with the standard techniques of CVS and amniocentesis (Bianchi et al, 
2002).  Isolated fetal cells were assessed by FISH analysis on interphase nuclei of 
cells.  After the first 5 years of the study 2744 maternal blood samples were analysed, 
making this study one of the largest studies of fetal cells so far (Bianchi et al, 2002). 
Of 3302 blood samples available for analysis approximately 17% failed to yield any 
fetal cells for analysis (Bianchi et al, 2002).  Of the remaining samples available for 
analysis the detection rate for aneuploidies was 74.4% which is lower than the 
current detection rates of 90% for the three stage contingency test (Wright et al, 
2006). 
 
Further studies have shown that the nuclei of FNRBCs disintegrate some time before 
they are expelled from the cell; this makes them an unsuitable target for FISH 
analysis and an unattractive prospect for NIPD (Babochkina et al, 2005).  Other fetal 
cells have also been detected in the maternal circulation; however these cells have 
been shown to persist in the maternal circulation for years and even decades, thus 
making them unsuitable for NIPD (Bianchi et al, 1996; Guetta et al, 2003). 
 
1.3.2.1.2 Acquisition of aneuploidy in cytotrophoblasts 
 
As well as the issues effecting the enrichment and use of FNRBCs, CTBs are also 
unsuitable for use in NIPD.  During the process of differentiation into the invasive 
phenotype CTBs acquire aneuploidies, which can lead to the cells becoming either 
hyperdiploid or hypodiploid (figure 1.5) (Weier et al, 2005).  This differentiation is 
thought to enable increased expression of the proteinases required for invasion and 
possibly as a mechanism for ensuring a short life span (Weier et al, 2005). 
 
There are new technologies in development, for the isolation and enrichment of fetal 
cells from maternal blood; such as a cell-sorting biochip (Biotech international 
USA); and other techniques which rely on the use of physiological cell properties to 
culture FNRBCs.  However the prospect of developing NIPD using fetal cells in the 
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maternal circulation is unlikely at present.  Diagnostics which make use of the cell-
free nucleic acids released by fetal cells are now sought after. 
1.4 Presence of cell-free fetal nucleic acids in the maternal circulation  
 
Since the discovery of fetal cells in the maternal circulation it has been hypothesised 
that fetal nucleic acids may well also circulate in the maternal peripheral blood.  
However what is not certain is whether or not it is possible to utilise them in clinical 
practice for NIPD.  The presence of cell-free fetal DNA (cff DNA) in the maternal 
circulation was first discovered, by identification of a Y chromosome-specific 
sequence SRY (Lo et al, 1997).  This was followed later by the detection of cell-free 
fetal RNA (cff RNA) in the maternal circulation (Poon et al, 2000), with the 
detection of ZFY-specific mRNA sequences, which relate to a zinc finger protein 
which is present on the Y chromosome (Poon et al, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5:  Common aneuploidies detected in a cytotrophoblast population  
The analysis of a population of 75 interphase cytotrophoblasts taken from a second 
trimester placenta shows that aneuploidies are common in CTBs.  Monosomies are 
shown in white, normal disomies are shown in grey and trisomies and other gains are 
shown in black, chromosomes 3, 6, 8, 9, 10, 11, 12, 16, 17, 18 and X are assessed.  
(Taken from Weier et al, 2005). 
 
 21 
1.4.1  Cell-free fetal RNA in the maternal circulation 
 
Cell-free RNA (cf RNA) was first discovered in the plasma and serum of cancer 
patients, it was proposed that cf RNA could be used as a diagnostic marker for 
tumour/cancer outcome in patients after chemotherapy, as in the case examples of 
malignant melanoma and nasopharyngeal carcinoma, respectively (Kopreski et al, 
1999; Lo et al, 1999).  Since the discovery of cf RNA in plasma and serum of cancer 
patients, the detection and quantification of cell-free fetal RNA (cff RNA) has been 
sought for the development of non-invasive prenatal diagnosis (NIPD). 
 
Cff RNA was first detected in the plasma of pregnant women, by use of the first 
fetal-specific RNA marker ZFY; a gene encoding transcripts for a zinc finger protein. 
ZFY is on the Y chromosome and therefore a male specific gene, and can only be 
detected in male bearing pregnancies (Poon et al, 2000).  The existence of cell-free 
plasma RNA (cfp RNA) is remarkable given the highly unstable nature of RNA and 
the fact that ribonuclease is present in the circulation (Reddi et al, 1976; Tsui et al, 
2002).  One study (Tsui et al, 2002), investigated the stability of endogenous cfp 
RNA extracted from plasma in comparison with commercially available human 
RNA.    Unfiltered blood stored at room temperature exhibited the greatest difference 
over three time points of 0, 6 and 24 hours after collection, with total mRNA levels 
increasing over time; blood stored at 4 0C did not vary significantly in its plasma 
RNA levels.  Non-particle-associated RNA in plasma was assessed by filtering 
plasma before extraction. Non-particle-associate RNA levels did not vary 
significantly in either blood stored at room temperature or at 4 0 C.  The 
concentration of mRNA was found to be highly stable in samples stored in ethylene 
diamine tetra acetic acid (EDTA) (figure 1.6).  Commercially available RNA was 
also added to plasma samples and assessed in a time course experiment, after 
incubation with the plasma for 5, 10 and 15 seconds, Trizol LS reagent was added 
(Invitrogen) to stop any reaction with ribonuclease in the plasma (figure 1.7).  
Exogenous RNA was presumed to be rapidly broken down by ribonuclease present 
in the plasma, demonstrating that cfp RNA is somehow protected from ribonuclease 
action.  The stability of cfp RNA indicates that it may be of diagnostic use in NIPD 
(Tsui et al, 2002). 
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Figure 1.6:  Effect of delayed processing of EDTA-stored blood on RNA plasma 
concentration  
(A) Shows unfiltered plasma RNA concentrations as measured at 0, 6 and 24 hours 
after blood collection.  All samples were stored with EDTA before processing at 
either room temperature (black line) and at 4 0C (dotted line).  (B) Shows filtered 
RNA in plasma as measured at intervals of 0, 6 and 24 hours after blood collection. 
All samples were stored with EDTA before processing at either room temperature 
(black line) or at 4 0C (dotted line).  (Taken from Tsui et al, 2002).  
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Figure 1.7: Time course for clearance of exogenous free-RNA from plasma 
Exogenous free-RNA (as measured by GAPDH mRNA levels) is cleared rapidly 
from plasma, with levels returning to normal after 5 seconds; this is presumably due 
to the action of ribonuclease in the plasma.  The small but finite levels of mRNA 
detected are assumed to be protected from ribonuclease action, by association with 
sub-cellular particles.  (Taken from Tsui et al, 2002). 
 
Cfp RNA has been shown in other studies to be protected by apoptotic bodies and 
other smaller sub-cellular particles (Hassleman et al, 2001; Ng et al, 2002).  The 
presence of RNA in apoptotic bodies has been reported, fluorescence microscopy has 
shown the presence of typically granulated structures, representing apoptotic bodies 
containing RNA (Hassleman et al, 2001).  A more advanced study showed the 
detection of cell-free mRNA in plasma after filtration with filters of various pore 
sizes of 5, 0.45 and 0.22 µm before quantitative analysis, showing that there is a 
stable background amount of RNA present in the plasma, which is associated with 
small sub-cellular particles. 
 
The next incremental discovery was the detection of cff RNA of placental origin in 
the maternal circulation (Ng et al, 2003).  It has been determined that the placenta is 
the major source of cff RNA in the maternal circulation, and that cff RNA can be 
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used for NIPD (Ng et al, 2003).  This was shown by the detection and measurement 
of two placentally expressed mRNAs throughout gestation, in a cohort of pregnant 
women.  The mRNAs measured were derived from the placental genes human 
placental lactogen (hPL) and the beta subunit of human chorionic gonadotropin 
(βhCG).  The measurement of each cff RNA marker correlated to plasma protein 
levels of each gene product (figure 1.8).  In addition hPL mRNA was shown to clear 
rapidly after delivery, and by 24 hours post delivery was undetectable (Ng et al, 
2003).  This further supports the utility of cff RNA as a useful resource in 
developing NIPD. 
 
Further characterisation studies have shown that circulating cfp RNA has a 
propensity toward being fragmented, with a bias toward a higher absolute quantity of 
5’ end mRNA detected in the plasma.  One study has shown that by designing 
primers which span mRNA transcripts, at the 5’ end the middle and the 3’ end that 
not all regions of the same transcript are equally abundant in plasma (Wong et al, 
2005).  The measurement of several transcripts with primers spanning the different 
amplicon regions, detected a higher absolute quantity for 5’ end fragments.  In each 
of the transcripts assessed the absolute amount of 5’ ended molecules as greater than 
that of the 3’ ended molecules; this is an important factor when choosing primers to 
assess transcripts for NIPD (Wong et al, 2005). 
1.4.2 Cell-free fetal RNA markers on Chromosome 21 
 
The first cff RNA marker discovered on Chromosome 21 is PLAC4 mRNA, as a 
placentally expressed message it is ideal as a marker as it is not contaminated by 
background maternal nucleic acids (Lo et al, 2007).  The PLAC4 marker was 
discovered by screening mRNA obtained from pregnant and non-pregnant women by 
microarray analysis (Tsui et al, 2004)  PLAC4 is readily detectable in plasma of 
pregnant women, and undetectable in non-pregnant individuals, it is also cleared 
rapidly after delivery, with no sequences detected 24 hours after delivery (figure 
1.9). 
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Figure 1.8: Levels of placenta derived mRNA and proteins in normal pregnancy 
(A) hPL mRNA and hPL protein levels in the maternal serum at all three trimesters 
correlate with each other increasing throughout gestation, hPL mRNA data are 
shown by clear boxes and hPL protein data are shown by grey boxes.  (B) βhCG 
mRNA and βhCG protein levels also correlate with each other, decreasing 
throughout gestation.  βhCG mRNA data are shown by clear boxes and βhCG 
protein data are shown by grey boxes.  The lines inside each box represent median 
values, the boxes mark the interval between the 25th and 75th percentiles, the 
whiskers denote the intervals between the 10th and 90th percentiles, and filled 
circles mark the data points outside of the 10th and 90th percentiles.  (Taken from 
Ng et al, 2003). 
 
 
 
 
 
1ST Trimester    2ND Trimester  3RD Trimester
1ST Trimester    2ND Trimester  3RD Trimester
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Figure 1.9:  Detection of PLAC4 mRNA in maternal plasma 
(A) PLAC4 mRNA levels increase throughout gestation.  The lines inside each box 
represent median values, the boxes mark the interval between the 25th and 75th 
percentiles, the whiskers denote the intervals between the 10th and 90th percentiles, 
and filled circles mark the data points outside of the 10th and 90th percentiles.  (B) 
Circulating PLAC4 mRNA is cleared rapidly after-delivery, to undetectable levels 24 
hours post delivery.  (Taken from Lo et al, 2007). 
 
In order to detect trisomy of Chromosome 21 the allelic ratio of single nucleotide 
polymorphisms (SNPs) must be detected in order to give the ratio of maternal alleles 
to paternal alleles (Lo et al, 2007).  In the case of the PLAC4 mRNA transcript the 
specific SNP (rs8130833 NCBI Build 36.2) is an A  G transition.  The allelic ratio 
of cfp RNA is presumed to reflect the gene dosage in cases of euploidy and trisomy 
(figure 1.10).  The detection of the ratio of SNPs can be used to detect an allele ratio 
of 2:1 in cases of trisomy 21 and a ratio of 1:1 in normal diploid cases (see section 
1.5.4.2).  Due to the number of molecules of RNA being in the range of 104 - 106 in 
the first trimester, PLAC4 mRNA is readily detectable, in the case of the specific 
SNP tested only 69/119 pregnancies were heterozygous and therefore assessable by 
the technique (Lo et al, 2007); the test detected 90% of trisomy 21 pregnancies in the 
sub group studied with 0% false positive results (Lo et al, 2007). 
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Figure 1.10:  Schematic of the allelic ratio strategy for the measurement of fetal 
trisomy using RNA  
(A) Normal and trisomic fetuses heterozygous at the transcribed SNP for PLAC4.  
“A” and “G” denote the SNPs for each respective allele.  (B) The gene is expressed 
in placental tissue; the ratio of the two RNA alleles in trisomy 21 is expected to 
differ from that of a normal placenta, as the result of the extra copy of the gene.  (C) 
The RNA transcripts are released into maternal blood and their relative abundance is 
reflective of that in the placenta.  In trisomy 21 the ratio of the two RNA alleles is 
expected to deviate from that of a normal pregnancy.  (Taken from Lo et al, 2007). 
 
Using the allelic ratio method with a number of informative (heterozygous) SNPs 
such as the one described (Lo et al, 2007); could provide enough coverage of the 
population to be used in routine clinical NIPD.  As the rate of heterozygosity of 
specific SNPs varies in different populations and the maximum theoretical 
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percentage of heterozygosity for any given SNP is 50%, a number of SNPs are 
required to ensure that at least one is informative (heterozygous) for the chromosome 
of interest in each test.  
1.5 Cell-free fetal DNA in the maternal circulation 
 
The passage of fetal cells into the maternal circulation has been well documented 
(Bianchi, 2004; Fisher et al, 1989; Librach et al, 1991; Weier et al, 2005).  Given the 
rarity of fetal cells in the maternal circulation and the technical difficulties of fetal 
cell enrichment (Bianchi et al, 1990; Chen et al, 2004; Kolvraa et al, 2005; Krabchi 
et al, 2001; Guetta et al, 2003); other avenues have been sought for the development 
of non-invasive prenatal diagnosis (NIPD), such as the use of cell-free DNA in the 
maternal circulation. 
 
The potential use cell-free DNA in plasma or serum was first developed as a tool for 
molecular diagnosis of cancer risk; as tumour DNA has been detected in the plasma 
and serum of cancer patients.  One example is presence of hypermethylated DNA in 
plasma from the APC gene, which may be a useful biomarker of aggressive disease 
in oesophageal adenocarcinoma patients (Kawakami et al, 2000).  Numerous studies 
have been undertaken in order to develop diagnostic tests based on the detection of 
cell-free tumour DNA in the circulation of cancer patients. 
 
The placenta has been well characterised as an invasive tissue (Fisher et al, 1989).  
Based on the hypothesis that the placenta has some cancer like properties Lo and 
colleagues began work on attempting to identify cell-free fetal DNA (cff DNA) in 
the circulation of pregnant women.  If cff DNA could be identified and isolated from 
maternal peripheral blood samples, it could potentially be used in diagnostic tests for 
NIPD of fetal aneuploidy. 
 
The first major breakthrough in NIPD came when cff DNA was detected in maternal 
plasma (Lo et al, 1997).  A PCR assay was developed for the detection of the “sex 
determining region Y” (SRY) gene, the product of which is the “testis determining 
factor” (TDF) which is responsible for male sex determination.  SRY is present on 
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the Y chromosome (Yp11.3).  Although SRY is a marker for cff DNA it can only be 
applied to male bearing pregnancies. 
 
 In a study of 30 pregnant women (all bearing a male fetus) plasma and serum from 
maternal peripheral blood collected were analysed by PCR assay of the SRY gene.  
Fetal (SRY) DNA was detected in 24/30 cases using maternal plasma as a source of 
cff DNA and in 21/30 cases using maternal serum as a source of cff DNA.  In the 
control group of 13 pregnancies in which the fetus was female and 10 non-pregnant 
women, serum and plasma samples were also assessed by SRY PCR assay; no SRY 
sequences were detected in these samples (Lo et al, 1997). 
 
1.5.1 Origin of cell-free fetal DNA in the maternal circulation 
 
In contrast to the traditional teaching that the placenta forms an impermeable barrier 
between the mother and fetus, many studies have shown that intact fetal cells 
circulate within the maternal blood.  There has been much speculation as to the 
tissue source of circulating cff DNA. Fetal cells circulating in the maternal 
circulation include: cytotrophoblasts (CTBs) which invade the maternal circulation, 
fetal lymphocytes, and fetal nucleated red blood cells (FNRBCs).  Another possible 
source is direct transfer of cff DNA from the amniotic fluid (Bianchi, 2004).   
 
Evidence suggests that the amount of cff DNA molecules present in the maternal 
circulation is up to 25 times greater than that which could be obtained from the DNA 
present in circulating fetal cells.  This indicates that circulating FNRBCs are not a 
major contributor to cff DNA in the maternal circulation (Lo et al, 1998 a). 
 
Cff DNA has also been detected in several other bodily fluids including: amniotic 
fluid, maternal urine, and maternal cerebrospinal fluid (Bianchi et al, 2001; Botezatu 
et al, 2000; Angert et al, 2004).  It is possible that the source of cff DNA circulating 
in the maternal circulation may originate from the fetus by leakage of the amniotic 
fluid; however conclusive studies have not been conducted to test this hypothesis so 
far.  The most likely source for the majority of cff DNA in the maternal circulation is 
the placenta (Bianchi 2004). 
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The definitive feto-placental circulation establishes approximately 28-30 days after 
conception.  By day 28 cff DNA is detectable in (80%) of all pregnancies.  The 
increase of cff DNA throughout gestation shows strong correlation with hCG levels 
in the maternal circulation (Ohashi et al, 2002; Sekizawa et al, 2001). 
 
These studies imply that the placenta is the major source of cff DNA in the maternal 
circulation; however they do not prove this conclusively.  In 2007 Alberry and 
colleagues demonstrated that the placenta is the major source of cff DNA in the 
maternal circulation, by testing the plasma of women undergoing anembryonic 
pregnancies (where an embryo fails to develop or terminates at an early stage of 
development).  In 5 anembryonic pregnancies cff DNA was detected using a DYS14 
gene PCR assay, the DYS14 gene is also present on the Y chromosome (Yp11.2) 
(Alberry et al, 2007). 
 
The amount of cff DNA detected was comparable to that of other normal 
pregnancies, indicating that the placenta is the major contributor of cff DNA in the 
maternal plasma (figure 1.11).  The range of cff DNA detectable in normal controls 
was 88.9-201.2 ge/ml and the range of detectable cff DNA in the anembryonic 
pregnancies was 80.1-770 ge/ml (Alberry et al, 2007). 
 
 
 
Figure 1.11:  Log distribution of cff DNA in anembryonic and normal 
pregnancies throughout gestation 
Cff DNA sequences from the DYS14 gene are detected in anembryonic pregnancies 
throughout “gestation” (□); at amounts which are comparable to that of regular 
pregnancies (●).  (Taken from Alberry et al, 2007). 
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One issue with the study is that the DYS14 assay was used to detect cff DNA; DYS14 
is a variable-multi copy gene, with copy numbers in males ranging from 
approximately 30-60 copies (Vodicka et al, 2007).  Therefore exact quantification of 
cff DNA cannot be compared between individuals; however the fact still remains 
that cff DNA was detected in anembryonic pregnancies; showing that the placenta 
does have a major role in the release of cff DNA into the maternal circulation. 
 
FNRBCs are also thought to contribute a small proportion of cff DNA and have been 
shown to undergo apoptosis in the maternal circulation.  FNRBCs have been shown 
to undergo apoptosis by (terminal UdTP nuclear end labelling (TUNEL).  TUNEL 
detects apoptotic cells by catalysing the binding of biotin labelled UdTP to nicks in 
double stranded DNA (Gavrieli et al, 1992).    In one study results showed 
approximately half of all FNRBCs were undergoing apoptosis (Sekizawa et al, 2000). 
 
1.5.2 Haematopoietic origin of cell-free maternal DNA 
 
Many studies have used markers such as SRY and DYS14, which are specific to male 
DNA.  This is because cff DNA in the maternal circulation is present in a high 
background of cell-free maternal DNA (cfm DNA).  If DNA can be released from 
fetal cells circulating in the maternal circulation, it is logical to assume that maternal 
circulating blood cells can also release DNA into the circulation.  Lo and colleagues 
developed a sex-mismatch bone marrow allotransplantation model; in order to 
identify the source of cell-free plasma DNA (cfp DNA) in otherwise healthy 
individuals (Lui et al, 2002). 
 
In the study blood was collected from male patients who had been the recipient of a 
bone marrow transplant from a female donor; and female patients who had been the 
recipient of a bone marrow transplant from a male donor.  Samples were collected 
from patients who had demonstrated engraftment of bone marrow by fluorescent in 
situ hybridization (FISH) analysis. Assay results for male DNA (SRY) and total DNA 
(β-GLOBIN) were used to calculate the percentage of cfp DNA which was male in 
origin.  Analysis of the percentage of SRY sequences detected was variable between 
the two patient groups.  Male recipients of bone marrow from female donors had a 
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much lower amount of detectable SRY DNA than female recipients who received 
bone marrow from a male donor.  This indicates that the higher levels of SRY DNA 
sequences detected in females were of haematopoietic origin (figure 1.12). 
 
The interpretation of that data is that the majority of cfp DNA is predominantly 
derived from cells originating from the haematopoietic lineage.  Although a small 
proportion of cfp DNA may originate from other tissues and organs, it has been 
determined that endothelial cells which line veins and arteries contribute very little if 
any cell-free DNA to the circulation (Jahr et al, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12:  Percentage of Y chromosome DNA present in the plasma of bone 
marrow transplantation patients 
The subject categories are shown on the x axis and the percentage of Y chromosome 
DNA in plasma is on the y axis.  SRY sequences originating from the Y chromosome 
are detected by real-time PCR.  The upper and lower horizontal bars denote 90th and 
10th percentiles respectively.  The upper and lower line in the boxes represent the 
75th and 25th percentiles and the line within each box represent the median.  Outliers 
are also shown (●).  (Taken from Lui et al, 2002). 
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1.5.3 Stability and size distribution of cell-free fetal DNA in the maternal 
circulation 
 
Cff DNA has been shown to be extremely stable when isolated from the maternal 
circulation. This may be due to association with sub-cellular particles after release 
from the cell by apoptosis (Sekizawa et al, 2000).  TUNEL staining has been used on 
FNRBCs to show that a proportion of FNRBCs are undergoing apoptosis. In one 
study by Sekizawa and colleagues 42.7% of FNRBCs were shown to be undergoing 
apoptosis compared to only 3.5% of maternal cells; whereas in another study the 
percentage of FNRBCs undergoing apoptosis was much higher at 95% (Kolialexi et 
al, 2004; Sekizawa et al, 2000). 
 
Due to the nature of these studies (collecting cells and assessing them in vitro) it is 
not possible to determine if the cells undergoing apoptosis would be doing so in vivo; 
as sample collection and procedures performed may unduly stress cells and cause 
them to undergo apoptosis.  What is also unknown is the rate at which cells in the 
circulation are undergoing apoptosis and if there are any external factors in the 
circulation which may affect this. 
 
The size distribution of cff DNA molecules when compared to that of cfm DNA 
molecules is relatively small; this suggests that fetal cells in the maternal circulation 
are undergoing apoptosis.  A number of studies have been conducted with the aim of 
detecting apoptosis in fetal cells (Gavrieli et al, 1992; Kolialexi et al, 2004; 
Sekizawa et al, 2000).  However, whilst detecting apoptosis of fetal cells; these 
studies overlooked their role in the production and release of fragmented fetal DNA. 
 
Later studies assessed the size of cff DNA molecules in the plasma of pregnant 
women (Chan et al, 2004; Chan et al, 2005 a; Koide et al, 2005; Li et al, 2004).  
Evidence has shown that cell-free DNA which is released from apoptotic cells is 
likely to be fragmented by nucleosomal cleavage (Giacona et al, 1998).  By 
separating plasma DNA from pregnant women by gel electrophoresis, it has been 
shown that cell-free DNA molecules are present in a wide range of sizes.  The study 
also showed that cff DNA is generally shorter than 300 bp in length (Li et al, 2004). 
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Another study by Chan and colleagues used a real-time PCR assay to amplify 
different sized amplicons of the SRY gene, to assess the size distribution of cff DNA.  
Each primer pair had the same forward primer and a different reverse primer to give 
an amplicon size distribution panel of 107 bp, 137 bp, 193 bp, 313 bp, 392 bp and 
524 bp.  These primers were used to amplify plasma DNA from pregnant women 
bearing a male fetus, and were compared to total cell-free DNA by a similar assay 
for the LEPTIN gene (7q31.3) (figure 1.13).  The data show that cff DNA is 
fragmented, and that the majority (< 99 %) of cff DNA molecules are smaller than 
313 bp in length (Chan et al, 2004). 
 
It is important to bear in mind the fact that cff DNA molecules are very small.  When 
developing primers for NIPD it is important to design primers which target small 
regions so as to maximize the potential for amplification of cff DNA fragments.  
Additionally it is important to note that cfm DNA molecules are on average much 
longer than cff DNA, with some overlap in size distribution.  This provides scope to 
use size separation techniques in order to enrich cff DNA for NIPD (Clausen et al, 
2007; Legler et al, 2007). 
 
1.5.3.1 Effects of sample collection and handling on cell-free fetal DNA levels  
 
Before samples can be analysed, they must first be collected and processed and in 
most cases stored before use.  One study has shown that the long-term storage of 
plasma DNA at -20 0C does not significantly degrade the DNA molecules when 
compared to plasma DNA that has only been stored for a month (Koide et al, 2005).  
Additional studies have also provided valuable information on the collection and 
storage of plasma DNA before use.  One study analysed a number of factors 
including: allowing blood to clot before plasma separation; the use of ethylene 
diamine tetra acetic acid (EDTA) in the storage of blood samples; the effect of repeat 
freeze-thawing of samples; and the effects of long term storage at -80 0C (Chan et al, 
2005 a). 
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Figure 1.13:  Fractional concentrations of fetal derived and maternal derived 
DNA in maternal plasma, as assessed by PCR of differently sized amplicons 
The numbers at the top of the plot (red) represent the amplicon sizes of the maternal 
fragments 105-798 bp, and underneath these values is the median fraction (red) 
represented by these amplicons 100-12 %.  The numbers the bottom of the plot (blue) 
represent the amplicon sizes of the maternal fragments 107-524 bp, and above these 
values is the median fraction (blue) represented by these amplicons 100-0 %.  The 
top middle and bottom lines on each bar represent the 75th, 50th, and 25th percentiles 
respectively; and the error bars represent the 95th and 5th percentiles.  (Taken from 
Chan et al, 2004). 
 
The results of the study offer insight into how samples should be collected and 
stored, for the maximum preservation of cff DNA whilst preventing maternal 
lymphocyte lysis.  Allowing blood to clot before the separation of the plasma 
fraction increases the amount of DNA in the samples; this is primarily due to the 
lysis of maternal lymphocytes and should be avoided in order to reduce the 
background of maternal DNA.  Storing plasma at -20 0C and thawing it once before 
use has little effect on the amount of cff DNA present in the sample, however repeat 
freeze-thaw cycles degrade DNA and cause further fragmentation.  Therefore, when 
DNA is extracted it should be aliquoted into separate tubes for individual usage.  The 
general consensus is that upon obtaining a blood sample, it should be stored in an 
EDTA tube at 4 0C and the plasma fraction should be separated no longer than 6 
hours after collection to minimise maternal cell lysis (Chan et al, 2005 a). 
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1.5.4 Kinetics of circulating cell-free fetal DNA 
 
Cff DNA is detectable in the maternal circulation only 5 weeks after conception.  To 
date a number of small studies have shown that transfer of cff DNA into the maternal 
circulation is a dynamic process and that cff DNA is cleared rapidly after delivery 
(Ariga et al, 2001; Birch et al, 2005; Guibert et al, 2003; Ingargiola et al, 2003; 
Smid et al, 2003).  The absolute amount of cff DNA and its ratio to cfm DNA 
increases throughout gestation (Ariga et al, 2001).  Cff DNA is also more readily 
detectable in the plasma fraction than the serum fraction, and is rapidly cleared post 
partum (Ariga et al, 2001). 
 
In strong agreement with the body of evidence in the literature, the increase in cff 
DNA throughout gestation has been shown to correlate with the increase of βhCG 
amounts, which is a product of the placenta.  Cff DNA is generally only detectable in 
the maternal circulation once the feto-maternal circulation is established (Guibert et 
al, 2003). 
 
Studies have also been undertaken to assess total cff DNA levels throughout 
gestation, one study assessed 246 male bearing pregnancies from time points ranging 
from 6-40 weeks.  The main aim of the study was to assess cff DNA (SRY) levels at 
each time point during gestation, to establish the feasibility of using cff DNA in 
NIPD (Galbiati et al, 2005).  Median values for cff DNA in the first trimester were 
found to be 9.1 diploid genome equivalents per ml ge/ml and in the second trimester 
16.6 ge/ml and in the third trimester 51.8 ge/ml.  Another study conducted by Birch 
and colleagues on a similar number of samples was found to agree with the findings 
of the Galbiati study, with the exception of slightly elevated cff DNA levels in the 
first and second trimesters (figure 1.14) (Birch et al, 2005). 
 
One issue with both studies is that they assess single time points in different 
pregnancies and do not follow single cases from early gestation to term.  This is 
likely to be due to the difficulty of regularly testing pregnant women and that 
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regularly collecting blood from pregnant women is unadvisable due the association 
of anaemia in some pregnancies.  
 
What both studies do show is that the amount of cff DNA increases throughout 
gestation, but cff DNA increases do not correlate exactly with gestational age, there 
is a small increase from the first trimester to the second and then a larger increase in 
the third trimester.  This may be due to placental breakdown in the third trimester 
before delivery (Birch et al, 2005).  Cff DNA levels also vary between individual 
pregnancies, with many pregnancies having much lower levels than the median 
levels detected. Cff DNA levels are expected to be the product of multivariate factors 
including: placental size, extravastion of cells and the rate of fetal cell apoptosis 
(Birch et al, 2005). 
 
In the study by Birch and colleagues, calibration curves were generated from 
commercially available human DNA (Promega, USA).  However, when generating 
calibration curves from genomic DNA, it is not shown that the DNA used was 
sonicated, and is used directly in the assessment of the plasma DNA samples.  Due 
to the fragmented nature of cfp DNA it is essential to fragment genomic samples, in 
order to more closely mimic the situation in plasma, to more accurately assess the 
amount of cfp DNA. 
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Figure 1.14:  Concentrations of cff DNA during gestation as determined by SRY 
assay 
Fetal genome copy number as extrapolated from SRY-PCR assay, increases 
throughout gestation, with a negligible increase from the first to second trimesters.  
The greatest increase is observed between the second and third trimesters.  The upper 
and lower limits of each box denote the 75th and 25th percentiles respectively and 
midline represents the median.  Median values are 15.89, 21.53 and 52.03 ge/ml at 
the first, second and third trimesters respectively.  The error bars represent the 10th 
and 90th percentiles.  Outliers (○) and extreme outliers (*) are also shown.  (Taken 
from Birch et al, 2005). 
 
1.5.4.1 Clearance of cell-free fetal DNA from the maternal circulation 
 
One aspect of cff DNA kinetics is that cff DNA is cleared rapidly after delivery.  Lo 
and colleagues demonstrated that the average half-life of cff DNA in the maternal 
circulation is 16.3 minutes in pregnancies delivered by caesarean section (Lo et al, 
1999 b).  They also demonstrated that cff DNA levels surge during delivery and are 
higher immediately after delivery than at any time point during the pregnancy, this is 
most likely due to placental breakdown and fetal cells being released into the 
maternal circulation (Lo et al, 1999 b).  Another study assessing cff DNA levels after 
conventional vaginal delivery also broadly agreed that cff DNA is cleared rapidly in 
most cases (Ingargiola et al, 2003).  However, both studies showed cases where cff 
DNA is not completely cleared 24 hours after delivery (figure 1.15) (Lo et al, 1999 b; 
Ingargiola et al, 2003). 
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Data from these studies indicate that the release of cff DNA into the maternal 
circulation is a dynamic process, requiring the continuous transfer of fetal DNA from 
the placenta in order to remain present throughout gestation.  One likely route of 
clearance is via the kidneys as cff DNA can be detected in urine (Botezatu et al, 
2000).  This means that cff DNA in the maternal circulation from one pregnancy 
does not persist for long periods after delivery, and therefore cannot be detected in 
subsequent pregnancies. 
 
The persistence of some fetal cells post partum is the only caveat by which cff DNA 
may be released into the maternal circulation outside of pregnancy, these cells are 
generally stable in the maternal circulation and can persist for a number of years 
(Bianchi et al, 1996; Guetta et al, 2003).  It is only upon sample collection and DNA 
extraction procedures that these cells may release cff DNA from a previous 
pregnancy.  This potential difficulty of detecting cff DNA from a previous 
pregnancy is overcome by the use of a specific protocol for sample collection and 
processing developed by Santacroce and colleagues, which completely prevents cff 
DNA from previous pregnancies from contaminating the sample from the current 
pregnancy (Santacroce et al, 2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15:  Log copies of cell-free DNA in the maternal plasma before and 
after delivery 
Log copies of cff DNA (SRY) and total DNA (GAPDH) per millilitre in maternal 
plasma.  Samples were collected before contraction, each hour during labour, 1 hour 
after delivery and 24 hours after delivery.  Most fetal (SRY) sequences are cleared 
post delivery.  (Taken from Inagargiola et al, 2003). 
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Blood collected is stored in EDTA tubes with formaldehyde to prevent any cell lysis 
from either maternal cells or cells from a previous pregnancy.  The blood is then 
centrifuged twice at 13,000 g to obtain plasma and the plasma is finally filtered (with 
a 0.22 µm pore filter).  This procedure stabilises any fetal cells present and removes 
them carefully to remove any potential for cff DNA from a previous pregnancy to be 
analysed (figure 1.16) (Santacroce et al, 2006).  Assessment of cff DNA was made 
by the detection of AMELOGENIN DNA marker which has a 6 bp difference in size 
between the X chromosome copy and the Y chromosome copy in the 3rd intron, with 
the X chromosome copy being 102 bp in length and the Y chromosome copy being 
108 bp in length, the presence of fetal DNA was measured in plasma DNA from 
women who had previously carried a male fetus but were not pregnant at the time of 
testing (figure 1.16) (Santacroce et al, 2006). 
 
One study stated that formaldehyde could be used for the stabilisation of maternal 
blood samples and greatly increases the amounts of cff DNA detected in each sample; 
these observations were attributed in part to the properties of formaldehyde, which 
caused two effects.  First, it was surmised that the cell membrane stabilising 
properties of formaldehyde prevented the lysis of circulating maternal blood cells, 
thus lowering the maternal background of cfm DNA. Second, formaldehyde’s 
nuclease inhibitory effect presumably helped preserve the cff DNA already present 
and prevented its loss by degradation (Dhallan et al, 2004).  Dhallan’s group claimed 
to be able to increase the proportion of cff DNA present from a maximum of about 
6% (Lo et al, 1998 a) to mean values of 20.2 and 25% from samples collected during 
various stages of gestation (Dhallan et al, 2004); another group supported these 
findings (Costa et al, 2004). However, several other groups followed this work in an 
attempt to reproduce the results, as this discovery would represent a major 
breakthrough for NIPD. One such study reported a moderate increase of cff DNA of 
between 1 and 3% (Chung et al, 2005); whilst other studies conducted by other 
researchers failed to reproduce the results reported by Dhallan’s group 
(Chinnapapagari et al, 2005). 
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Figure 1.16:  Reduction of fetal 
DNA contamination from previous 
pregnancy 
Panels A-C show the effect of various 
treatments on plasma samples from 
non-pregnant woem whom had 
previously carried a male fetus.  (A) 
Shows the amount of Y DNA 
contamination after gentle 
centrifugation at 3,000 g.  (B) Shows 
the amount of Y DNA contamination 
after double centrifugation at 13,000 g.  
(C) Shows the amount of Y DNA 
contamination after double 
centrifugation at high speed and 
filtration.  Only by double 
centrifugation of plasma samples at 
13,000 g followed by filtration can 
DNA from previous pregnancies be 
eliminated from current samples.  
(Taken from Santacroce et al, 2006).  
1.5.4.1.1 Clearance of methylated and unmethylated DNA 
 
One factor which may affect the clearance of cell-free plasma DNA is the role of the 
immune system in pregnancy, depending on whether cell-free plasma DNA is 
methylated or unmethylated there may be bias of clearance of specific sequences.  It 
is well documented that bacterial unmethylated CpG DNA acts as an antigen which 
drives the humoral TH1 immune response (Agren et al., 2006; Yoshikawa et al., 
2006). It is therefore possible that unmethylated CpG DNA originating from 
maternal leukocytes or placental tissue may also elicit a response.  In the case of 
systemic lupus erythematosus (SLE) it has been shown that a lack of methylation in 
peripheral blood mononucleocytes causes an autoimmune response as the 
unmethylated CpG DNA mimics the antigenic properties of bacterial CpG DNA 
(Januchowski et al., 2004).  It has also been suggested that methylated CpG DNA 
may be preferentially present in the circulation, due to the re-modelling of chromatin 
in nucleosomal DNA, perhaps biasing the levels of cff DNA present in the maternal 
circulation (Herman et al., 2004).  The situation regarding the immune response to 
cell-free DNA during gestation is unclear, and requires further study (Puszyk et al, 
2008 ). 
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1.5.4.2 Cell-free fetal DNA kinetics and diagnostic testing 
 
The kinetics of cff DNA transfer into the maternal circulation is an important factor 
in the development of assays for NIPD, it is crucial to take into account the low 
levels of cff DNA obtained from maternal plasma; at the lower end of the scale the 
amplification of low copy number of cff DNA molecules may cause stochastic 
effects similar to that of allelic drop-out, which is the failure of an allele in a sample 
to amplify during PCR. 
 
A careful study by Old and Stallard analysed the sampling errors inherent with the 
low copy numbers of cff DNA.  By tabulating the expected numbers of cff DNA 
molecules from a standard 3ml sample of blood and accounting for standard errors, 
the minimum sample size for accurate NIPD was calculated.  The two main methods 
of cff DNA detection were also compared and the minimum sample requirement for 
each test was calculated (Old and Stallard, accepted for publication). 
 
The simplest method of detecting an aneuploidy is to measure the relative amount of 
the target chromosome by selecting a region located on the chromosome and 
amplifying it by real time PCR assay, and comparing the product with that of another 
region on another chromosome.  For example a Chromosome 21 specific PCR 
product could be compared to a Chromosome 1 PCR product, this method is termed 
relative chromosome dosage (RCD).  In a normal pregnancy the RCD is 2:2, 
however in a trisomy pregnancy the RCD is 3:2 (Chim et al, 2005; Chan et al, 2006; 
Old et al, 2007; Old and Stallard, accepted for publication). 
 
The alternative method of detecting Chromosome 21 trisomy is to utilise single 
nucleotide polymorphisms (SNPs), which are single base sequence changes which 
may or may not differ depending on whether the allele is maternal in origin or 
paternal in origin.  In a normal pregnancy the allelic ratio (AR) of SNPs is expected 
to be 1:1 in a normal pregnancy, however in a trisomic pregnancy the ratio would be 
2:1 or 0.5:1 (see section 1.4.2).  This is the allelic ratio method. (Tong et al, 2006; 
Old and Stallard, accepted for publication).  
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Both techniques are capable of being applied in a single tube test on the same sample, 
thereby reducing the error rates associated with product detection in real time PCR 
platforms, which may be as much as 0.6 cycle thresholds (Ct) (BIORAD, USA). 
 
The low numbers of cff DNA molecules present, pose a difficult technical challenge, 
one that can only be overcome by the development of a panel of markers for cff 
DNA (table 1.1).  Using the data from table 1.1, the volume of blood required for 
each test is calculated for different confidence intervals.  Setting a relatively high 
standard for a diagnostic test, with a false positive rate of 0.01% and a false negative 
rate of 0.01%, the number of cff DNA genome equivalents (ge) required for the AR 
test is 72, and the number of cff DNA molecules for an RCD test is 216. 
 
Assuming that there is a mean number of molecules present of 16.36 ge/ml (Birch et 
al, 2005) and that each (ge) genome equivalent contains 2 DNA molecules, the 
volume of blood required for the RCD test is calculated to be 216/(16.36 x 2)= 
6.6mls.  In the AR test the number of DNA molecules for each allele is counted 
separately, the volume of blood required for the AR test is calculated to be 
72/16.36= 4.4 mls (Old and Stallard, accepted for publication).   
 
One potential solution to the problem posed by sampling error caused by low cff 
DNA copy number is to use multiple biomarkers in an assay.  By assaying marker 
using multiplex techniques, each biomarker is independent and subject to sampling 
error. However, independent biomarker quantifications can be combined to give a 
better estimate of RCD or AR.  (Old and Stallard, accepted for publication). 
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Table 1.1:  Number of fetal DNA molecules required for non-invasive prenatal 
diagnostic tests 
Numbers of cff DNA molecules required to be assayed for the indicated false 
positive and false negative rates, for both tests are given.  The number for the allelic 
ratio test equates to copy numbers required, whereas the numbers for the relative 
chromosome dosage test (in parenthesis) equate to the number of cff DNA molecules 
required. 
 
1.5.5 Non-invasive prenatal diagnosis of paternally inherited genetic 
disorders 
 
NIPD using cff DNA is already offered in some countries for specific genetic 
conditions.  In most cases these are conditions where paternally inherited DNA 
sequences which are not present in the maternal genome can be used as fetal specific 
DNA markers, some examples follow. 
 
Fetal sexing can be used to assess risk for certain sex-linked genetic disorders.  
Haemophilia is an X chromosome linked genetic disease where males are affected 
with defective blood clotting factors and females are carriers of the disease. 
False 
positive 
rate 
 
Number of DNA molecules required for AR (and RCD) 
method 
 False 
negative 
rate  =  
0.05 
False 
negative 
rate  =  
0.025 
False 
negative 
rate  =  
0.01 
False 
negative 
rate  =  
0.005 
False 
negative 
rate  =  
0.001 
0.05 39 (108) 46 (130) 55 (158) 62 (178) 77 (224) 
0.025 45 (130) 53 (153) 63 (184) 70 (206) 85 (255) 
0.01 53 (158) 62 (184) 72 (216) 80 (240) 96 (293) 
0.005 59 (178)  68 (206)  79 (240) 87 (266) 104 (321) 
0.001 73 (224) 83 (255) 95 (293) 103 (321) 122 (382) 
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In a small study fetal sexing was offered to women who were carriers of haemophilia, 
using an SRY PCR assay; successful fetal sexing by the detection or absence of SRY 
sequences was 100%. This means that in the case of haemophilia diagnosis, non-
invasive fetal sexing can be offered in the first instance, instead of invasive tests 
such as amniocentesis or CVS (Santacroce et al, 2006). 
 
As part of routine prenatal care, NIPD for the Rhesus D blood group is offered in the 
U.K, France and the Netherlands (Lo et al, 1998, Sekizawa et al, 2007).  This test 
provides the basis for administration of anti-D immunoglobulin as prophylaxis in 
pregnancies where the fetus is confirmed as RHD+ and the mother is RHD- 
(Sekizawa et al, 2007).  The detection of RHD+ sequences can be used to predict 
fetal RHD status either by conventional or by real-time PCR.  This is important for 
the prevention of fetal haemolytic disease, where an RHD- mother becomes 
sensitised to an RHD+ fetus, which initiates a maternal immune response to produce 
IgG anti-D antibodies, which can cross the placenta and destroy fetal blood cells, 
giving rise to fetal anaemia and jaundice (Van der Schoot et al, 2006). 
 
In the Caucasian population the RHD- phenotype is caused by a deletion of the RHD 
gene, whereas in over 80 % of the African population the phenotype is caused by a 
non-functional copy of the RHD gene, RHD ψ the RHD pseudogene.  Using a PCR 
assay for exons 4, 5 and 6 it is possible to distinguish RHD- from RHD ψ, which 
enables detection of all RHD- cases with 100 % accuracy and provides the basis of 
the non-invasive test for RHD (Finning et al, 2002).  A non-invasive test has also 
been developed for β-Thalassemia major, the test is based on a PCR assay designed 
to detect a paternally inherited –CTTT deletion in the gene which is the most 
common mutational cause of β-Thalassemia (Chiu et al, 2002 b). 
 
Adrenal congenital hyperplasia is detectable by assay of intragenic polymorphic 
markers in intron 2 of the CYP21 gene.  Used alongside the analysis of extragenic 
minisatellite sequences, successful detection of normal paternal sequences excludes 
healthy female fetuses, and allows the administration of the therapeutic drug 
dexamethasone, which reduces or prevents virilisation of affected females fetuses in 
utero, preventing the development of external genitalia (Chiu et al, 2002 a; Rjinders 
et al, 2001). 
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Myotonic dystrophy is an autosomal dominant disorder, associated with the unstable 
expansion of a CTG trinucleotide repeat in the 3’ untranslated region of the DM 
KINASE gene.  Affected individuals are heterozygous for the expanded allele.  
Myotonic dystrophy is characterised by the wasting of muscles (muscular dystrophy), 
heart defects, endocrine defects and difficulty in relaxing muscle (myotonia).  Most 
notably, the highly variable age of onset decreases with successive generations 
(Amicucci et al, 2000). 
 
The current scope of non-invasive prenatal diagnosis is so far limited to the detection 
of paternally inherited DNA sequences, which are not present in the maternal 
genome, for these limitations to be overcome the development of fetal-sex and 
paternal-mutation independent  cff DNA specific biomarkers is required.  Universal 
fetal-specific DNA markers would be of great benefit, in the diagnostic tests 
mentioned above, as they could be exploited as controls for the verification of the 
presence and quantity of cff DNA. 
1.6 Discovery of putative fetal-specific epigenetic markers for use in 
non-invasive prenatal diagnosis 
 
In 2005 Lo and colleagues hypothesised that it may be possible to detect cff DNA in 
the maternal circulation, by detecting epigenetic differences between fetal and 
maternal peripheral blood leukocyte DNA.  Epigenetic differences are those 
differences that result in a change of phenotype without a change in DNA sequence 
(see pages 49 -52).  They developed a novel model system, using placenta DNA and 
maternal blood DNA in order to measure epigenetic differences between the two 
tissues (Chim et al, 2005). 
 
Applying bisulfite conversion of DNA to detect the methylation status of the 
MASPIN gene promoter (18q21.3), differential methylation was detected between 
placental DNA and maternal leukocyte DNA.  MASPIN was proposed to be the first 
epigenetic biomarker of cff DNA.  DNA with the placenta methylation signature was 
detected in the plasma of pregnant women (Chim et al, 2005). 
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Hypomethylated MASPIN or (U MASPIN) is the first potential epigenetic biomarker 
of cff DNA, levels of U MASPIN increase throughout gestation and U MASPIN is 
cleared rapidly after delivery (figure 1.17). 
 
The development of a novel model system for the discovery of epigenetic 
biomarkers appeared to be an important breakthrough in NIPD.  This potentially 
provided a much needed method for the identification of epigenetic fetal biomarkers, 
which could be used for the detection of aneuploidies (Chim et al, 2005). 
 
An additional putative epigenetic biomarker was discovered in 2006, using the same 
model system and by detecting DNA with placental methylation signature a novel 
marker on the RASSF1A gene promoter (3p21.3) (Chan et al, 2006).  The RASSF1A 
biomarker is the opposite of the MASPIN biomarker, in that it is methylated in 
placenta DNA and unmethylated in maternal leukocyte DNA.  Markers whereby the 
fetal DNA is methylated are most useful as this allows the removal of the 
hypomethylated maternal DNA by methylation-sensitive restriction assay, leaving 
hypermethylated fetal RASSF1A undamaged (Chan et al, 2006).   
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Figure 1.17:  U-MASPIN concentrations throughout gestation and clearance 
after delivery 
(A) The box plots of U-MASPIN concentrations in the first, second and third 
trimesters are shown in copies/ml of maternal plasma.  U-MASPIN increases 
throughout gestation.  The line within each box denotes the median, the limits of 
each box denote the 75th and 25th percentiles and error bars denote the 90th and 10th 
percentiles. Outliers are also shown (●).  (B)  Plots show levels of U-MASPIN in 
copies per ml of maternal plasma, before delivery and 24 hours after delivery in 
paired samples.  U-MASPIN is cleared rapidly after delivery.  (Taken from Chim et 
al, 2005). 
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The assessment of RASSF1A in the maternal circulation involves the digestion of 
plasma DNA by the methylation–sensitive restriction enzyme BstU I (Tsui et al, 
2007).  RASSF1A levels increase throughout gestation and are not detectable in non-
pregnant women (figure 1.18) additionally RASSF1A sequences are cleared post 
delivery (Chan et al, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18:  RASSF1A concentrations in maternal plasma during pregnancy 
The whiskers represent the 90th and 10th percentiles and the upper, middle and lower 
box limits represent the 75th, 50th and 35th percentiles respectively.  The Y axis 
shows copy numbers on a logarithmic scale.  (Taken from Chan et al, 2006). 
 
1.7 Epigenetics 
 
Epigenetics is the term which refers to the changes in gene expression that are stable 
between cell divisions and sometimes between generations that do not involve 
changes in the underlying DNA sequence of the organism (Bird, 2007).  In a broader 
context epigenetics is the term given to all of the processes and events occur around 
the genome, but do not alter the DNA sequences, even where stable inheritance has 
not been demonstrated (Ptashne, 2007).  Epigenetic mechanisms include DNA 
methylation, histone methylation, histone deacetylation, and chromatin remodelling. 
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1.7.1 DNA methyltransferases methylate DNA  
 
DNA methylation in mammalian cells occurs at the 5’ position of Cytosine 
nucleotides which are followed by a Guanine in a CpG dinucleotide (p denotes the 
phosphate backbone, indicating that the nucleotides are on the same linear DNA 
strand rather than in a complementary pair).  Approximately 70% of all CpGs are 
methylated and although CpG sequences are under-represented in the genome they 
can be found in relative abundance in the promoter region and first exon of genes in 
regions termed CpG Islands (CGIs) (Robertson and Wolffe, 2000). 
 
5-methylCytosine does not exist in the cellular environment as a free nucleotide; in 
normal somatic cells the addition of a methyl group to Cytosine occurs after DNA 
replication and is catalysed by DNA methyltransferase (DNMT)(Bestor, 2000; Dahl 
and Guldberg 2003).  DNMTs are proteins which catalyse the addition of methyl 
groups to Cytosine nucleotides in CpG dinucleotides (figure 1.19) (Chen et al, 2005).  
 
There are two types of DNA methyltransferases: de novo methyltransferases and 
maintenance methyltransferases, the de novo methyltransferases DNMT3a and 
DNMT3b are responsible for methylating previously unmethylated cytosines, and 
the maintenance DNA methyltransferase DNMT1 copies pre-existing patterns onto 
new DNA strands during DNA replication (Klose and Bird, 2006).  Another DNA 
methyltransferase has been identified, DNMT2 shows weak DNA methyltransferase 
activity, and its deletion from embryonic stem cells causes little detectable effect on 
DNA methylation (Hermann et al, 2003). 
 
Figure 1.19:  Schematic of Cytosine and 5-MethylCytosine 
The structure of Cytosine (left) and 5-MethylCytosine (right) are shown.  The methyl 
group is added to the 5 carbon on the ring structures of the Cytosine molecule.  
(Taken from Shiraishi et al, 2002). 
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An additional protein has also been included in the DNA methyltransferase family, 
DNMT3L (DNA methyltransferase like protein), on the basis that this protein has a 
highly conserved N-terminal PHD-like zinc finger domain with corresponding 
domains on DNMT3a and DNMT3b  (Chen et al, 2005). 
 
1.7.2 Role of DNA methylation in transcriptional silencing 
 
DNA methylation produces a reversible protrusion from the major groove of DNA 
and is capable of altering local recognition signals (i.e. transcription factors) in the 
same way as it can block the action of methylation-sensitive restriction enzymes 
(preventing cleavage site recognition) (Eden and Cedar, 1994). 
 
Most methylated CpGs are found within parasitic DNA elements in the human 
genome, as well as retrotransposons such as endogenous retroviruses, L1 elements 
and ALU elements. Parasitic DNA elements represent a significant threat to the 
structural integrity of the genome because they can mediate recombination between 
non-allelic repeats, which can cause chromosome rearrangements or translocations. 
Also active retrotransposons can integrate into and disrupt genes (Montagna et al, 
1999; Kazazian, 1998; Robertson and Wolffe 2000).  Local Cytosine methylation 
can interfere with transcription factor binding, and can also interfere with 
transcription when the first exon is methylated preventing the action of DNA 
polymerase (Robertson and Wolffe 2000), it is thought that this occurs in the same 
way as methylation-sensitive enzymes are blocked (Eden and Cedar, 1994).  
Methylated Cytosine can also recruit methyl-binding proteins (MBPs) which also 
function to repress transcription.  MBPs contain a methyl-binding domain (MBD) 
which functions to recognise the methyl group on the Cytosine residue, Methyl-CpG 
binding domain protein 2 (MeCP2) was the first MBP characterised; it contains 2 
structural domains, an MBD and a transcriptional repressor domain (TRD) (Nan et al, 
1997). 
 
In addition to MeCP2 there are other methyl-binding domain family members, 
proteins included in this family are: KAISO, MBD1, MBD2 and MBD3.  How these 
proteins repress transcription is not fully understood, however it has been shown that 
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MBPs can bind repressors and histone deacetylases, which leads to a change in 
chromatin conformation to a condensed inactive state (Miranda and Jones, 2007).  
One theory is that DNA methylation causes the recruitment of MBPs which in-turn 
interact with histone deacetylases to form histone deacetylation complexes (HDACs), 
which is followed by the conformational change of chromatin to heterochromatin 
and the methylation of histone proteins (figure 1.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20:  Links between DNA methylation, histone modification and 
chromatin remodelling 
(A) A model of DNA methylation directing histone methylation.  DNA methylation 
patterns are established through de novo methylation by DNA methyltransferases 
DNMT3a and DNMT3b and are maintained by DNMT1.  Methyl binding proteins 
(MBPs) and histone deacetylase complexes (HDACs) are then recruited to the 
methylated CpG DNA in order to induce histone deacetylation and silencing.  (B) A 
model of histone methylation directing DNA methylation.  Methylated histone H3K9 
acts as a signal for the inactive state chromatin, by recruiting histone protein 1 to 
methylated histones, which may in turn recruit DNA methyltransferases directly or 
indirectly, in order to stabilise inactive chromatin.  (C) A model for chromatin 
remodelling driving DNA methylation.  The ATP-dependent chromatin –
remodelling and DNA helicase activities of proteins such as ATRX and Lsh, might 
facilitate DNA methylation and histone modification by unwinding nucleosomal 
DNA to increase its accessibility to DNMTs, HDACs and histone methyltransferases 
(HMTs).  (Taken from Li, 2002). 
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1.7.3 Role of DNA methylation in embryonic development and 
imprinting of gametes 
 
During female embryogenesis one of the X chromosomes is randomly chosen to be 
inactivated in each cell, leading to transcriptional silencing of thousands of genes on 
the X chromosome (Clerc and Avner, 1998).  The X inactivation process converts 
one of the X chromosomes from the active euchromatin form to the transcriptionally 
silent heterochromatin form (Avner and Heard, 2001). DNA methylation is involved 
in this inactivation.   
 
DNA methyltransferases are essential for de novo methylation of DNA during 
development.  In mice the fertilised egg undergoes a wave of demethylation during 
pre-implantation development, which erases part of the inherited parental 
methylation pattern.  After implantation the embryo undergoes a wave of de novo 
methylation, which establishes a new embryonic methylation pattern (Okano et al, 
1999).  The biological function of this de novo methylation is unknown; however it 
is essential for successful development. 
 
Demethylation accompanied by de novo methylation occurs in gametogenesis, this is 
mediated by the DNA methyltransferases DNMT3a and DNMT3b, this process is 
essential for the establishment of parental imprinting of gametes before fertilisation  
(Tremblay et al, 1995).  Genomic imprinting is a form of epigenetic gene regulation, 
which determines parent-of-origin-specific gene expression during embryonic 
development.  The oocyte and sperm cell each contribute the same DNA to form a 
zygote; however, epigenetic imprinting of specific genes ensures that only 1 copy of 
the parent’s alleles is expressed.  Epigenetic paternalisation occurs in mitotically 
dividing spermatogonial stem cells and in meiotically dividing spermatocyte progeny, 
in order to endow sperm with imprinted alleles.  Epigenetic maternalisation is 
restricted to the oocyte growth phase of folliculogenesis and takes place not during 
DNA replication, but during dictyate arrest in meiosis I (Kierszenbaum, 2002).  
 
Inactivation of DNMT3a and DNMT3b disrupts de novo methylation.  In one study 
mouse embryonic stem cells (ES cells) were raised to determine the function of de 
novo methylation, and whether or not the function of either protein overlaps.  
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DNMT3a +/- and DNMT3b +/- mice were grossly normal, however DNMT3a -/- 
mice died after 4 weeks of birth and DNMT3b -/- embryos did not survive to term.  
DNA methylation was measured by the methylation of endogenous retroviral DNA, 
it was also found that DNA was methylated to normal levels in DNMT3a -/- mice 
and slightly under-methylated in DNMT3b -/- mice. However, mice with both 
DNMT3a -/- and DNMT3b -/- embryos were highly under-methylated (Okano et al, 
1999).  In addition to the overlapping functions of DNMT3a and DNMT3b it was 
found that DNMT3b is required for the methylation of centromeric minor satellite 
DNA, which consists of tandem repeats of copy numbers between 50,000 and 
100,000 (Okano et al, 1999).  These data show that knock out of one copy of either 
or both genes does not have a deleterious effect on development, indicating an 
overlapping in the function of these proteins; however, if both copies of either gene 
are deleted normal development does not occur. 
 
DNMT1 is the maintenance methyltransferase, the function of which is coupled to 
DNA replication.  DNMT1 methylates hemimethylated DNA after DNA replication 
and, the knock out of the DNMT1 gene leads to global demethylation and embryonic 
lethality after a few rounds of replication (Howell et al, 2001; Li et al, 1992; Okano 
et al, 1999). 
 
Differences in the methylation profiles of placenta and peripheral blood leukocyte 
tissues, due to the action of DNA methyltransferases are expected to form the basis 
of epigenetic markers by which cell-free fetal DNA can be isolated from the 
background of maternal DNA in the circulation. 
1.7.4 Epigenetic study of DNA methylation 
 
Methylation of DNA can modify gene expression by silencing transcription without 
changing the function or primary nucleotide sequence of a gene (Dahl and Guldberg, 
2003).  During the process of DNA methylation, methyl groups added to the 
Cytosine residues provide a chemical marker by which identical DNA sequences can 
be distinguished. 
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1.7.4.1   Genomic methylation mapping by methylated DNA 
immunoprecipitation 
 
Monoclonal antibodies raised against 5-methylCytosine provide a powerful tool for 
the enrichment of methylated DNA sequences (Dahl and Guldberg, 2003).  
Methylated DNA immunoprecipitation (MeDIP) was developed as a tool for 
genomic methylation analysis as it does not require specific sites such as those 
required for methylation-sensitive restriction assays and is not as laborious as 
bisulfite sequencing (Weber et al, 2005). 
 
This approach for the immunocapturing of fragmented methylated DNA is capable 
of providing up-to a 90 fold enrichment of methylated DNA depending on the 
proportion of methylated CpGs in the sequence (figure 1.21).  The use of MeDIP in 
combination with comparative genomic hybridisation (CGH) or DNA microarrays, 
can provide ‘methylation maps’ of whole chromosomes, showing regions where 
methylated DNA is over-represented and regions where methylated DNA is under-
represented (Wilson et al, 2006). 
 
Before immunoprecipitation can be performed, DNA must be fragmented to 
approximately 200-300 bp in length. Oligonucleotides on microarray platforms are 
between 60 -70 bp in length, this means that any methylated CpGs detected on an 
array may be up-to 200 bp upstream or downstream from the position of the 
oligonucleotide signal.  The inaccuracy of detection by the array means that higher 
resolution techniques such as methylation-sensitive restriction enzyme (MSRE) 
analysis or bisulfite sequencing are required to determine the exact sequence location 
of any methylated CpGs. 
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Figure 1.21:  Methylated DNA enrichment by MeDIP 
(A) Denatured genomic DNA is hybridised with the anti-5-methylCytosine antibody 
(α-5mC) and methylated DNA is isolated by immunoprecipitation.  (B) Correlation 
between enrichment and the number of methylated Cytosines on four DNA 
sequences, created by the restriction of ALU repeat DNA sequences.  Enrichment 
increases linearly with the increasing number of methylated Cytosines.  (Taken from 
Weber et al, 2005). 
 
A 
B 
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1.7.4.2 DNA methylation profiling by (MSRE) analysis 
 
MSRE analysis is the simplest method of DNA methylation analysis; this is achieved 
by use of MSREs to cleave at specific restriction sites, which contain CpG 
dinucleotides.  The most commonly used MSRE is Hpa II, which has the restriction 
site CCGG, and does not cleave at its restriction site where the internal Cytosine is 
methylated.  MSRE digestion of DNA can be coupled with either conventional or 
real-time PCR to detect the methylation of specific CpG sites (figure 1.22). 
 
A comprehensive study of allelic methylation was carried out by Yamada and 
colleagues, they assessed 149 CGIs on Chromosome 21, containing the Hpa II 
restriction site and measured the methylation status of peripheral blood cell DNA 
(Yamada et al, 2004).  The study showed that it is possible to use a methylation-
sensitive restriction enzyme to detect differentially methylated sequences, and to that 
the technique is adaptable for high through put analysis. 
 
One limitation of MSRE analysis is that the CpG in question must lie within a 
restriction enzyme site and in the case of Hpa II this is only the applicable to 3.9% of 
CpGs on non-repetitive sequences in the human genome (Weber et al, 2005).  
Another limitation is that MSRE analysis can only be used to identify completely 
methylated or completely unmethylated DNA sequences, and any incompletely 
methylated sequences cannot be assessed accurately. 
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Figure 1.22:  Methylation-sensitive restriction endonuclease analysis of DNA 
Shows the methylation-sensitive restriction enzyme Hpa II and its cleavage site 
CCGG.  In the presence of an unmethylated Cytosine Hpa II cleaves its restriction 
site.  However, in the presence of a 5-MethylCytosine Hpa II does not cleave its 
restriction site.  Following PCR of methylated and unmethylated DNA fragments 
only methylated DNA fragments will produce a product  
 
1.7.4.3 Bisulfite conversion of DNA and associated techniques  
 
There are a number of techniques which rely on the chemical modification of DNA 
in order to detect methylation.  The Sss I acceptance assay was one of the first 
techniques developed for the measurement of methylated DNA.  Sss I DNA 
methyltransferase is an orphan DNA methyltransferase, which recognises any CpG 
and uses S-adenosylmethionine (SAM) as a methyl donor in CpG methylation.  
Using tritium labelled SAM the number of unmethylated CpGs can be directly 
assessed by scintillation measurement of the pooled sample of DNA.  However this 
technique does not provide an accurate measurement of individual CpGs (Wu et al, 
1993). 
 
-C-C-G-G-
-G-G-C-C-
Hpa II cuts  only if  
central Cytosine is 
unmethylated
Methylated siteUnmethylated site
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The Sss I acceptance assay was followed by the development of chloroacetaldehyde 
assay, which was an assay for genome wide methylation, which relied on the 
detection of the intensely fluorescent ethenocytosine derivative of 5-methylCytosine, 
after bisulfite conversion of DNA.  Methylation was quantified by fluorimeter 
readings.  However, the chloroacetaldehyde assay, still lacked the sensitivity to 
assess individual CpGs (Dahl and Guldberg, 2003). 
 
These methods have been superseded by bisulfite conversion of DNA.  Treatment of 
genomic DNA with sodium bisulfite effectively deaminates unmethylated Cytosine 
residues to Uracil under specific conditions, where 5-methylCytosines are 
deaminated at a very slow rate (Frommer et al, 1992).  Bisulfite converted DNA 
differs from genomic DNA, as unmethylated Cytosine is converted to Uracil, 
whereas methylated Cytosines are retained; this causes the 2 strands of bisulfite 
DNA to be non-complementary. 
 
The bisulfite conversion of DNA is based on the deamination of Cytosine to Uracil.  
Genomic DNA is prepared by sonication, shearing, or digestion with restriction 
enzymes.  The DNA is then denatured with sodium hydroxide and treated with a 
concentrated solution of sodium bisulfite at pH 5.  The DNA is then desalted and 
desulfonated with sodium hydroxide, before being neutralised, desalted, and finally 
dissolved in water for use (figure 1.23) (Grunau et al, 2001). 
 
Bisulfite converted DNA can then be amplified by bisulfite-specific PCR primers for 
(BS-PCR); or by methylation or unmethylation-specific PCR (MS-PCR or US-PCR).  
Bisulfite-specific primers (BSPs) hybridise with bisulfite converted DNA, the 
primers do not include CpG sites, and the assumption is made that single Cytosines 
are transformed to Uracil and incorporated as Thymine during PCR (Li and Dahiya 
2002). 
 
Methylation specific primers (MSPs) hybridise with methylated bisulfite converted 
DNA; primers include CpG sites which are assumed to retain their Cytosines.  
Unmethylation-specific primers (USPs) hybridise with unmethylated bisulfite 
converted DNA (i.e. the transformed DNA); primers include CpG sites in which the 
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Cytosines are assumed converted to Thymine.  This is because after PCR with Taq 
DNA polymerase Uracil is incorporated into the PCR product as Thymine. 
 
 
 
 
 
 
Figure 1.23:  Sodium bisulfite conversion of Cytosine to Uracil 
Treatment of Cytosine (1) with sodium bisulfite under acidic conditions (pH 5) 
yields 5,6-dihydroCytosine-6-sulfonate (12).  This product is susceptible to 
hydrolytic deamination at C4 and is easily converted to 5,6-dihydroUracil-6-
sulfonate (13).  After desulfonation by treatment with NaOH, the final product is 
Uracil (14).  (Taken from Shiraishi et al, 2002). 
 
Bisulfite conversion can be combined with a number of techniques in order to 
effectively assess DNA methylation.  Techniques include bisulfite sequencing, 
combined bisulfite restriction analysis (COBRA) and melt curve analysis.  COBRA 
relies on the detection of a fluorescent tag on one of the primers after bisulfite-
specific PCR (BS-PCR); restriction of the BS-PCR product allows the detection of 
different fragments from that product which indicate its methylation profile.  One of 
the most comprehensive studies on DNA methylation profiling was undertaken at the 
end of 2006.  Using bisulfite sequencing of genomic DNA, high resolution 
methylation profiles were obtained for 12 different tissue types including: leukocyte 
subsets CD4+ and CD8+ and placenta on chromosomes 6, 20 and 22.  This was one 
of the first major attempts to assess DNA methylation at the genomic level.  In total 
2524 amplicons on 873 genes were analysed on chromosomes 6, 20, and 22; 
including 5’ untranslated regions, intronic regions, exonic regions and transcription 
factor binding sites (Eckhardt et al, 2006).   
 
Approximately 27% of loci were hypomethylated (<20% methylation), and 42% of 
loci were hypermethylated (>80% methylation), with 30% of CpGs methylated in a 
heterogeneous pattern (20-80% methylation).  This study is an important landmark, 
showing that bisulfite sequencing can be used to produce high throughput 
methylation profiles of genomic regions at the resolution of single nucleotides.  The 
data generated from this study is an important resource, which in the context of 
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NIPD could be used to provide targets for candidate biomarkers (Eckhardt et al, 
2006).  
 
Restriction enzyme digestion can be used to reveal DNA methylation dependent 
sequence differences in bisulfite-specific PCR products.  This procedure is termed 
COBRA and can be used to analyse the fractions of methylated and unmethylated 
DNA from a BS-PCR product (Xiong and Laird, 1997).  The sequence conversion of 
a C → T can lead to creation of a new restriction site, as well as the retention of the 
Cytosine can lead to the retention of a restriction site.  In a mixed sample of 
methylated and unmethylated DNA molecules, the methylated and unmethylated 
fraction can be determined by COBRA, to give a direct measurement of the 
percentage of each fraction, by the detection of a fluorescent tag in the primer of 
each product by a genetic analyser (Xiong and Laird, 1997).   
 
Another technique termed melt curve analysis (MCA) can be performed after BS-
PCR.  The PCR product can be melted over a temperature gradient in order to assess 
the level of DNA methylation.  Because G:C base pairs between complementary 
DNA strands contain 3 hydrogen bonds and A:T base pairs have 2 hydrogen bonds, 
DNA sequences with a higher G:C content have a higher melting temperature 
(denaturing temperature) Tm than sequences with a higher A:T ratio.  Thus BS-PCR 
is followed by temperature gradient melting of DNA.  Methylated sequences have a 
higher Tm than unmethylated sequences as they retain their G:C content (Guldberg 
et al, 2002).  Most real-time PCR machines such as the BIORAD I-cycler carry out 
post-amplification melt profile analysis as standard. 
 
In review MeDIP is a useful technique when combined with CGH or microarray 
analysis, it can provide methylation patterns for entire chromosomes in a single 
experiment, which can be used to target regions of interest. MSRE analysis is a 
simple technique, which is amenable to high throughput of techniques such as 96 
well PCR and can also be used to provide information on methylation at the level of 
a single CpG.  Bisulfite conversion is a laborious technique, as is not easily 
amenable to high through put analysis; however, its use in high throughput methods 
can yield high resolution information on selected regions of the genome. 
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1.8 Summary of current biomarker discovery for NIPD 
 
1.8.1 Recent developments in cell-free DNA markers for non-invasive 
prenatal diagnosis 
 
Putative epigenetic markers for cff DNA have been discovered on chromosomes 18, 
3 and 21, using the model system first proposed by Chim and colleagues in 2005 
(Chim et al, 2005; Chan et al, 2006 and Chim et al, 2008).  On the basis of the early 
discovery of the MASPIN marker, and by use of the model system I discovered 
several novel candidate epigenetic biomarkers on Chromosome 21 (Old et al, 2007).  
However it is unlikely that any of the cff DNA markers discovered so far either by 
the Lo group or by my own research could form part of a non-invasive diagnostic 
test. 
 
So far I have discovered that after testing CEBs on plasma DNA from pregnant 
women (Old et al, 2007), the methylation signature of placenta DNA is not 
maintained throughout pregnancy (see chapter 8). In addition to this the markers 
published by the Lo group are unlikely to be used in diagnostic test as they are not 
true biomarkers for first trimester plasma DNA.  The methylation signature of 
placenta DNA for the MASPIN marker is significantly different to that of maternal 
blood cell DNA at the third trimester.  However, the two tissue types are less easily 
distinguished during the first trimester, with completely unmethylated placenta DNA 
making up a smaller proportion of circulating cff DNA in the first trimester (Chim et 
al, 2005). 
 
The discovery of an additional potential marker of cell-free fetal DNA was published 
in 2006.  Hypermethylation of the RASSF1A gene is associated with an increased 
risk of many types of cancer and is located on chromosome 3.  RASSF1A was 
published as a universal fetal DNA marker epigenetic biomarker by Chan and 
colleagues (Chan et al, 2006); but has been shown to be variable in it’s specificity 
for cff DNA (data presented by Aitcha Ait Soussan at SAFE PhD Workshop, 
Bologna 2008). 
 
 63 
The latest proposed markers on Chromosome 21 are PDE9A and U-CGI137 markers 
have been also only been shown to match the epigenetic profile of placenta DNA in 
the third trimester.  So far they have not been shown to be concordant during either 
the first or second trimesters, also the paucity of methylated CpG sites in the U-
CGI137 putative marker is noted by the authors (Chim et al, 2008). 
 
Having conducted my own research using the model system and by testing candidate 
epigenetic biomarkers with plasma DNA from pregnant women (see chapter 8), one 
conclusion which can be drawn is that the model system is not appropriate for the 
discovery of epigenetic biomarkers as the peripheral blood leukocyte DNA and term 
placenta DNA do not accurately represent the DNA populations present in the 
plasma of pregnant women (see chapter 9). 
 
1.8.2 Recent developments in cell-free fetal RNA markers for non-
invasive prenatal diagnosis 
 
On 04/06/2008 Sequenom a US company, which has purchased the intellectual 
property rights with regard to cell-free fetal nucleic acids, issued a press release.  The 
release stated that from a small study of 200 plasma samples from pregnant women 
that 100% of trisomy 21 cases were detected with 0% false positive results.  The 
company also reported that the test offered coverage of 93% (for the US Caucasian 
population).  In a blind study out of 180 samples 3 trisomy 21 samples were detected 
with 0% false positive results, and of a smaller blind study 7/21 trisomy 21 cases 
were detected with 0% false positive results (www.sequenom.com). 
 
These results look promising, however it is still desirable to develop DNA based 
NIPD as it relies on much simpler and cost effective technology, to give an even 
more rapid response from sample collection to result; as the measurement of cff 
DNA does not rely on reverse transcription to be assessed.  Also using cff DNA 
would eliminate the small risk of misdiagnosis caused by cases of undetected 
confined placental mosaicism. 
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1.9 Aims 
 
The main aim of the project is to develop fetal specific DNA markers for the 
detection of cff DNA sequences originating from fetal Chromosome 21 in the 
maternal circulation.  This will require the use molecular techniques in order to 
distinguish epigenetic modifications (CpG methylation) between cff DNA and cfm 
DNA.  This will be achieved by the identification of a number of sites of differential 
methylation, between term placenta genomic DNA and adult female leukocyte 
genomic DNA as candidates for epigenetic biomarkers.  
 
Once candidate epigenetic biomarkers have been identified, further testing and 
validation using plasma DNA samples from pregnant and non-pregnant women will 
be required. 
 
To determine the utility of analysing DNA methylation in the circulation, the ratio of 
methylated to unmethylated CpG DNA will be assessed in plasma DNA.  This is in 
order to end any speculation as to the preferential clearance of unmethylated CpG 
DNA plasma.  This work will require the measurement of the allelic ratio, of an 
imprinted DNA sequence, in order to determine if either methylated or unmethylated 
CpG DNA are cleared preferentially. 
 
Further to the suitability of using DNA in the circulation as a biomarker, the relative 
abundances of specific DNA sequences will be assessed by real-time PCR, in order 
to determine if the general assumption that all DNA sequences are represented 
equally in the circulating genome (Chan et al, 2005 b).  The PCR efficiency of each 
sequence will be analysed to give quantitative data on the relative abundances of 
each sequence in plasma DNA. 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
 
 
Chapter 2 
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2.1 Reagents and suppliers 
 
Applied Biosystems (Warrington, Yorkshire, UK) 
 
Universal PCR Mastermix (5ml) Cat No.  4304437 
 
BioChain (Hayward, California USA) 
 
Peripheral blood leukocyte genomic DNA (100 µg) Cat No.  D1234148 
Placenta genomic DNA (100 µg) Cat No.  D1234200 
 
Fermentas (Vilnius, Lithuania) 
 
BstU I restriction enzyme (2500 U/ml) Cat No.  ER0922 
Restriction site 5’ CG/CG 3’ 
pUC19 plasmid DNA (50 µg) Cat No.  SD0061 
Taq I restriction enzyme (10,000 U/ml) Cat No.  ER0671 
Restriction site 5’ T/CGA 3’ 
   
Taq DNA polymerase (5U/ml) Cat No.  EP0402 
 
First Link (Birmingham, UK) 
 
Raw human female plasma (HIV/HCV Negative) (25-10ml) self-declared non-
pregnant (special order) 
Raw human male plasma (HIV/HCV Negative) (10 ml) (special order)  
 
Fisher Scientific (Leicester, UK) 
 
Sodium Hydroxide, analytical grade reagent (500g) Cat No.  S/4920/53 
 
Helena Biosciences (Tyne and Wear, UK) 
 
Agarose, molecular biology grade reagent (500g) Cat No.  8201-07 
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Invitrogen (Abingdon, Oxfordshire, UK) 
 
DEPC-treated H2O, pyrogen-free (100ml) Cat No.  75-0024 
 
Platinum Taq polymerase kit (5u/ml) Cat No.  10966-034 
 
New England Biolabs Ltd (Hitchin, Hertfordshire, UK) 
 
BamH I (20,000 U/ml) Cat No.  R0136L 
Restriction site 5’ G/GATCC 3’ 
   
Hha I (20,000 U/ml) Cat No.  R0139L 
Restriction site 5’ GCG/C 3’ 
   
Hpa II (10,000 U/ml) Cat No.  R0171L 
Restriction sites 5’ C/CGG 3’ 
   
Promega Ltd (Southampton, UK) 
 
pGEM-T Easy Vector System Kit (20 reactions) Cat No.  A1380 
 
QIAGEN Ltd (Crawley, West Sussex, UK) 
 
QIAamp DNA Blood Maxi kit (50 reactions) Cat No.  51194 
 
QIA-quick Gel Extraction kit (50 reactions) Cat No.  28704 
 
QIAquick PCR purification kit (50 reactions) Cat No.  28104 
 
QIAprep spin miniprep kit (50 reactions) Cat No.  27104 
 
Sigma-Aldrich Ltd (Gillingham, Dorset, UK) 
 
Ethidium bromide (10mg/ml) Cat No.  E1510-10ml 
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Hydroquinone 99% pure (100g) Cat No.  H9003-100G 
 
Sodium metabisulfite ACS reagent 97% pure (100g) Cat No.  255556-100G 
 
2.1.1 Department of Biological Sciences media preparation 
 
10 M Ammonium acetate (770g of ammonium acetate in 1 litre H2O). 
 
LB Ampicillin Agar plate (15g bacto-agar/litre, 100µg Ampicillin/ml) 30ml per  
plate 
 
LB Medium (10:5:10) (10g bact-tryptone + 5g bacto-yeast extract + 10g NaCl in 1 
litre H2O, adjusted to pH 7.0 with 5M NaOH) 
 
SOC Medium (20g bact-tryptone + 5g bacto-yeast extract +0.5 g NaCl in 950 ml 
H2O) shake until dissolved + 10ml 250mM KCL + adjust to pH 7.0 with 5M NaOH 
+ 20ml 1M glucose +5ml 2M MgCl2. 
 
3M Sodium Acetate (408.1g sodium acetate in 800ml H2O, adjusted to pH 6.5 with 
dilute glacial acetic acid, adjusted to 1 litre with H2O. 
 
5x TBE (54g Tris Base + 27.5g boric acid + 20ml 0.5 M EDTA pH 8.0).  Adjusted 
to 1 litre with H2O. 
 
2.2 General laboratory equipment  
 
Most PCR assays were run using the BIORAD iCycler IQ5 Multicolor Real-Time 
PCR detection system.  In some cases the ABI prism 7000 was used for TAQMAN 
Real-Time PCR. 
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Horizon 11.14 and Thermo Classic tanks were used for gel electrophoresis.  Gene 
Genius Bio-imaging system (SYNGENE) was used to view gels. 
 
Plasma samples were separated by centrifugation using a Beckman Ultracentrifuge 
and DNA was extracted using the Heraeus Megafuge 20R. 
 
2.3  DNA samples 
 
Genomic placenta DNA was supplied by (BioChain, USA) Cat No.  D1234200. 
 
Genomic peripheral blood DNA was supplied by (BioChain, USA) Cat No.  
D1234148. 
 
Plasma DNA from non-pregnant (self-declared) individuals was supplied by (First 
Link Ltd, Birmingham, UK) by special order. 
 
Plasma DNA from pregnant women was supplied by Dr Manu Vatish (Warwick 
Medical School).  Samples were collected before and after delivery from women 
undergoing elective surgery for delivery at Warwick University Hospital, under local 
ethical approval 07/H1210/150. 
2.3.1 Plasma storage 
Blood samples collected were stored in EDTA vacutainers at 4 0C until separation of 
plasma.  Plasma was obtained by centrifugation at 1,600g for 10 minutes and at 
16,000g for 10 minutes.  Plasma was stored at -20 0C before DNA extraction. 
 
 
 
 
 
 
 
 
 
 
 70 
2.3.2 Primers  
Primer Name  Chromosome 
location (NCBI 
36.3) 
 
Sequence  Details 
GNAS_1_1F 20q13.3 
 
5’ ctt cca aaa agg 
gac cca tc 3’ 
Genomic DNA 
GNAS_1_1R 20q13.3 
 
5’ agc ctc ctc tct tcc 
cac tc 3’ 
Genomic DNA 
GNAS_1_5F 20q13.3 
 
5’ gat ttt ttt tgt ttt tat 
gga ttt agg 3’ 
Bisulfite DNA 
GNAS_1_5R 20q13.3 
 
5’ cta acc aac taa 
acc tcc tct ctt c 3’ 
Bisulfite DNA 
Chr_14_500_F 14q22 5’ gca aca agg tgc 
att tag ca 3’ 
Genomic DNA 
Chr_14_500_R 14q22 5’ tta ggc caa tgc 
aaa gta agc 3’ 
Genomic DNA 
MPH 1F (MASPIN 
SEQUENCE 1) 
18q21.3 5’ tac ttt ttg tgc cac 
caa cg 3’ 
Genomic DNA 
MPH 1R (MASPIN 
SEQUENCE 1 
18q21.3 5’ cag gac cgg aag 
gtg aaa ta 3’ 
Genomic DNA 
MPH 2F (MASPIN 
SEQUENCE 2 
18q21.3 5’ tat ttc acc ttc cgg 
tcc tg 3’ 
Genomic DNA 
MPH 2R (MASPIN 
SEQUENCE 2) 
18q21.3 5’ ctt cca aaa ggc ctc 
caa c 3’ 
Genomic DNA 
PDE9A F 21q22.3 5’ ggc gtc tga cgt ctc 
cag 3’ 
Genomic DNA 
PDE9A R 21q22.3 5’ tgg agt  tgc agt 
act tgc tga 3’ 
Genomic DNA 
RASSF1A F 3p21.3 5’ ctc att gag ctg cgg 
gag ctg gca 3’ 
Genomic DNA 
RASSF1A R 3p21.3 5’ tgg ggt tgc acg 
cgg tgc cc 3’ 
Genomic DNA 
CpG Negative F 21q22 5’ tcc caa aac cca 
ata aaa gc 3’ 
Genomic DNA 
CpG Negative R 21q22 5’ ttt ccc cct gac aat 
ctc tc 3’ 
Genomic DNA 
Beta Actin F 7p15-p12 5’ gcg ccg ttc cga 
aag tt 3’ 
Genomic DNA 
Beta Actin R 7p15-p12 5’ cgg cgg atc ggc 
aaa 3’ 
Genomic DNA 
21-58-F 21q22.3 5’ ttc tgt gca act ttc 
gct  tg 3’ 
Genomic DNA 
21-58-R 21q22.3 5’ cgt ctc tca ctc cct 
gca ct 3’ 
Genomic DNA 
21-58 SHORT F 21q22.3 5’ agg aaa ccc agc 
gag cag 3’ 
Genomic DNA 
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Primer Name  Chromosome 
location (NCBI 
36.3) 
 
Sequence  Details 
21-210 SHORT F 21q22 5’ aag gca gga ggt 
ttc tgt cc 3’ 
Genomic DNA 
21-210 SHORT R 21q22 5’ gaa cac act gcg 
cgc ttt a 3’ 
Genomic DNA 
1-16 SHORT F 1q21 5’ aga cct ccg gtt tct 
ggt tt 3’ 
Genomic DNA 
1-16 SHORT R  1q21 5’ gag agc ctg gct 
aga aaa agg 3’ 
Genomic DNA 
2-28 SHORT F 2p14 5’ ttg gag cta aca gct 
tct gtc tt 3’ 
Genomic DNA 
2-28 SHORT R 2p14 5’ gaa ggc tcg ggg 
tga gtc 3’ 
Genomic DNA  
1-50 SHORT F 1q31.2 5’ act gtg gag ccc 
ggg tct gt 3’ 
Genomic DNA 
1-50 SHORT R 1q31.2 5’ tgg aag ttt cat ccc 
tgg ag 3’ 
Genomic DNA 
12-42 SHORT F 12q24 5’ gac caa cca gcc 
tga caa ac 3’ 
Genomic DNA 
12-42 SHORT R 12q24 5’ tca ccg caa cct 
ccg cct 3’ 
Genomic DNA 
18-29 FV1 18p11.2 5’ gtt agc ttt cct tca 
gcc gg 3’ 
Genomic DNA 
18-29 RV2 18p11.2 5’ gca ctt ggc gac 
agc cgg tg 3’ 
Genomic DNA 
21-37-1F 21q21 5’ agt cgc agg aag 
ctc taa cg 3’ 
Genomic DNA 
21-37-1R 21q21 5’ agt ttg gct gaa 
agg tca gg 3’ 
Genomic DNA 
21-43-3F 21q22 5’ gcc agg aac tcc 
agt gag ac 3’ 
Genomic DNA 
21-43-3R 21q22 5’ tct ttg gtt tat ggc 
gct gt 3’ 
Genomic DNA 
21-107 SHORT F2 21q22.3 
 
5’ cgc att ggt ttc tga 
tgg a 3’ 
Genomic DNA 
21-107 SHORT R2 21q22.3 
 
5’ gtg gtc ggg tgc 
tag atg tt 3’ 
Genomic DNA 
18-CR SHORT F 18q21 5’ aag agc gct cca 
tga agc ca 3’ 
Genomic DNA 
18-CR SHORT R 18q21 5’ gtc ctc act tcc ttg 
cgt gt 3’ 
Genomic DNA 
22-09 F 22q12.2 5’ ttc tta gga cgg gaa 
cga tg 3’ 
Genomic DNA 
22-09 R 22q12.2 5’ ggg tac agt tac 
cgc tca cc 3’ 
Genomic DNA 
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Primer Name  Chromosome 
location (NCBI 
36.3) 
 
Sequence  Details 
Beta-Globin F 11p15.5 5’ gtg cac ctg act cct 
gag gag a 3’ 
Genomic DNA 
Beta-Globin R 11p15.5 5’ cct tga tac ca acc 
tgc cca g 3’ 
Genomic DNA 
Beta Globin 5’ VIC 
Probe 3’ TAMRA 
11p15.5 5’ aag gtg aac gtg 
gat gaa gtt ggt gg 3’ 
Genomic DNA 
SRY F Yp11.3 5’ tcc tca aaa gaa 
acc gtg cat 3’ 
Genomic DNA 
SRY R Yp11.3 5’ aga tta atg gtt gct 
aag gac tgg at 3’ 
Genomic DNA 
SRY 5’ VIC Probe 
3’ TAMRA  
Yp11.3 5’ cac cag cag taa 
ctc ccc aca acc tct tt 
3’ 
Genomic DNA 
21-128 F 21q22.3 
 
5’ tga gag gca ttg 
caa act aga tg 3’ 
Genomic DNA 
21-128 R 21q22.3 
 
5’ cca gcg tct ttt atc 
tgc agt tg 3’ 
Genomic DNA 
21-58 MSP F 21q22.3 
 
5’ agg gga gag ggt 
agg aaa ttt agc gag 
tag tag ctc 3’ 
Methylated DNA 
21-58 MSP R 21q22.3 
 
5’ gaa aaa aaa acc 
ccc tac cta cat acc 
tac ctt acc g 3’ 
Methylated DNA 
AIRE A1 F 21q22.3 5’ tag ttt ttg tta ggg 
ttt tga gat t 3’ 
Bisulfite DNA 
AIRE A1 R 21q22.3 5’ acc cac caa aac 
aac tac ctt aa 3’ 
Bisulfite DNA 
MCM3AP F 21q22.3 5’ gaa gtt agg tgg 
gag gag att tt 3’ 
Bisulfite DNA 
MCM3AP R 21q22.3 5’ act att cca cct tac 
aac tta aaa ac 3’ 
Bisulfite DNA 
H19 DMR F 11p15.5 5’ gta tag tat atg ggt 
att ttt gga ggt ttt 3’ 
Bisulfite DNA 
H19 DMR R 11p15.5 5’ taa ata tcc tat tcc 
caa ata acc c 3’ 
Bisulfite DNA 
MASPIN F  18q21.3 5’ gaa tgg aga tta 
gag tat ttt ttg tgt tat 
3’ 
Bisulfite DNA 
MASPIN R  18q21.3 5’ act tcc aaa aaa cct 
cca aca tat 3’ 
Bisulfite DNA 
LM18-58A F 18q21 5’ aga cag aca ctt 
gtc ttg cag aa 3’ 
Genomic DNA 
LM18-58A R 18q21 5’ gtc ctc act tcc ttg 
cgt gt 3’ 
Genomic DNA 
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Table 2.1:  DNA oligonucleotide primers  
Shows all of the primers used throughout the project, most oligonucleotides were 
supplied by (VH-BIO, Newcastle, UK) Probes were supplied by (Applied 
Biosystems California, USA).  Primers were designed using the web-based program 
primer 3 input (Rozen and Skaletsky, 2000).  Bisulfite specific primers and 
methylation specific primers were designed using the web-based program 
MethPrimer (Li and Dahiya, 2002).  Bisulfite specific primers amplify all bisulfite 
DNA sequences and primer sequences do not contain any CpGs, although the 
internal amplicon may contain CpG sites.  Methylation specific primers amplify 
bisulfite converted DNA only contain methylated CpGs in their sequences, primers 
are designed to contain CpGs, which are retained after bisulfite conversion.  For 
clarification only the current primers for each region are given. 
 
2.4 Methods 
 
2.4.1 Extraction of DNA from plasma 
DNA was extracted from plasma samples using the QIAamp Blood Maxi kit 
(QIAGEN, UK); using the purification of DNA from whole blood spin protocol, 
according to the manufacturer's instructions.   
The following alterations were made:  
Up to 10 mls of plasma was used as the input as opposed to whole blood. 
Step 13 b was chosen to gain maximum yield. 
Samples were ethanol precipitated after elution from the column. 
2.4.1.1 Ethanol precipitation of plasma DNA 
 
Samples from the DNA Maxi kit are eluted in 1ml. 
Each sample was split equally into 2x 1.5 ml eppendorf tubes and labelled 
accordingly.  50 µl of 3M sodium acetate was added to each tube (to give a final 
concentration in solution of 3mM).  1ml of (96-100%) ethanol was added to each 
tube, the tubes were incubated overnight.  The tubes were then centrifuged at 13,000 
rpm at 4 0C for 30 minutes and the supernatant was carefully removed with a 1ml 
pipette.  The centrifugation step was repeated for an additional 5 minutes and any 
remaining supernatant was removed with a 200 µl pipette.  The samples were then 
allowed to air dry in a fume cupboard for 5-10 minutes, and both samples were re-
hydrated and recombined in 30 µl in a single tube. 
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2.4.2 Enzyme restriction  
 
Taq I restriction digestion of bisulfite-specific PCR products for COBRA: 
Enzyme mix: 
Taq I enzyme 10 µl (100 units) 
10 x Taq I buffer 15 µl 
DDH2O 25 µl 
Final reaction volume Σ 50 µl  
 
(5 µl of enzyme mix is used to digest each PCR product) a mix without enzyme is 
used as a negative control for digestion. Samples are incubated at 65 0C for 1 hour). 
BamH I digestion for the fragmentation of commercial genomic DNA prior to 
bisulfite conversion: 
 
Input genomic DNA x µl (10 µg) 
BamH I enzyme 3.5 µl (70 units) 
10 x BamH I buffer 10 µl 
BSA 1 µl 
DDH2O y µl 
Final reaction volume Σ 100 µl (sample concentration is 100ng/µl). 
 
Samples are incubated at 37 0C for 2 hours. 
 
Hpa II or Hha I digestion of commercial genomic DNA for screening of biomarkers: 
 
Input genomic DNA x µl (10 µg) 
Hpa II enzyme 10 µl (100 units) OR Hha I enzyme 10 µl (200 units) or both 
10 x buffer 4 10 µl 
DDH2O y µl 
 
Final reaction volume Σ 100 µl (sample concentration is 100ng/µl). 
 
Samples are incubated at 37 0C for 2 hours and the enzyme is inactivated by 
incubation at 65 0C for 20 minutes. 
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Hpa II or Hha I digestion of plasma DNA for screening of biomarkers: 
 
Plasma DNA 10 µl 
Hpa II enzyme 1 µl (10 units) OR Hha I enzyme 1 µl (20 units) or both 
10 x buffer 4 1 µl 
 
Σ 12 µl 
 
Samples were incubated at 37 0C for 40 minutes and the enzyme was inactivated by 
incubation at 65 0C for 20 minutes, negative controls with water instead of enzyme 
were also used. 
2.4.3 PCR 
Reagent  Volume (final concentration) 
H2O 12.5 µl 
10 x PCR buffer 2.5 µl (1 x PCR buffer) 
10 mM dNTPs 1.0 µl (0.1mM) 
25 mM MgCl2 3.0 µl (3mM) 
2.5 µm Forward primer 2.0 µl (0.2 µM) 
2.5 µm Reverse primer 2.0 µl (0.2 µM) 
Taq DNA polymerase (Fermentas) 1.0 µl (5 units) 
Total volume of reagents 24.0 µl 
Genomic DNA input (100 ng/µl) 1.0 µl 
Final total volume  25.0 µl 
 
Table 2.2:  Standard PCR protocol for biomarker screening 
Standard PCR cycle used was 35 cycles of (95 0C 30s, 60 0C 30s, 72 0C 1min) 
followed by a holding step at 4 0C. 
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Reagent  Volume (final concentration) 
2 x SYBR green mastermix  12.5 µl  
2.5 µm Forward primer 2.0 µl (0.2 µM) 
2.5 µm Reverse primer 2.0 µl (0.2 µM) 
H2O 3.5 µl  
Total volume of reagents 20.0 µl 
Genomic bisulfite converted DNA input 
(20 ng/µl) 
5.0 µl 
Final total volume  25.0 µl 
 
Table 2.3:  Nested PCR conditions for methylation-specific PCR of the AIRE 58 
biomarker 
PCR cycle conditions for the pre-amplification step:  1 cycle of 95 0C for 15 minutes, 
32 cycles of (95 0C 30s, 60 0C 30s, 72 0C 30s) 1 cycle of 55 0C for 1 min and 
(melting gradient 80 cycles of 55 0C + 0.5 0C every 10s).  Samples were diluted 200 
fold and the PCR amplification step was repeated for the second step of the nested 
PCR. 
 
 
Reagent  Volume (final concentration) 
2 x SYBR green mastermix  12.5 µl  
2.5 µm Forward primer 1.0 µl (0.2 µM) 
2.5 µm Reverse primer 1.0 µl (0.2 µM) 
H2O 5.5 µl  
Total volume of reagents 20.0 µl 
Genomic bisulfite converted DNA input 
(20 ng/µl) 
5.0 µl 
Final total volume  25.0 µl 
 
Table 2.4:  Methylation-specific PCR conditions for optimal AIRE 58 
biomarker MSPs 
PCR cycle conditions: 1 cycle of 95 0C for 15 minutes, 40 cycles of (95 0C 30s, 69 
0C 30s, 72 0C 30s) 1 cycle of 55 0C for 1 min and (melting gradient 80 cycles of 55 
0C + 0.5 0C every 10s). 
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Reagent  Volume (final concentration) 
2 x TAQMAN Universal mastermix  12.5 µl  
10 µm Forward primer 0.75 µl (0.3 µM) 
10 µm Reverse primer 0.75 µl (0.3 µM) 
10 µm VIC Probe- TAMRA  0.5 µl (0.2 µM) 
H2O 5.5 µl  
Total volume of reagents 20.0 µl 
Plasma  DNA input (20 ng/µl) 5.0 µl 
Final total volume  25.0 µl 
 
Table 2.5:  TAQMAN Real-time PCR on ABI PRISM 7000 platform for plasma 
DNA testing 
PCR cycle conditions: 1 cycle of 50 0C for 2 minutes, 1 cycle of 95 0C for 15 
minutes 45 cycles of (95 0C 15s, 60 0C 1 min). 
2.4.4. Gel electrophoresis 
All gels were 1.5 % agarose with 10 µl of 10mg/ml ethidium bromide (Sigma, UK) 
per 100 ml of 1x TBE solution.  All gels were run in either 11.14 Horizon gel tanks 
or Thermo Classic tanks. 
 
2.4.5 Bisulfite conversion of plasma DNA 
 
Due to the problematic nature of performing bisulfite conversion of DNA on small 
amounts of DNA, our laboratories standard operating protocol for the bisulfite 
conversion of plasma DNA is given in detail below. 
 
DNA is first extracted from plasma using the QIAamp DNA Blood maxi kit 
(QIAGEN, UK).  The final volume of each plasma DNA sample was assessed (30 µl) 
and 1/9th of the total volume of 3M sodium acetate was added to each sample (3.3 µl).  
5.3 µl of 0.471ng/µl pUC 19 plasmid DNA (2.5 µg) was added to each sample for 
use as carrier DNA.  2 volumes of ethanol plus an additional 30 µl were added to 
each sample, each sample was mixed by inverting the tube 6 times.  Each sample 
was incubated at -20 0C overnight. 
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NEXT DAY 
Before starting one heating block was set to 65 0C and one programmable heating 
block was set to 97 0C.  Samples were centrifuged at 13,000 rpm at 4 0C for 30 
minutes.  The supernatant was carefully removed with a 1ml pipette and re-spun to 
remove any remaining supernatant.  DNA pellets were allowed to air dry in a fume 
cupboard for 10-20 minutes; and were re-suspended in 30 µl of H2O.  Small volumes 
of 10M NaOH and 3M NaOH were prepared.  3.66 µl of 3M NaOH were added each 
sample, and each sample was incubated on the hot bars at 65 0C for 20 minutes. 
 
SODIUM BISULFITE PREPARATION (IN ABSENCE OF LIGHT) 
1x 50 ml falcon tube and 1 x 15 ml falcon tube are covered in foil.  In the 15 ml 
falcon: 0.22g of hydroquinone was diluted in 10mls of dd H2O and dissolved by 
inverting gently about 50 times.  The final concentration of hydroquinone was 0.2 M.  
In the 50 ml falcon:  5.7g of Sodium metabisulfite was diluted in 8mls of dd H2O, 
and mixed by inverting 6 times.  500 µl of fully dissolved 0.2 M hydroquinone was 
added to the sodium metabisulfite; add 400 µl of 10M NaOH to the sodium 
metabisulfite solution to equilibrate the solution to pH 5.0. 
 
The solution was mixed by inverting twice, and the pH using an indicator strip.  The 
solution was allowed to stand for 5 minutes to allow a precipitate to form; the 
precipitate must not be disturbed when aliquoting.  Sample tubes were covered with 
foil and 400 µl of sodium bisulfite solution was added to each tube, the solution was 
mixed by inverting each tube 6 times.  Samples were placed on a heating block at 95 
0C for 7-10 minutes, and switched to 55 0C for a total incubation time of 4 hours.  
1.66mls of buffer PB were added to labelled 15 ml Falcon tubes.  An Eppendorf with 
dd H2O is laced on hot bars now at 95 0C for use later. 
 
When the bisulfite conversion reaction was completed the DNA solution was added 
to the falcon tubes with PB buffer.  Each sample was then processed by QIAquick 
PCR column according to the manufacturer’s protocol.  Each sample is eluted in 100 
µl Hot H2O.  11 µl of 3M NaOH was added to each sample and mixed by pipetting; 
each sample was then incubated at 37 0C for 20 minutes to denature the DNA.  167 
µl of 5M ammonium acetate was added to each sample and mixed by pipetting and 
incubated at room temperature for 5 minutes.  834 µl of absolute ethanol was added 
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to each sample and mix by inverting the tubes.  Samples were incubated overnight at 
-20 0C. 
 
NEXT DAY 
Each sample was centrifuged at 13,000 rpm for 15-30 minutes at 4 0C to remove the 
supernatant and the centrifugation was repeated for 5 minutes to allow any further 
supernatant to be removed. 
 
All DNA pellets were re-suspended in 30 µl of hot H2O. 
 
2.4.6 Cloning and sequencing 
 
PCR product cloning was done using the pGEM –T Easy vector systems (Promega, 
USA) according to the manufacturer’s instructions. 
 
2.4.6.1 Analysis of clones using Clustal  
 
Samples were analysed in the applied biosciences sequence scanner program (ABI 
sequence scanner 1.0) are converted to text files.  The clones added to master 
notepad files and save in text format, any anti-sense strand clones were converted to 
the sense strand by use of (Clone Manager suite software).  Alignments for each set 
of clones were made and written as postscript files using the Clustal X programme 
v1.81. 
2.4.7 Sonication of DNA 
DNA was pulse sonicated in 4 rounds of 15 seconds with rest periods on ice to 
ensure DNA did not over heat, using a standard sonicator (MSE, UK). 
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Chapter 3 
 
Imprinting of cell-free plasma DNA 
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3.1  Aims 
 
The main routes by which cell-free plasma DNA (cfp DNA) enters the circulation is 
by apoptosis of leukocytes and exocytosis of nuclei by maturing erythrocytes.  In 
order to use DNA methylation as a tool for the detection of specific DNA, it must 
first be determined that the methylation profile of cellular DNA is maintained in cfp 
DNA.  The data presented in this chapter describes the relative abundance a specific 
sequence of cfp DNA.  The sequence lies within the GNAS1 gene promoter.  GNAS1 
is an imprinted DNA sequence, in that it contains sequences with parent-of-origin-
specific allelic methylation patterns.  The region studied also contains a single 
nucleotide polymorphism (SNP) to allow allelic identification (figure 3.1).  Work on 
the cloning and sequencing presented in this chapter was completed in collaboration 
with Kamalit Chatha. 
 
3.2   Introduction 
 
DNA is released by cells in the circulation during the process of apoptosis of 
leukocytes and by exocytosis of nuclei by maturing erythrocytes (Bianchi et al, 
2004; Bischoff et al, 2005; Koide et al, 2005; Kolialexi et al, 2004 and Sekizawa et 
al, 2000).  In order for DNA methylation to be a viable tool for the identification of 
fetal specific DNA sequences; methylated and unmethylated CpG DNA sequences 
present in circulation must maintain the same methylation profiles as their cellular 
counter parts.  One factor which may affect the levels of methylated and 
unmethylated CpG DNA in the circulation is the immune system.  It has been well 
documented that in certain pathological conditions bacterial unmethylated CpG 
DNA acts as a pathogen associated molecular pattern (PAMP) and can stimulate an 
immunogenic response (Agren et al, 2006; Ahmad-Nejad et al, 2002; Cornelie et al, 
2004 and Yoshikawa et al, 2006).  Bacterial CpG motifs are short sequences 
consisting of a CpG flanked by two purines at the 5’ end and two pyrimidines at the 
3’ end.  These sequences occur 20 times less frequently in mammalian genomes 
(Hemmi et al, 2000).  The presence of unmethylated CpG sequences in the plasma 
can also stimulate auto-immune responses, as is the case in the auto-immune disease 
systemic lupus erythematosus (SLE) (Januchowski et al, 2004).  Bearing these 
publications in mind it is a reasonable hypothesis that unmethylated CpG DNA 
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sequences may stimulate an immune response and interact with immune-cells in the 
circulation. 
 
It has also been suggested that due to chromatin remodelling in nucleosomal DNA, 
methylated DNA may persist in the circulation for longer periods than unmethylated 
DNA (Herman, 2004).  Taken together these two scenarios may mean that there is a 
bias towards the presence of methylated CpG DNA and clearance of CpG 
unmethylated DNA in the circulation.  Very little research has been carried out to 
assess the levels of methylated CpG and unmethylated CpG DNA in the human 
circulation.  The work here has carefully assessed the levels of the methylated 
maternal allele of GNAS1 and the unmethylated paternal allele of GNAS1 (figure 
3.1). 
 
The experiments presented here attempt to address the situation of methylated and 
unmethylated CpG DNA sequences for unique single copy genes and does not 
address the special circumstances of high repeat sequences such as ALU, which is 
heavily methylated or the inactivated X Chromosome.  
 
 
 
 
 
 
 
 
 
Figure 3.1:  Imprinted XL region of the GNAS1 gene 20q13 
Shows a diagram of the various overlapping GNAS1 gene transcripts.  The imprinted 
XL region is shown; which is methylated on the maternal allele and unmethylated on 
the paternal allele, methylated regions are indicated by asterisks.  Also shown is the 
SNP rs1800905 (NCBI 36.3) (Taken from Eggermann et al, 2007). 
 
Using the XL imprinted region of the GNAS1 gene it is possible to assess the level of 
methylated and unmethylated CpG DNA in plasma, by measuring the allelic ratio of 
the maternal (methylated) and paternal (unmethylated) alleles.  The SNP rs1800905 
can be used to distinguish between the maternal and paternal alleles. 
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The data from these imprinting experiments will provide a measurement of CpG 
methylated and CpG unmethylated DNA, which is present in plasma, if either DNA 
form is present in excess, there could be detrimental implications for the use of 
epigenetic DNA biomarkers. 
3.3  Status of imprinted cell-free DNA in plasma 
 
DNA was extracted from the plasma of normal healthy individuals (First Link, U.K) 
using the QIAamp DNA blood Maxi Kit (QIAGEN, U.K).  The DNA was amplified 
by PCR and then each PCR product was divided equally into two samples and one 
sample was digested with FnuD II (Fermentas, USA) the other was not digested.  
This allowed each sample to be identified as either a heterozygote or a homozygote 
for the SNP re 1800905, by comparison of digested and undigested OCR products by 
gel electrophoresis. (figure 3.3).  In the presence of the G SNP the site CGCG is 
completed allowing digestion of the PCR product; however in the presence of the A 
SNP the sequence CGCA does not cleave when digested with FnuD II, in the case of 
heterozygote the digested PCR product should show two bands of approximately 
equal intensity (figure 3.3).  The full length of the GNAS1 amplicon is 192 bp, with 
fragments of 134 bp and 58 bp when the SNP is cleaved, the amplicon sequence and 
SNP site are shown (figure 3.2). 
 
CAAAGAAGCCCACCCGCCGTGACGCGTCCCCGGAGTCCCCTTCCAAAAAGGGACCCATCCCCATCCGG
CGTCACTAATGGAGGACGCCGTCCAGATTCTCCTTGTTTTCATGGATTCAGGTTAGTTGCCCACCGCT
AAACTGGGGAGCCTGAGGGCGGTGTGGGAGCAGCGCRGGTGGAAAGGAGGTGAGAAGGAAAGGCAGGT
CAGGGGCGAGTGGGAAGAGAGGAGGCTCAGCTGGTCAGCCTGGGATCGGGGGTCAGGGTGAGGCGGCG 
 
Figure 3.2:  GNAS1 amplicon sequence map 
Showing the GNAS1 amplicon as defined by the genomic primers (in bold), all CpGs 
are highlighted in red, with CpGs internal to the bisulfite-specific PCR amplicon in 
yellow.  The SNP rs1800905 is an A to G transtion marked as R in the sequence and 
is adjacent to a 5' C which may form an additional SNP -dependent CpG. The 
bisulfite converted amplicon is shorter, the position of the bisulfite primers are given 
(underlined). 
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Figure 3.3:  Gel electrophoresis image of digested and undigested GNAS1 PCR 
products of plasma DNA 
Sample W6 is homozygous for the G allele; this is shown by the complete digestion 
of the PCR product by FnuD II in lane W6 D when compared to the undigested 
product labelled W6 U.  Sample W7 is also homozygous for the G allele; this is 
shown by the complete digestion of the PCR product by FnuD II in lane W7 D when 
compared to the undigested product labelled W7 U.  Sample W8 is heterozygous 
containing both an A allele and a G allele; as it is partially digested as shown in lane 
W8 D, when compared to W8 U. This is indicated by the presence of two bands, 
were the G allele is cleaved, but the A allele remains undigested.  The lane marked 
MW shows 100 BP molecular weight DNA ladder (Geneflow, UK).  
 
Cellular controls of placenta DNA and peripheral blood leukocyte DNA were 
selected.  Leukocyte DNA was used to represent the cellular fraction of blood as a 
broader indicator of the situation of cells in the peripheral blood, and could be used 
as a direct comparison to plasma DNA.  Placenta DNA was chosen as a cellular 
control in order to identify the methylation status of DNA in a solid tissue. By 
coincidence all of the four control samples assessed were heterozygotes (figure 3.4). 
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Figure 3.4:  Gel electrophoresis image of digested and undigested PCR products 
of leukocyte and placenta DNA for the GNAS1 region 
Samples prefixed B10 and A70 are leukocyte DNA samples (BioChain, USA); 
samples prefixed A80 and A90 are placenta DNA (BioChain, USA); prefixes denote 
the first three characters of each sample’s respective batch number.  By coincidence 
all of the controls were heterozygous for the GNAS1 SNP.  Lanes B10 D, A70 D, 
A80 D and A90 D all show two bands after digestion with FnuD II, when compared 
to their undigested counterparts in lanes; B10 U, A70 U, A80 U and A90 U 
respectively.  The four lanes marked N are PCRs which were run with a non-
template control.  The lanes marked MW denote the 100bp DNA molecular weight 
ladder used as a reference for product size (Geneflow, UK). 
 
To more accurately assess relative abundances of methylated and unmethylated 
GNAS1 sequences, plasma samples were collected from normal healthy individuals 
and DNA was extracted using the QIAamp DNA blood maxi kit (QIAGEN, U.K).  
The plasma DNA was then bisulfite converted and the GNAS1 region was amplified 
with bisulfite-specific primers.  The bisulfite-specific PCR product was then cleaned 
on a column (QIAGEN, U.K) and inserted into a vector using the pGEM T-Easy 
Vector system (Promega, U.S.A).  Colonies were selected and the sequencing was 
processed by molecular biological services (Warwick, U.K), using the ABI prism 
3130xl genetic Analyser.  The sequences were then analysed with ABI sequence 
scanner software and aligned using Clustal X v1.81.  Overall the ratio of methylated 
to unmethylated alleles in cfp DNA was 1:1 (p=0.773), as assessed by heterozygous 
samples, the homozygous control samples also had a ~1:1 ratio (p=0.756) of 
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maternal to paternal alleles and acted as a control for any PCR bias which may have 
arisen due to the presence of the SNP (figure 3.5). 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE W8SAMPLE K6 SAMPLE K7
Additional CpG in sequence 
created by G SNP
= unmethylated cytosine in 
CpG
= methylated cytosine in 
CpG
SAMPLE K8 SAMPLE W6
= unmethylated cytosine in 
CpG
= methylated cytosine in 
CpG
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Figure 3.5:  Sequencing data from the BS-PCR products of GNAS1 
In this diagrammatic representation of the GNAS1 sequence the paternal allele is 
unmethylated and the maternal allele is methylated.  Each CpG in the sequence runs 
5’ to 3’ left to right and is represented as either a clear circle (with unmethylated 
cytosine) or a filled circle (with methylated cytosine).  The transition from A to G 
allele creates an additional CpG site only present in the G allele.  In (A) all of the 
plasma samples K6, K7 and W8 are from heterozygous donors.  The K6 sample has 
7 maternal alleles and 14 paternal alleles.  The K7 sample has 10 maternal alleles 
and 7 paternal alleles.  The W8 sample has 7 maternal alleles and 6 paternal alleles. 
In (B) the plasma DNA samples K8 and W6 are homozygous for the G allele.  The 
K8 sample has 10 maternal alleles and 12 paternal alleles.  The W6 sample has 12 
maternal alleles and 8 paternal alleles.  In (C) both of the peripheral blood leukocyte 
genomic DNA samples are heterozygous.  The BC1 sample has 7 maternal alleles 
and 12 paternal alleles.  The BC2 sample has 12 maternal alleles and 4 paternal 
alleles. 
 
3.4  Allelic ratio controls 
 
As an additional control the relative abundance of a non-imprinted allele was 
measured, a unique single copy sequence on chromosome 14 was selected which 
contains an SNP site rs1742500 (NCBI build 36.3).  This SNP has a C/T transition 
and where the C is present a GCGC Hha I site is created, whereas in T alleles the site 
= unmethylated cytosine in 
CpG
= methylated cytosine in 
CpG
Additional CpG in sequence 
created by G SNP
SAMPLE BC1 SAMPLE BC2
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GTCG is not cleaved by Hha I.  After the initial testing with restriction a Hha I assay 
to select heterozygotes (data not shown); the plasma DNA samples of several 
heterozygotes were cloned and sequenced to assess the ratio of C:T alleles and 
determine the relative abundance of alleles at the non-imprinted locus (figure 3.6).  
The ratio of C alleles to T alleles was approximately 1:1 showing that there was no 
specific bias for either the sequences selected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6:  Clustal X data, showing 
sequencing for the Chromosome 14 
SNP with short flanking sequence 
All of the plasma samples represented 
here are pooled from donors whom 
were heterozygous for the rs1742500 
SNP; the whole sample set is shown.  
Of the 25 colonies selected, 12 contain 
the C allele and 13 contain the T 
allele.  Showing that the ratio of C:T 
is approximately 1:1. 
 
 
 
3.5  Discussion 
 
The imprinted XL locus on GNAS1 was analysed in the plasma DNA of normal 
healthy individuals by bisulfite sequencing (figure 3.5).  Alleles were distinguished 
by their methylation profile and as an additional control by their SNP (in 
heterozygous cases only).  In the three plasma samples which were identified as 
heterozygous (figure 3.5 A) the combined number of maternal (methylated) alleles 
was 24 and the combined number of paternal (unmethylated) alleles was 27.  These 
data show that the ratio of methylated to unmethylated alleles is approximately 
equal.  The homozygous plasma DNA samples K8 and W6 (figure 3.5 B) also had an 
almost equal number of methylated to unmethylated alleles, with 22 methylated 
maternal alleles and 20 unmethylated paternal alleles.  These are the same as the 
heterozygous results and show that there was no PCR bias caused by the presence of 
the SNP.  By including the homozygous plasma DNA samples into the data set, the 
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number of maternal (methylated) alleles is 46 and the number of paternal 
(unmethylated) alleles is 47; which is approximately 1:1. 
 
In the adult peripheral-blood leukocyte genomic DNA controls (figure 3.5 C) 
samples BC1 and BC2 have a combined number of 19 maternal (methylated) alleles 
and 16 paternal (unmethylated) alleles which is also approximately 1:1.  This shows 
that the relative abundances of methylated to unmethylated DNA sequences in are 
equal in both the cellular compartment of whole blood and the in the cfp DNA. 
 
As a further control the allelic ratio of another SNP on Chromosome 14 was also 
assessed on the same set of plasma DNA samples.  This genomic locus was assessed 
as an additional control to ensure that the allelic ratio of a non-imprinted region was 
also equal and that the results obtained from the analysis of the GNAS1 region were 
not by chance (figure 3.6). 
 
These data suggest that there is no specific mechanism for the clearance of CpG 
unmethylated DNA in the plasma of healthy individuals.  The data also suggests that 
there is no mechanism by which CpG methylated DNA is preferentially retained in 
the plasma of healthy individuals.   
 
A number of plasma DNA samples were analysed, four of which were found to be 
heterozygous by methylation-sensitive restriction assay, of the 25 alleles assessed 12 
alleles carried the C SNP and 13 alleles had the T SNP (figure 3.6). 
 
These data show for the first time that methylated and unmethylated CpG DNA 
present in the circulating plasma are equally abundant in normal healthy individuals.  
This is of great importance in the field non-invasive diagnosis and is crucial for the 
development of any diagnostic test which relies on the detection of differentially 
methylated cell-free plasma DNA; such as those being developed in cancer diagnosis 
and prenatal care.  The equal abundance of the DNAs indicates the absence of 
mechanisms that differentially affect the release or clearance of unmethylated or 
methylated DNA in plasma.  Were differential mechanisms evident, then variation in 
these mechanisms between individuals, or variation in the immune status or other 
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factors, could have a drastic consequence for the use of epigenetic DNA biomarkers 
in plasma. 
 
One interesting use of imprinted genes potentially could be the development of fetal-
specific DNA markers for non-invasive prenatal diagnosis.  Taking the GNAS1 locus 
studied here as an example; by knowing that the maternal allele is methylated in the 
fetus, it may be possible to detect the switch in methylation patterns if the imprinted 
allele is combined with an SNP.  In cases where the mother is heterozygous for a 
specific SNP on an imprinted gene and the fetus inherits the opposite SNP from the 
father whom is homozygous, fetal DNA may be detected by allelic ratio (figure 3.7). 
 
In cases where the heterozygousity of a specific SNP (within an imprinted gene) is 
approaching 50 % the allelic ratio of fetal DNA could be measured in approximately 
6% of pregnancies.  This is an unattractive prospect for most diagnostic procedures 
however; one exciting possibility is the potential use of this technique to determine 
whether it is the maternal or paternal X chromosome which is inactivated in the 
placenta or whether X-inactivation is random.  If X-inactivation is parent-specific 
(preferably paternal) this could potentially provide the ability to distinguish the fetal 
X chromosome from the non-invasive prenatal diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7:  Schematic diagram showing the combination of imprinting and 
SNP analysis for the detection of fetal DNA 
In cases where imprinted loci coincide with a SNP, which has a high rate of 
heterozygousity, fetal DNA which is maternally imprinted can be distinguished 
completely, but only in the small percentage of cases where the mother is 
heterozygous for the SNP and the father is homozygous, and the paternal allele 
inherited is differential to the maternal.  
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Such a situation could be assessed by the bisulfite sequencing of maternal plasma 
DNA and by measurement of allelic ratio, as both of the fetal alleles, in the case 
scenario shown (figure 3.7) are not present in the maternal genome. 
 
 
 
 
 
 
 
Results 
 
 
 
Chapter 4 
 
Representation of DNA sequences in 
cell-free plasma  
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4.1  Aims 
 
Cell-free DNA in the circulation is derived from a range of cells which are 
predominantly haematopoietic in origin (Lui et al, 2002).  It is proposed that 
apoptosis is the main route by which stable DNA is released by cells into the 
circulation (Bischoff et al, 2005; Sekizawa et al, 2000).  However the precise 
mechanism of DNA release has yet to be elucidated and may also include the release 
of DNA by normal healthy lymphocytes (Anker and Stroun, 2006; Stroun et al, 
2001).  What has been assumed up until this point is that genomic DNA sequences, 
which are released by cells into the circulation, are equally abundant, at least in the 
case of single copy genes, so far it has already been demonstrated that ALU repeat 
DNA sequences are more abundant than single copy sequences in plasma and serum 
(Stroun et al, 2001). 
 
In this chapter, by the use of carefully calibrated real-time PCR, the relative 
abundance of several DNA sequences in plasma is assessed.  The measurement of 
the relative abundance of different DNA sequences is important; if the relative 
abundance of each sequence is variable between individuals, this may mean that 
methods such as relative chromosome dosage (RCD) which rely on comparison of 
DNA abundances are not suitable for the accurate measurement of cell-free plasma 
DNA.  
4.2  Introduction  
 
Cff DNA and cfm DNA have been assessed in many studies and by many 
methodologies; studies have suggested that cff DNA is placental in origin and cfm 
DNA is haematopoietic in origin (Alberry et al, 2007; Bianchi 2004; Lui et al. 2002).  
Other studies have assessed the increase in cff DNA concentration throughout 
gestation and its rapid clearance after delivery (Birch et al, 2005; Galbiati et al, 
2005; Lo et al, 1998 a and Smid et al, 2006).  Very few studies have been carried out 
to assess the relative abundance of different cell-free DNA sequences present in 
plasma.  One investigation into the genomic representation of plasma DNA in 
pregnant women has been conducted by method of comparative genomic 
hybridisation (CGH) analysis, coupled with fluorescent in situ hybridisation (FISH) 
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analysis (Chan et al, 2005 b).  Cell-free plasma DNA was obtained from 10 pregnant 
women, and amplified by degenerate oligonucleotide primed (DOP)-PCR; the 
products of DOP-PCR were then labelled with biotin-16-dUTP and digoxigenin by 
nick translation and stained with either avidin conjugated fluorescein isothiocyanate 
(FITC) or IgG-conjugated tetramethylrhodamine isothiocyanate (TRITC). 
 
This was followed by counterstaining with an anti-fade solution containing 4,6, 
diamino-2-phenylindole (DAPI).  Digital images of the stained chromosomes were 
captured and averaged fluorescence ratios along each chromosome were calculated 
using a digital imaging system (Chan et al, 2005 b). 
 
The results of the study were that each sample of plasma DNA from pregnant 
women contained an approximately even genomic representation of chromosomes.  
This is a low resolution technique for the approximate measurement of DNA, which 
averages fluorescence of DNA sequences along the length of a chromosome (Chan et 
al, 2005 b).  By contrast the use of real-time PCR to assess the relative abundance of 
specific cfp DNA sequences is an accurate and direct method of addressing the 
question of equal representation of cell-free DNA sequences in the circulation. 
 
4.3 Importance of sonicating genomic DNA before calibration of 
primers 
 
Carefully calibrated real-time PCR has been widely used to determine the amount of 
fetal (male) or total DNA in plasma during pregnancy (Birch et al, 2005).  However, 
the abundance of cell-free plasma DNA sequences has not been accurately assessed 
relative to other sequences present.  Here, 6 sets of primers were calibrated using a 
dilution series of two preparations of leukocyte DNA (labelled B10 and A70 after 
the first three characters of their respective batch numbers).  Importantly, the 
leukocyte DNA was sonicated to give a broad size distribution with approximately 
80% of the mass between 2.0 kb and 200bp; similar to the size distribution of plasma 
DNA (Puszyk et al 2008b accepted for publication; Chan et al, 2004 and Li et al, 
2004).  Not sonicating the DNA before PCR can cause inaccurate quantification of 
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DNA sequences; as high molecular weight DNA is not representative of cfp DNA 
and does not amplify so efficiently (figure 4.1; figure 4.2). 
 
It is of note that in most of the published studies on quantification of cfp DNA, 
sonication has not been employed, leading to a potentially substantial inaccuracy.  
The extent of the inaccuracy is likely to be sequence-dependent.  Thus, the presence 
of inverted repeat sequences in long fragments would be expected to influence the 
PCR efficiency and hence apparent quantification (figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1:  Size fractionation data for sonicated and non-sonicated leukocyte 
DNA 
Non-sonicated genomic peripheral blood leukocyte DNA for sample A70 is shown 
in the lane marked LGEN A70.   Non-sonicated genomic leukocyte DNA for 
sample B10 is shown in the lane marked LGEN B10.  Sonicated leukocyte DNA for 
sample A70 is shown in the lane marked LSON A70.  Sonicated leukocyte DNA for 
sample B10 is shown in the lane marked LSON B10.  The size distribution of the 
sonicated DNA samples is approximately 2000 -100 bp and is representative of the 
size distribution of DNA in plasma.  Lanes marked MW show banding for a 100bp 
molecular weight DNA ladder (Invitrogen). 
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4.4 Calibration of individual primer pairs with sonicated and non-
sonicated leukocyte DNA in serial dilution 
 
One of the most important things to consider when developing any diagnostic, which 
relies on the use of cell-free plasma DNA, is whether or not all of the DNA 
sequences are in equal abundance, and whether or not these abundances vary 
between individuals.  The relative abundances of 6 DNA sequences were assessed in 
the plasma DNA from healthy individuals.  The primer efficiencies were also 
assessed; and the relative abundance of efficiency-matched primer pairs were found 
to vary (data not shown).  
 
As well as testing the relative abundances of the specific DNA sequences, the 6 
primer pairs were also used as an additional test for the preferential clearance of CpG 
unmethylated DNA or the retention of CpG methylated DNA in plasma.  Three 
primer pairs were designed to amplify DNA regions known to be methylated; these 
were MPH1, MPH2 and PDE9A (table 4.1).  Two primer pairs were designed to 
amplify DNA regions known to be unmethylated in plasma DNA these were 
RASSF1A and Beta-Actin; a third primer pair was designed to contain no CpG sites 
and therefore be completely unmethylated, this was the CpG-Negative primer set 
(table 4.1).  Using non-sonicated genomic leukocyte DNA to calibrate the 6 primer 
sets yields a range of data with cycle threshold (Ct) values for real-time PCR 
reactions ranging from 25.25 Cts to 35.08 Cts (figure 4.2). 
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Figure 4.2:  Real-time PCR amplification data for primers using a non-
sonicated leukocyte DNA template 
PCR cycle threshold (Ct) each reaction is plotted against the number of DNA 
molecules, to give a line of best fit for each primer set.  Three sets of primers were 
designed for DNA regions known to be methylated in plasma: MPH 1 primers (○), 
MPH 2 primers (x) and PDE9A primers (▲).  Three sets of primers were designed 
for regions known to be unmethylated in plasma DNA β-Actin primers (■); 
RASSF1A primers (◊) and primers which spanned a region not containing any CpG 
sites, Non-CpG primers (*).   
 
Using sonicated DNA to mimic the size distribution of cell-free plasma DNA 
changes the dynamic of the Real-time PCR reaction; improving the efficiency of all 
reactions.  The range of cycle threshold (Ct) values for the matched dataset ranging 
from 24.38 Cts to 32.86 Cts which is lower than the non-sonicated DNA control 
(figure 4.2; figure 4.3). 
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Figure 4.3:  Real-time PCR amplification data for primers using a sonicated 
leukocyte DNA template 
PCR cycle threshold (Ct) each reaction is plotted against the number of DNA 
molecules, to give a line of best fit for each primer set.  Three sets of primers were 
designed for DNA regions known to be methylated in plasma: MPH 1 primers (○), 
MPH 2 primers (x) and PDE9A primers (▲).  Three sets of primers were designed 
for regions known to be unmethylated in plasma: β-Actin primers (■); RASSF1A 
primers (◊) and primers which spanned a region not containing any CpG sites, Non-
CpG primers (*).  As this DNA is more representative of the size distribution of 
DNA in plasma the lines of best fit can be used to determine the relative DNA 
concentration of plasma DNA samples using the Ct values obtained after real-time 
PCR amplification with a specific primer pair. 
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Table 4.1:  Abundances of DNA copies in cell-free plasma DNA 
Primer pairs for the 6 DNA regions listed were used to measure the abundance of 
cell-free DNA in the plasma of 6 normal, non-pregnant individuals (identified as 
donors 772-777). The sequences MPH1 and MPH2 are regions which, are defined by 
two primer pairs that lie within the differentially methylated region of the MASPIN 
promoter, which is completely methylated in plasma. PDE9A primers define a DNA 
region which is completely methylated in plasma. The RASSF1A primers define a 
region which is unmethylated in plasma.  CpG-NEGATIVE primers define a region 
which lacks the CpG dinucleotide and is therefore unmethylated. The BETA-ACTIN 
region is unmethylated in plasma. Abundances are rounded to nearest value of 10 
molecules/ml. 
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4.5 Primers selected for Real time PCR  
 
             Plasma donor identifier  (sex) 
 
             Plasma DNA copies (molecules/ml)  
        
 
DNA region 
(primers 5’-3’, amplicon size, methylation status in plasma) 
 
chromosome 
 
772 (f) 
 
773 (m) 
 
774 (m) 
 
775 (m) 
 
776 (m) 
 
777 (m) 
 
MPH1 
( TACTTTTTGTGCCACCAACG ,  CAGGACCGGAAGGTGAAATA, 95 bp, 
methylated) 
 
18 
 
930 
 
1430 
 
920 
 
1130 
 
1720 
 
920 
 
MPH2 
( TATTTCACCTTCCGGTCCTG , CTTCCAAAAGGCCTCCAAC, 113 bp, 
methylated) 
 
18 
 
450 
 
590 
 
360 
 
680 
 
2600 
 
330 
 
PDE9A 
( GGCGTCTGACGTCTCCAG , TGGAGTTGCAGTACTTGCTGA, 94 bp, 
methylated) 
 
21 
 
310 
 
360 
 
190 
 
380 
 
1270 
 
230 
 
RASSF1A 
( CTCATTGAGCTGCGGGAGCTGGCA , TGGGGTTGCACGCGGTGCCC, 
109 bp, unmethylated) 
 
3 
 
250 
 
180 
 
130 
 
210 
 
1200 
 
210 
 
CpG-NEGATIVE (C21-ORF-128) 
( TCCCAAAACCCAATAAAAGC,  TTTCCCCCTGACAATCTCTC, 83 bp, 
unmethylated) 
 
21 
 
510 
 
750 
 
550 
 
620 
 
1980 
 
450 
 
BETA-ACTIN 
( GCGCCGTTCCGAAAGTT , CGGCGGATCGGCAAA, 137 bp, 
unmethylated) 
 
7 
 
100 
 
100 
 
100 
 
80 
 
200 
 
50 
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4.6 Discussion 
 
Each of the 6 primer sets were calibrated using a dilution series of two preparations 
of adult peripheral-blood leukocyte genomic DNA (figure 4.3).  The leukocyte DNA 
was sonicated to give a broad size distribution with approximately 80 % of DNA 
fragments between 2.0 kb and 200 bp in length, similar to the size distribution of 
plasma DNA (figure 4.1).  Data for both non-sonicated (figure 4.2) and sonicated 
(figure 4.3) DNA serial dilutions is given, however only data from the sonicated 
DNA serial dilution was used to calibrate plasma DNA abundances as it more 
closely mimics the size distribution of plasma DNA.  Each of the 6 sequences 
defined by the primer pairs are unique in the human genome and gave a negligible 
primer dimer product (data not shown). 
 
The data show that there is no consistent effect from DNA methylation on the 
relative abundance of DNA sequences in the plasma; as MPH2 and PDE9A 
sequences (both methylated sequences) are neither markedly more or less abundant 
than RASSF1A and CpG-negative  sequences (both unmethylated sequences) (table 
4.1). 
 
It is also observed that the pattern of relative abundances of DNA in plasma is not 
sex dependent, (although further samples would be required to test this observation). 
The sample from donor 772 was female and the relative abundances from this 
plasma source do not differ greatly from that of other samples 774 and 777, which 
were collected from male donors (table 4.1).  What is interesting is the range of 
variation between the relative abundance of different DNA sequences in plasma.  
The largest difference in sequence abundance is between MPH1 and Beta-Actin 
sequences, with MPH1 sequences detected in up-to 18.4 fold higher abundances than 
Beta-Actin sequences, in plasma from donor 777 (table 4.1). 
 
Additionally unexpected results were observed between MPH1 and MPH2 
sequences.  The two primer pairs MPH1 and MPH2 prime for two regions on the 
MASPIN gene, and the sequences which they amplify overlap by 32 bp.  It is 
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reasonable to assume that as the sequences overlap they should be relatively equal in 
abundance.  However, the sequences differ by as much as 2.78 fold in plasma DNA 
with MPH1 being more abundant than MPH2, although not exclusively as is the case 
with plasma from donor 776 (table 4.1).  This may be an indication of some form of 
non-random cleavage of DNA, which effects relative abundance in a specific way.  
Note also that donor 776 has the highest overall amounts of cfp DNA.  This may 
indicate that this sample has undergone post-collection cell lysis. 
 
These data show that DNA sequences circulating in plasma of normal healthy 
individuals are not equally abundant.  This is the first time that the question of the 
relative abundance of specific DNA sequences in plasma has been addressed, 
challenging the assertion of the previous study, which relied on the averaged 
measurement of chromosome fluorescence (Chan et al, 2005), that all DNA 
sequences are represented equally in plasma. 
 
This has important implications for non-invasive diagnostic tests.  It may not be 
possible to accurately measure cfp DNA by use of relative chromosome dosage 
(RCD) unless the relative abundances show a remarkable level of stability.  Thus it 
may be possible to compare sequences using normalised relative chromosome 
dosage (NRCD).  However, inter-individual variation in the relative plasma DNA 
levels may ultimately mean that assessment by NRCD or RCD is not possible.  
Currently the most attractive method for the detection of trisomy using cell-free 
plasma DNA is the allelic ratio (AR) method as this relies on the assessment of 
alleles of the same sequence and not the comparison of different sequences.  
Additionally the smaller number of cff DNA molecules required for AR make it a 
more attractive technique (Table 1.1) (Old and Stallard, accepted for publication). 
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5.1  Aims 
 
First proposed by Chim and colleagues upon the discovery of the potential 
epigenetic marker MASPIN (Chim et al, 2005), the use of peripheral blood 
leukocyte DNA and term placenta DNA as surrogates for maternal leukocyte DNA 
and cell-free fetal DNA, has since become the standard technique for the detection 
of epigenetic biomarkers.  Methylation-sensitive restriction endonuclease (MSRE) 
analysis is one method by which the presence or absence of a methylated cytosine 
can be assessed.  MSRE analysis of adult peripheral blood leukocyte and term 
placenta can be used to identify candidate epigenetic biomarkers (CEBs) on 
Chromosome 21 and other autosomes for use in non-invasive prenatal diagnosis.  
CEBs discovered by this technique require further characterisation on plasma DNA 
from pregnant women, in order to confirm results using the model system (see 
chapter 7).  
5.2  Introduction  
 
Chim and colleagues discovered the first potential epigenetic marker for cff DNA on 
the promoter of the MASPIN gene on Chromosome 18, using their novel model 
system of peripheral blood leukocyte and term placenta DNA (Chim et al, 2005).  In 
addition to this a further candidate epigenetic marker of cff DNA has also been 
identified on the promoter of the RASSF1A gene on chromosome 3 (Chan et al, 
2006) by the application of the same method.  Most recently potential epigenetic 
biomarkers have also been discovered on Chromosome 21 (Chim et al, 2008).  Using 
the model system, DNA sequences on chromosomes 1, 2, 12, 18 and 21 were 
digested with the methylation sensitive restriction endonucleases Hpa II,  Hha I and 
FnuD II;  in order to assess the CpG sites within the restriction sites for the presence 
or absence of methylated cytosine.  In total 366 DNA regions were selected by the 
fulfilment of either one of the three following criteria: 1) Location within or 
proximal to a gene promoter relative to the transcriptional start site.  2) Location 
within or proximal to a gene promoter identified as being differential by virtue of 
expression profile, with data being obtained from a publicly available database 
SymAtlas (Smets et al, 2006).  3) Location within a random DNA region, either 
intergenic or non-intergenic region. 
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5.3  Identification of differentially methylated regions on Chromosome 
21 by methylation-sensitive restriction analysis 
 
MSRE analysis using HpaII restriction digestion, with term placenta and peripheral 
blood leukocyte genomic DNA, was performed to screen for differentially 
methylated regions on Chromosome 21. The restriction endonuclease HpaII cuts 
DNA at unmethylated CCGG target sites, whereas if the site comprises a methylated 
C residue at the included CpG sequence, the target site remains uncut. DNA regions 
including one or more methylated (and therefore uncut) target sites are resistant to 
HpaII and hence can be amplified by polymerase chain reaction (PCR) primer pairs 
spanning the methylated sites, leading to a DNA band upon agarose gel 
electrophoresis (figure 1.22; figure 5.1) (see page 72 for primers). 
 
 
 
Figure 5.1:  Gel electrophoresis image of methylation-sensitive restriction 
endonuclease analysis on Chromosome 21 
HpaII-digested placenta genomic DNA is marked (pl) and HpaII-digested peripheral 
blood leukocyte DNA is marked (b) non-template PCR controls (–) are indicated. 
Lanes marked with an asterisk indicate PCR products for the 21–58 primer pair, 
indicating the absence of a strong band and hence hypomethylation in digested blood 
genomic DNA, compared with hypermethylation in placenta genomic DNA. Other 
blood and placenta DNA pairs of lanes indicate non-differential methylation for 
DNA regions defined by other primers in the screen of Chromosome 21 regions. The 
presence of bands indicates methylation of HpaII sites in both genomic DNA 
samples; absence of bands indicates absence of methylation in both genomic DNA 
samples.  M = DNA marker lane.  (Taken from Old et al, 2007). 
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5.4  Identification of differentially methylated regions on Chromosome 
22 by methylation-sensitive restriction analysis 
 
MSRE analysis of peripheral blood leukocyte and term placenta DNA has also been 
used to assess sequences on Chromosome 22, for use as control markers on non-
trisomic chromosomes.  An additional candidate marker was elucidated by following 
previous work published on the epigenetic profile of Chromosome 22 (Eckhardt et 
al, 2006).  Among the regions assessed by MSRE analysis, a candidate epigenetic 
marker was identified on the Oncostatin M (OSM) gene on Chromosome 22, which 
encodes a growth regulator which inhibits the proliferation in a number of tumour 
cell lines.  The region contains 1 Hpa II restriction site and 1 Hha I restriction site 
and both contain CpGs with methylated cytosines in placental DNA and 
hypomethylated in peripheral blood DNA.  One region was detected as being 
differentially methylated in the Chromosome 22 screen (figure 5.2 ) (see page 71 for 
primers). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2:  Gel electrophoresis image of methylation-sensitive restriction 
endonuclease analysis of Chromosome 22 
Gel electrophoresis image showing PCR products from peripheral blood leukocyte 
DNA (L) and placenta DNA (P) with non-template controls (N).  Each set of DNA 
products has been digested with either Hpa II (first three lanes) or HhaI (*) before 
PCR amplification with primers for the candidate epigenetic biomarker 22-09.  
These data indicate that placenta DNA is methylated whereas peripheral blood 
leukocyte (by the presence of a PCR product) and that peripheral blood leukocyte 
DNA is unmethylated (by the absence of a product band).  The 100 bp DNA 
molecular weight ladder is marked (M). 
300 bp
200 bp
100 bp
MWMW L L P NP N
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5.5  Identification of differentially methylated regions on chromosomes 
1, 2 and 12 by gene expression profile analysis and methylation-
sensitive restriction analysis 
 
Regions were also selected on the basis of their expression profiles, as determined by 
analysis of expression profiling microarray data, which is publicly available on the 
SymAtlas website (http://symatlas.gnf.org/SymAtlas/).  Some CEBs were detected 
on chromosomes 1, 2 and 12 (figure 5.3) (see pages 70-72 for primers). 
 
 
 
 
 
 
 
 
 
 
Figure 5.3:  Gel electrophoresis image of methylation-sensitive restriction 
endonuclease analysis of targets identified by expression profiling 
Each DNA region selected is represented by three lanes L, P, N.  All of the markers 
from the expression profiling screen shown here are differentially methylated; these 
lanes show (from left to right) primer pairs 2-28, 1-16, 21-128, 1-50 and 12-42.  The 
DNA region amplified by the last pair of primers 12-42 (denoted by Δ) are not 
differentially methylated as is shown by the amplification of both peripheral blood 
leukocyte and placenta DNAs.  The third set of primers (21-128) are differentially 
methylated, however there is a background of methylated DNA in the peripheral 
blood.  MW denotes the 100 bp DNA molecular weight ladder (Invitrogen, UK). 
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Table 5.1: Panel of candidate epigenetic biomarkers discovered by methylation-
sensitive restriction analysis 
All of the candidate epigenetic biomarkers detected by methylation-sensitive 
restriction analysis are shown; with additional information, including chromosome 
location, laboratory nomenclature, associated Genbank name of the closest gene and 
methylation status in both placenta DNA and peripheral blood leukocyte DNA.  
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5.6  Panel of candidate epigenetic biomarkers 
Methylation Status 
Chromosome location Laboratory designation of marker 
Associated Gene 
(Genbank symbol) 
Placenta Leukocyte 
21q22.3 21-58 AIRE + - 
21q22.3 21-107 CLDN14 + - 
21q22.3 21-128 ERG + - 
21q22.3 21-210 C21orf1 + - 
1q23.1-q24.1 1-16 CD48 + - 
1q32.1 1-50 FAIM3 + - 
2p14 2-28 ARHGAP25 + - 
12q24 12-42 SELPLG + - 
22q12 22-09 OSM + - 
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5.7  Discussion 
 
The model system first proposed by Chim and colleagues can be used to successfully 
identify potential epigenetic biomarkers of cff DNA (Chim et al, 2005; Chan et al, 
2006).  A recent development in the field has been the identification of two putative 
epigenetic biomarkers on Chromosome 21 (Chim et al, 2008).  By use of the model 
system it has been possible to identify a panel of candidate epigenetic biomarkers 
(CEBs) on Chromosome 21 and other autosomes. 
 
Primers were designed for regions of between 300-400 bp on the promoter regions of 
genes (promoter regions were characterised as the first 2.25 kb upstream of the 
putative translation initiation site).  With DNA regions selected being CpG rich but 
not within CpG islands.  Each region selected contained at least one or more 
restriction site for the methylation-sensitive restriction enzymes Hpa II and Hha I. 
 
DNA regions selected were either chosen at random (intergenic spaces or random 
promoters) or by use of gene expression profiling data from the SymAtlas website 
(Smets et al, 2006) comparing over expression in whole blood and under expression 
in placenta and vice versa.  It seems that whichever selection method is used to select 
regions for analysis, differentially methylated regions can be detected readily, 
provided that enough regions are tested. 
 
In total 366 regions were assessed on all chromosomes including 152 on 
Chromosome 21, with only a few regions detected as differentially methylated 
(approximately 3 %).  On the Chromosome 21 analysis the first differentially 
methylated region detected was the 58th primer pair assessed; this CEB was therefore 
termed 21-58 (figure 5.1).  The DNA region which the 21-58 primers amplify is 
located on the AIRE gene promoter is methylated in placenta and unmethylated in 
placenta DNA (figure 5.1). 
 
An additional CEB was also detected on Chromosome 22 this CEB was termed 22-
09 as it was discovered with the 9th primer pair tested (figure 5.2).  CEBs were also 
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identified from analysis of targets from gene expression profile data, CEBs were 
detected on chromosomes 1, 2 and 12 (figure 5.3) and on Chromosome 18 (data not 
shown). 
 
These data show that MSRE analysis can be used to identify CEBs.  These data 
represent the first CEBs discovered on Chromosome 21 (Old et al, 2007).  Using the 
model system it is possible to readily detect CEBs which may potentially have a use 
in non-invasive prenatal diagnosis (table 5.1).  Further CEBs are required, as the 
number of cff DNA molecules in plasma of pregnant women during the first 
trimester is low, and increasing the number of markers can be taken to have the same 
effect as taking a larger sample (Old and Stallard, accepted for publication).  Also by 
increasing the number of CEBs the coverage of chromosomes increases and enables 
the distinction between fetal trisomy and mosaicism or chromosomal translocation.  
The position of CEBs on each chromosome is important, as in some cases 
chromosome translocations may occur which duplicate only a part of the 
chromosome; therefore if for instance CEBs are located on the p arm of a 
chromosome but a translocation occurs on the q arm of a chromosome, this would 
not be detected.  By having CEBs at a number of loci on any given chromosome, 
increases the chances of detecting a chromosome translocation. 
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6.1  Aims 
 
The data sets presented in this chapter describe how epigenetic biomarkers can be 
discovered by methylated DNA immunoprecipitation (MeDIP) of DNA.  The data 
sets presented in this chapter were obtained by collaboration with Dr Nigel Carter's 
group at the Sanger Institute.  The data presented in this chapter refer to the 
discovery and further characterisation of two candidate epigenetic biomarkers, one 
on Chromosome 21 and one on Chromosome 18 using the MeDIP with whole blood 
and placenta DNA. 
 
6.2  Introduction 
 
 MeDIP is another method by which the methylation of DNA can be assessed.  
Using the antibody Anti-5-Methylcytosine can provide up to a 90 fold enrichment of 
methylated DNA in a dose dependent sequence dependent manner (Weber et al, 
2005; Wilson et al, 2006).  The methylation profiling of chromosomes 6, 20 and 22 
has been partially completed; by bisulfite sequencing of DNA regions (Eckhardt et 
al, 2006).  Methylation profiling of chromosomes 18 and 21 using MeDIP has been 
undertaken at the Sanger institute (Cambridge, UK).  Using whole blood and 
placenta DNA samples were divided equally with one half of the sample precipitated 
with Anti-5-Methylcytosine and the other not.  The samples were then labelled with 
fluorescent dyes cy3 and cy5 are co-hybridised onto a tiling microarray for either 
Chromosome 18 or Chromosome 21.  Immunoprecipitated DNA was compared with 
non-immunoprecipitated DNA by hybridisation to a tiling array.  Each tiling array 
consists of 60-70 mer oligonucleotides, distributed along the chromosome with gaps 
in between them as indicated (figure 6.1; figure 6.3).  In order to detect methylated 
regions for each tissue on either Chromosome 18 or Chromosome 21; the array data 
for each tissue are then compared to give differentially methylated regions between 
whole blood DNA and placenta DNA (figure 6.1; figure 6.3).  Candidate epigenetic 
biomarkers were characterised further by MSRE analysis. 
 
Using MeDIP combined with microarray technology enables methylation profiling 
of entire chromosomes, which greatly improves the efficiency of CEB discovery.  
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Figure 6.1:  Methylation microarray data for whole blood and placenta DNA on 
Chromosome 18 
Shows tiling microarray data for a region on Chromosome 18 ranging from 
nucleotides 58950400- 58960800 (NCBI build 36.2).  Each bar indicates an 
oligonucleotide on the chromosome and gives a signal after hybridisation of either 
under-representation or over-representation on a log 2 scale.  The difference between 
immunoprecipitated placenta DNA and untreated placenta DNA is shown in green; 
the difference between immunoprecipitated whole blood DNA and untreated whole 
blood DNA is shown in yellow.  The subtractive difference between placenta DNA 
and whole blood DNA is shown in black.  The area circled in red and showing two 
red signals is a region which is hypermethylated in placenta DNA and 
hypomethylated in whole blood DNA.  This signal indicates the region of a 
candidate epigenetic biomarker on Chromosome 18. 
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6.3  Differentially methylated regions on Chromosome 18 
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Further characterisation of the CEB from the tiling array data by MSRE analysis 
confirms that the region is differentially methylated between peripheral leukocyte 
and placenta DNA (figure 6.2). 
 
 
 
 
 
 
 
 
 
 
Figure 6.2:  Methylation restriction assay data for the LM18-58A primers from 
the Chromosome 18 tiling array 
Primers were designed for the region highlighted by the microarray data, including 
200 bp upstream and downstream of the region (for  the reason that the DNA was 
sonicated and fragments between 70-150 bp may have bound to the oligonucleotides 
which are 60-70 bp in length).  Genomic leukocyte (L) and genomic placenta (P) 
were diluted in serially diluted; the figures given show [DNA] in picograms and 
double digested with Hpa II and Hha I. The gel data shows that leukocyte DNA 
(L625-39) is almost completely digested whereas placenta DNA (P625-39) is 
undigested.  This confirms the differential methylation suggested by the MeDIP 
array.  The lane labelled N is a non -template control and the lane labelled MW 
contains a 100 bp molecular weight DNA ladder (Invitrogen, UK).  
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Figure 6.3:  Methylation microarray data for whole blood and placenta DNA on 
Chromosome 21 
Shows tiling microarray data for a region on Chromosome 21 ranging from 
nucleotides 37517400- 37522500 (NCBI build 36.2).  Each bar indicates an 
oligonucleotide on the chromosome and gives a signal after hybridisation of either 
under-representation or over-representation on a log 2 scale.  The difference between 
immunoprecipitated placenta DNA and untreated placenta DNA is shown in purple; 
the difference between immunoprecipitated whole blood DNA and untreated whole 
blood DNA is shown in green.  The subtractive difference between placenta DNA 
and whole blood DNA is shown in black.  The area circled in red and showing a red 
signal is a region which is hypermethylated in placenta DNA and hypomethylated in 
whole blood DNA.  This signal indicates the region of a candidate epigenetic 
biomarker on Chromosome 21. 
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6.4  Differentially methylated regions on Chromosome 21 
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Further characterisation of the region detected on the Chromosome 21 tiling array by 
MSRE analysis identifies a region containing two CpG sites which are methylated in 
placenta DNA and unmethylated in peripheral blood leukocyte DNA (figure 6.4). 
 
 
 
 
 
 
 
Figure 6.4:  Methylation restriction assay data for the 21-37 primers from the 
Chromosome 21 tiling array 
Primers were designed for the region highlighted by the microarray data, including 
200 bp upstream and downstream of the region (for  the reason that the DNA was 
sonicated and fragments between 70-150 bp may have bound to the oligonucleotides 
which are 60-70 bp in length).  Genomic leukocyte DNA digested by Hpa II is 
denoted (L) and digested by Hha I is denoted (L*) and genomic placenta DNA 
digested by Hpa II is denoted (P) and when digested by Hha I is denoted (P*).  The 
gel data shows that leukocyte DNA is completely digested Hpa II and almost 
completely digested by Hha I; whereas placenta DNA is undigested.  This confirms 
the differential methylation suggested by the MeDIP array.  The lanes labelled (N 
and N*) are non -template controls and the lanes labelled MW contain a 100 bp 
molecular weight DNA ladder (Invitrogen, UK).  
 
6.5  Discussion 
 
MeDIP can be used to enrich methylated DNA prior to application to whole 
chromosome tiling microarray.  Selective data received from the Sanger institute 
(Cambridge, UK) from Chromosome 18 and Chromosome 21 tiling arrays has 
provided targets for CEBs on these chromosomes. 
 
Tiling array data on Chromosome 18 indicated a number of CEBs, one of which is 
located between 58956000 bp and 58956800 bp on Chromosome 18 (NCBI 36.2).  
Placenta and whole blood DNA samples were collected and divided equally, one half 
of each sample was immunoprecipitated with anti 5-Methylcytosine, and each 
sample was then labelled with either cy3 or cy5 fluorescent dyes.  The 
immunoprecipitated samples were compared with the untreated samples to establish 
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methylation maps of chromosomes 18 and 21 for each tissue, a further comparison 
between the tissue types was then made showing regions where methylated DNA 
was over represented or under represented (figure 6.1; figure 6.3).  Signals on each 
tiling array represent oligonucleotides from 60-70 bp along the length of each 
chromosome, and signal strength is measured within a log 2 scale of -3 fold to +3 
fold, with positive signals indicating over-representation of methylated DNA and 
negative signals indicating under-representation of methylated DNA (figure 6.1; 
figure 6.3). 
 
One signal between 58956000 and 58956800 on Chromosome 18 shows a region 
which is over-represented in placenta and under-represented in whole blood; this 
region is indicated by the red histogram signal, indicating a strong subtractive 
difference between the enrichment of placenta DNA and that of whole blood DNA 
(figure 6.1).  This region was further characterised by design of primers for shorter 
amplicons between 70-150 bp for use with MSRE analysis.  One primer pair termed 
LM18-58-A amplifies a region of 148 bp containing a single Hpa II site and a single 
Hha I site, which are differentially methylated between placenta DNA and peripheral 
blood leukocyte DNA (figure 6.2). 
 
Tiling array data for Chromosome 21 shows a strong signal between 37519800 bp 
and 37520100 bp, with methylated DNA indicated as under-represented in whole 
blood and methylated DNA indicated as over-represented in placenta (figure 6.3).  
Further characterisation of the region with a primer pair termed 21-37 which 
amplifies a region of 92 bp containing a single Hpa II site and a single Hha I site, 
which are differentially methylated between placenta DNA and peripheral blood 
leukocyte DNA (figure 6.4). 
 
These data indicate that MeDIP can be used to detect methylated regions across 
entire chromosomes, and provide target regions for the discovery of CEBs.  These 
regions require further characterisation by higher resolution techniques such as 
MSRE analysis to define CEBs more accurately. 
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7.1  Aims 
 
Two of the first candidate epigenetic biomarkers (CEBs) to be identified have been 
further characterised with in-depth analysis of their methylation profiles.  Bisulfite 
conversion of DNA followed by cloning and sequencing of PCR products (bisulfite 
sequencing) has been used to compare the methylation profiles of leukocyte and term 
placenta DNA (BioChain, USA).  In addition, methylation-specific primers (MSPs) 
have been optimised for one of the regions.  Data presented in this chapter focuses 
on the characterisation of 2 CEBs, both of which are located on Chromosome 21, 
and both of which are located on the promoter region of the AIRE gene.  The 
COBRA analysis of the AIRE and MASPIN products was prepared by Dr Francesco 
Crea. 
 
7.2  Introduction 
 
Using the model system of leukocyte and term placenta DNA, two CEBs have been 
characterised on the promoter of the AIRE gene.  The AIRE gene is an autoimmune 
regulator and the methylation of the gene has been previously studied (Murumagi et 
al, 2003).  The region studied by Murumagi and colleagues refers to a CpG island 
300 bp upstream of the transcriptional start site and is not overlapped by either of the 
regions included in this study.  Following up on initial data from the methylation 
sensitive restriction assay (figure 5.1) in addition to the original marker (termed the 
58 region another region was detected on the AIRE gene promoter by bisulfite 
conversion of DNA and Bisulfite specific PCR (BS-PCR).  This region has been 
termed the A1 region of the AIRE promoter. 
 
Each region has been characterised by a combination of methylation-specific 
techniques including: bisulfite sequencing, methylation-specific PCR, melt curve 
analysis of bisulfite-specific PCR products and combined bisulfite and restriction 
analysis (COBRA). 
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7.3  Location of the 58 and A1 regions on the AIRE promoter on 
Chromosome 21. 
 
The 58 region is located between -1859 and -1651 nucleotides relative to the putative 
translational start site and is hypermethylated in placenta DNA and is 
hypomethylated in peripheral blood leukocyte DNA, it contains 4 CpG sites within 
the region studied (figure 7.1).  The A1 region is located further upstream between -
486 and -305 nucleotides relative to the translational start site, and is methylated in 
the opposite way to the 58 region, with hypomethylated placenta DNA and 
hypermethylated peripheral blood leukocyte DNA (figure 7.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1:  Schematic diagram of the AIRE gene promoter showing candidate 
epigenetic biomarkers 
The 58 region and A1 region sequences are located within the AIRE gene promoter 
region. The nucleotide numbers that define the regions are indicated, relative to the 
transcriptional start site of the AIRE gene.  Vertical arrows indicate the presence of 
CpG sites. 
 
7.4  Epigenetic profile of the 58 region 
 
Cloning and sequencing of BS-PCR products for the 58 region of the AIRE gene 
promoter was carried out in order to assess the methylation status of DNA in 
peripheral blood leukocyte and term placenta tissues (table 7.1).  The data show that 
nucleotide 
positions are 
relative to the 
translation
start site
AIRE gene
The AIRE gene promoter region
-1859 -1651
10 CpG          
sites
A1 region
Unmethylated 
in placenta
-305-486
4 CpG sites
“58” region
Hypermethylated 
in placenta
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leukocyte DNA is largely unmethylated, whereas placenta DNA is heavily 
methylated (table 7.1). 
7.5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.1:  Methylation profile of the 58 region of the AIRE promoter 
Shows methylation of the four CpG sites in the 58 region sequence from 5' to 3' ends. 
Cloning and sequencing of BS-PCR amplicons, showing methylated (filled circles) 
and unmethylated CpG sites (open circles) at four CpG sites within the 58 region.  
The relevant cytosine bases are located at nucleotides –1945, –1933, –1899 and –
1892 relative to the translational start site of the AIRE gene (Murumagi et al, 2003). 
Most clones show substantial methylation in term placenta DNA (B), while nearly 
all are unmethylated in peripheral blood leukocyte DNA (A). 
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7.5 Optimisation of methylation specific primers for the 58 region of 
the AIRE gene promoter 
 
The data from the bisulfite sequencing of the 58 region show that the 58 region is a 
good candidate epigenetic biomarker.  On the basis of this data methylation-specific 
primers (MSPs) were designed using the web-base program MethPrimer (Li and 
Dahiya, 2002).  MSPs contain CpG sites, which after bisulfite conversion of DNA 
can be used to amplify methylated DNA but not unmethylated DNA, due to the 
retention of cytosines in CpGs in methylated DNA sequences and the loss of 
cytosines in CpGs in unmethylated DNA sequences.  The first pair of 58 MSPs was 
able to detect low amounts of methylated placental DNA, in a background of 
unmethylated peripheral blood leukocyte DNA, however this assay required nested 
PCR to efficiently detect placental DNA (figure 7.2) (see page 70 for primers). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2:  PCR quantification data from nested-PCR with placenta DNA 
spiked in a background of leukocyte DNA 
During the initial stages of methylation-specific primer (MSP) optimisation for the 
58 region, primers were not highly differential in single-amplification PCR format.  
However after nested PCR, it was observed that as little as 1% placenta DNA could 
be detected in a background of leukocyte DNA.  Leukocyte bisulfite converted DNA 
had a Ct value of 20.9; leukocyte bisulfite converted DNA spiked with 1% of 
placental bisulfite converted DNA had a Ct value of 20.0 and when spiked with 5% 
placenta bisulfite converted DNA a Ct value of 19.1 and with 10% placenta DNA 
18.2 Ct. 
Leukocyte 
bisulfite 
converted DNA
Plus 1% bisulfite  placenta DNA
Plus 5% bisulfite  placenta DNA
Plus 10% bisulfite  placenta DNA
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The original set of 58 region MSPs demonstrated that relatively low amounts of 
methylated placental DNA could be detected in a background of unmethylated 
peripheral blood leukocyte DNA however the primers were inefficient (figure 7.2).  
New MSPs were designed using the MethPrimer programme (Li and Dahiya, 2002). 
The new primers were designed to be more efficient and able to preferentially 
amplify methylated placental DNA in a single PCR reaction (figure 7.3) (see page 72 
for primers). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3:  Real-time PCR quantification data for the optimised methylation-
specific primers for the 58 region 
Optimised MSPs for the 58 region of the AIRE promoter on Chromosome 21 were 
used for real-time PCR amplification of bisulphite-converted DNA. The mean cycle 
threshold (Ct) for bisulphite-converted placenta DNA is 25.7 Cts and for bisulphite-
converted blood DNA it is 32.4 Cts. Thus placental DNA is amplified at a much 
earlier Ct as indicated by the ∆Ct of 6.7 cycles.  RT-PCR analysis was in triplicate. 
By extrapolation, this degree of specificity is expected to allow identification of 1% 
cell-free fetal DNA of placental origin in maternal plasma. 
 
7.6  Characterisation of the A1 region of the AIRE gene promoter 
 
In addition to the 58 region of the AIRE gene promoter, further methylation analysis 
was also carried out on the A1 region of the AIRE promoter.  After BS-PCR the 
BIORAD iCycler can be programmed to perform a temperature gradient, by which 
the PCR products are melted and data are recorded regarding the melting 
temperature (Tm) of each product.  The temperature gradient can be used to detect 
differences between the melting temperatures of BS-PCR products derived from the 
amplification of peripheral blood leukocyte and term placenta DNAs.  After bisulfite 
Leukocyte DNA product
Placenta DNA product
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conversion of DNA unmethylated cytosines are converted to uracil, and during PCR 
and are incorporated into the PCR product as thymine by Taq DNA polymerase; the 
overall effect is to cause a C → T transition in unmethylated DNA, whereas 
cytosines within CpG sites in methylated DNA sequences are protected.  One 
advantage of this technique is that CpGs are measured in the context of the whole 
amplicon; therefore there must be a significant cumulative difference in the 
methylation of the CpGs, for a different Tm to be detected. 
 
The melting profile of the A1 region was assessed, along with the MASPIN putative 
epigenetic marker, the imprinted locus H19 DMR and a non-differentially 
methylated region MCM3AP (figure 7.4).  The MASPIN promoter, was used as a 
positive control, and has previously been shown to include a 204 bp region that is 
largely unmethylated in term placenta DNA, but methylated in leukocyte DNA. As 
expected, the melting profile of the leukocyte amplicons peak at about 2.5°C higher 
than placenta DNA amplicons (figure 7.4 C). The H19 locus on human chromosome 
11 was also analysed.  The melting profiles of this region are bimodal curves, with 
the difference in melting profile peaks being relatively large, about 3.0°C (figure 7.4 
B). The bimodal curves are similar for both the leukocyte and placenta DNAs (figure 
7.4 B).  The MCM3AP promoter region displays melting profiles with single peaks 
from leukocyte and placenta DNA, with no clear shift in the melting profiles (figure 
7.4 A).  For the A1 region, leukocyte DNA is hypermethylated in comparison with 
placenta DNA, as indicated by the shift of 1.5°C in the melting profile peaks of the 
182 bp amplicons (figure 7.4 D). The A1 region of the AIRE gene promoter region 
was therefore identified as a potential epigenetic biomarker for NIPD of trisomy 21. 
 
The differences in methylation status of the A1 region of the AIRE gene promoter 
were analysed by cloning and sequencing the 182 bp amplicons from bisulfite-
converted leukocyte and placenta DNA (table 7.2).  Of particular interest is the 
presence of clones (2/29) from placenta DNA that are completely unmethylated at all 
10 sites of the AIRE promoter region, with no example (0/29) of a completely 
unmethylated clone in leukocyte DNA. Considering sites 1, 3, 5, and 7 together, 
17/29 clones from placenta are unmethylated at all of these four sites, whereas there 
is no clone (0/29) from leukocyte DNA that is unmethylated at all four sites (table 
7.2 A; 7.2 B). 
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Figure 7.4:  Melt curve analysis of BS-PCR products 
Shows the melting profiles of BS-PCR products from four primer pairs: MCM3AP; 
H19 DMR; MASPIN and the 21-A1 region.  Melting profiles for a 122 bp upstream 
region of the MCM3AP gene located at Chromosome 21q22.3. The upper curve 
represents leukocyte DNA, the lower placenta DNA.  Melting profiles for a 225 bp 
region of the imprinted DMR of the H19 locus positioned at chromosome 11p15.5. 
The upper curve represents leukocyte DNA, the lower placenta DNA.  Melting 
profiles for a 204 bp region of the MASPIN promoter located at Chromosome 
18q21.3. Note that the curve for leukocyte DNA displays a peak shifted to a 
temperature about 2.5 °C higher than that for placenta DNA.  Melting profiles for the 
181 bp A1 region upstream of the AIRE gene at Chromosome 21q22.3. Note that the 
curve for leukocyte DNA displays a peak shifted to a temperature about 1.5 °C 
higher than that for placenta DNA. 
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Table 7.2:  Methylation profile of bisulfite-converted DNAs from the A1 region 
of the AIRE promoter 
Shows the specific methylation profile of the A1 region in leukocyte and placenta 
tissues.  The position of each CpG for each of the 10 CpG sites is given relative to 
the translational start site. The rows depict the methylation status of each clone. 
Filled and unfilled circles represent methylated and unmethylated CpG sites, 
respectively.  (A) Shows the methylation profile for the A1 region in leukocyte DNA, 
which is hypermethylated, with ~77% of CpGs methylated.  (B) Shows the 
methylation profile of the A1 region in the placenta DNA, which is hypomethylated 
with ~74% of CpGs unmethylated.  The placenta DNA shows a general reduction in 
methylation patterns in comparison with leukocyte DNA.  The four CpG sites: - 461, 
- 448, - 418 and - 402 form 4 Taq I restriction sites when methylated.  All of the 
leukocyte sequences (29/29) have at least one methylated CpG at 1 of the 4 sites.  
Whereas (17/29) sequences in placenta DNA are unmethylated at all 4 of the CpG 
sites. 
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Table 7.2 A:  Methylation profile of bisulfite converted leukocyte DNA for the 
A1 region of the AIRE promoter 
oooo29
28
oooo27
o26
oooo25
oooo24
o23
ooooo22
oo21
20
oooooo19
o18
oo17
o16
oooooo15
o14
o13
oo12
oooo11
o10
oo09
08
07
o06
ooooooo05
oo04
o03
oooo02
01
- 347-356- 380- 402- 405- 418- 433- 448- 451- 461
 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.2 B:  Methylation profile of bisulfite converted placenta DNA for the A1 
region of the AIRE promoter 
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Combined bisulfite conversion and restriction assay (COBRA) was used to examine 
the methylation status of the A1 region. When methylated, the four CpG sites at 
positions 1, 3, 5 and 7 of the A1 region make up four Taq I restriction sites in 
bisulfite converted DNA. In unmethylated DNA these CpG sites do not give rise to 
Taq I restriction sites.  To carry out a high resolution and quantitative COBRA of the 
A1 region PCR was performed on bisulfite-converted DNA, the products were 
digested with Taq I, and analysed by capillary electrophoresis, on a BioRad Experion 
microfluidic electrophoresis apparatus.  The MASPIN gene was used as a control, 
and was highly discriminatory between placenta and leukocyte DNA (figure 7.6 A).  
The A1 region was also highly discriminatory, with an undigested product present in 
the placental DNA product and no undigested product in the leukocyte DNA product 
(figure 7.6 B).  These data show that the A1 region is a good CEB for the detection 
of fetal trisomy 21. 
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Figure 7.5:  High resolution COBRA using capillary 
electrophoresis 
Amplicons of the MASPIN and A1 region were derived from 
placenta and leukocyte bisulfite converted DNA. This was followed 
by end-labelling using a 5’-FAM labelled reverse primer. The 
products were digested with Taq I restriction endonuclease, and 
analysed by capillary electrophoresis using fluorescence detection of 
end-labelled fragments. (A) The fluorescence trace of the MASPIN 
amplicons demonstrates very clearly the difference between the 
placenta and leukocyte DNA with a large uncut peak for the 
placenta but no uncut signal for the leukocyte amplicons.  (B) The 
A1 amplicons show a similar differential pattern with a large uncut 
peak for placenta and a very small signal for the leukocyte 
amplicons; although there are methylated fragments detected this is 
expected as the placenta is bathed in maternal blood, this data is 
concordant with that of the sequencing. The large peaks of low 
molecular weight product at the far left of each run are caused by 
primer dimerisation. 
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7.7 Discussion 
 
Two of the earliest CEBs identified on Chromosome 21 have been extensively 
characterised by MSRE analysis and bisulfite sequencing and melt curve analysis.  
The two CEBs are both located on the AIRE gene promoter and have opposing 
methylation profiles (figure 7.1). 
 
Bisulfite sequencing of peripheral blood leukocyte and term placenta DNA shows 
that the 58 region is hypomethylated on leukocyte DNA and hypermethylated in 
placenta DNA.  With 5.9 % of CpGs methylated in leukocyte DNA and 68.8 % of 
CpGs methylated in placenta DNA (table 7.1). 
 
Methylation-specific primers were optimised for the 58 region of the AIRE promoter.  
The initial primers required nested PCR to detect differences in methylation of 
placenta and leukocyte DNA, although 1% of placenta DNA could be detected in a 
background of 99% leukocyte DNA, with increases of placenta DNA detectable in a 
dosage dependent manner (figure 7.2).  Optimisation of methylation-specific primers 
for the 58 region was successful with the primers amplifying placenta DNA 6.7 cycle 
thresholds before leukocyte DNA, meaning that the 58 MSPs are able to detect 1.03 
% of placental DNA in a background of leukocyte DNA (figure 7.3). 
 
These data indicate that the 58 region is a strong CEB and could be used in non-
invasive diagnostic test, for the detection of cff DNA in a large background of 
maternal DNA.  As in all tests there is a consistent difference between the 
methylated placenta DNA and the unmethylated leukocyte DNA, which shows that it 
is possible to detect the low amount of ~1 % of placenta DNA in a background of 
leukocyte DNA; this level of detection is required as cff DNA can constitute as little 
as 1% of DNA in the maternal circulation. 
 
The methylation profile for the two tissues in the A1 region is opposite to that of the 
58 region; with peripheral blood leukocyte DNA being methylated and term placenta 
DNA being unmethylated in the A1 region.  When identifying CEBs the methylation 
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of the leukocyte DNA is not preferable, as it means additional techniques are 
required to assess the epigenetics of the biomarker. 
Instead of direct assessment by MSRE analysis alternative techniques are required, 
which alter unmethylated DNA sequences (bisulfite conversion) and allow analysis 
by temperature gradient (melt curve analysis) or enable the digestion of the 
methylated fraction (COBRA). 
 
Alongside several controls the melt products of bisulfite converted DNA for the A1 
region of the AIRE promoter were analysed (figure 7.4).  The data show that the 
leukocyte DNA BS-PCR product has a higher melting temperature than the placenta 
DNA BS-PCR product.  The placenta DNA product melts at 80 0C and the leukocyte 
DNA product 81.5 0C.  This cumulative difference between the 10 CpG sites of the 
A1 region sequence indicates that leukocyte DNA is hypermethylated and placenta 
DNA is hypomethylated. 
 
Further characterisation of the A1 region by bisulfite sequencing shows the 
methylation profile of the region with the methylation of every CpG in the sequence.  
The data show that leukocyte DNA is hypermethylated with approximately 77% of 
all CpGs being methylated and that placenta DNA is hypomethylated with 74% of 
all CpGs being unmethylated (table 7.2). 
 
Additional testing by combined bisulfite restriction analysis (COBRA) also 
confirmed the consistent differences in methylated between leukocyte and placenta 
DNA on the A1 region.  After bisulfite conversion the BS-PCR products are digested 
with Taq I the methylated CpGs are digested and the unmethylated cytosines 
transformed to Thymine, removing the Taq I restriction site (figure 7.5).  MASPIN is 
used as a control as it is methylated in the same way as the A1 region (figure 7.5 A).  
The data from the A1 COBRA products shows that there is a large amount of 
undigested-intact product in the placenta DNA; however the leukocyte DNA product 
is completely digested (figure 7.5 B).  This is because the digestion of bisulfite 
converted DNA relies on the retention of cytosines in the Taq I sites in the A1 
sequence.  Coincidently there are four CpG sites which lie within Taq I restriction 
sites in the A1 region; these CpGs are located at -461, -448, -418 and -402.  0% of 
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clones being unmethylated at all four sites in leukocyte DNA and 58% of clones are 
completely unmethylated at all four sites in placenta DNA (table 7.2). 
 
The data from the bisulfite sequencing shows that the four CpG site which make the 
Taq I restriction sites are completely unmethylated in 58% of the sequences 
assessed, this means that the remaining sequences have methylation in at least one of 
these sites (table 7.2 B).  This finding is supported by COBRA data, showing some 
fragments are cleaved in the placenta DNA (figure 7.5 B), which means that only a 
proportion of the placenta DNA can be assessed. 
 
Taken together these data strongly indicate that the A1 region is a good CEB and 
that with further development, this marker could potentially be used as part of a non-
invasive diagnostic test for the detection of fetal trisomy.  Further testing with 
plasma DNA from pregnant women is required to validate both CEBs, to determine 
if the placenta DNA methylation signature is detectable in the plasma DNA of 
pregnant women and not present in the plasma DNA of non-pregnant women. 
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8.1 Aims 
 
Since the discovery of cell free fetal DNA (cff DNA) in the maternal circulation (Lo 
et al, 1997) unique biomarkers have been sought after to provide, a method of 
identifying cff DNA which is independent of fetal sex.  So far several potential 
epigenetic markers have been reported (Chim et al, 2005; Chan et al, 2006 and Chim 
et al, 2008).  Using the model system of leukocyte versus placenta DNA a novel 
panel of candidate epigenetic biomarkers (CEBs) has been developed, data in this 
chapter describes the further characterisation of these CEBs using plasma DNA from 
pregnant individuals.  Having discovered several CEBs on a number of 
chromosomes (see chapters 5, 6, and 7) further characterisation and validation of the 
fetal specificity of these potential markers is required.  This chapter presents data on 
the characterisation of CEBs using plasma DNA samples collected from pregnant 
women and non-pregnant women. 
8.2 Introduction 
 
In order to assess each CEB, primers for each region were required to be redesigned 
in order amplify the smaller DNA fragments present in plasma; using the web-based 
program Primer3input (Rozen and Skaletsky, 2000).  This is due to the fact that cff 
DNA has a smaller size distribution of DNA molecules compared to that of cfm 
DNA and genomic placenta DNA.  Various studies have assessed the properties of 
cff DNA in the maternal circulation and all agree that cff DNA has a smaller size 
distribution of DNA molecules than cfm DNA (Chan et al, 2004; Zimmerman et al, 
2004; Chan et al, 2005 and Koide et al, 2005).  It has been established the majority 
of cff DNA is shorter than 300 bp in length (Li et al, 2004); and suggested that most 
cff DNA has undergone nucleosomal cleavage and is in fact shorter than 193 bp in 
length (Chan et al, 2004).  One study has shown that by using a range of primers to 
define amplicons of different sizes (63 bp – 524 bp) on the SRY gene; that the 
amount of cff DNA detected is in relation to the size of the amplicon.  It was shown 
that in comparison to a 63 bp amplicon for the SRY gene that each longer amplicon 
detected fewer copies of the gene in matched samples.  An amplicon of 107 bp only 
detected 53.1 % of the sequences detected by the 63 bp amplicon; this amount 
decreased to 0.0% when the largest amplicon of 524 bp was used (Koide et al, 2005). 
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The CEBs were redesigned to give amplicons of between 70-150 bp in order to 
maximise their potential to amplify cff DNA.  Suitable markers from the leukocyte 
and placenta experiments were then assessed with plasma DNA collected from 
pregnant women prior to delivery. 
8.3 Redesign of candidate epigenetic biomarkers for use on plasma 
DNA 
 
Primers for each of the CEBs were designed using the web-based programme 
Primer3input (Rozen and Skaletsky, 2000) to give amplicons of between 70 and 150 
bp, these primers were then tested on leukocyte and placenta DNA in order to ensure 
that they still amplify the correct regions efficiently (figure 8.1).  The most 
auspicious CEBs shown are: 2-28, 1-50, 21-107, 18-CR and 21-58 (figure 8.1).  
These CEBs are methylated in placenta DNA and unmethylated in peripheral blood 
leukocyte DNA; other candidates were discarded after further testing. 
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Figure 8.1:  Optimisation of short amplicon primers for candidate epigenetic 
biomarkers 
Each set of primers is denoted by the following nomenclature, the first number 
denotes the chromosome on which the primers are designed and the second numbers 
and/or letters denote the screen or battery of tests which those primers came from.  
Each set of PCR products is digested with Hpa II or Hha I (*).  The products of each 
specific primer pair are labelled (L) for leukocyte DNA, (P) for placenta DNA and 
(N) for non-template control.  Primers 21-43 are either non-differential or have not 
amplified (lanes 21-43 L and 21-43 P), this may meant that either both leukocyte and 
placenta DNA are hypomethylated of the primers have failed to amplify in both 
cases. Primers 12-42 are non-differential, this is shown for the 12-42 primers as both 
leukocyte and placenta DNA products have amplified a PCR product (lanes 12-42 L 
and 12-42 P) meaning that they are both hypermethylated.  The primer sets 2-28, 1-
16, 1-50, 21-107, 18-CR, and 21-58 have amplified regions which are differentially 
methylated shown in lanes (2-28 L and 2-28 P; 1-16 L and 1-16 P; 1-50 L and1-50 P; 
21-107 L and 21-107 P; 18-CR L and18-CR P; 21-58 L and 21-58 P).  The three 
primer sets 21-107, 18-CR and 21-58 also contain Hha I sites and were assessed at 
these sites also shown in lanes marked *.  Only 21-58 was partially differentially for 
a Hha I site shown (21-58 L*).  MW denotes the 100 bp DNA ladder (Invitrogen, 
UK). 
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8.4  Assessment of candidate epigenetic biomarkers on plasma DNA 
 
Further development of CEBs was then carried out using plasma DNA extracted 
from 3 pregnant women and 3 non-pregnant women.  First the total cell-free plasma 
DNA was assessed using primers for beta globin (figure 8.2). This was followed by 
the assessment of CEBs 21-107, 22-09 and LM18-58A, which were the most 
promising candidate epigenetic markers, data forLM18-58A is shown (figure 8.4).  
Although the CEB 21-128 was not shown to be completely differential in peripheral 
blood leukocyte and placenta DNA (figure 8.1) it was also assessed to provide an 
additional control (figure 8.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2:  Assessment of total cell-free plasma DNA by PCR with beta globin 
primers 
Lanes marked PP1-PP3 show PCR products for beta globin from plasma DNAs from 
pregnant women in their third trimester.  Lanes marked NP1-NP3 show PCR 
products for beta globin from plasma DNAs from non-pregnant women.  The lane 
marked PL is a placental DNA positive control and the lane marked N is a non-
template negative control.  MW denotes the 100bp DNA ladder (Invitrogen, UK). 
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Figure 8.3:  Assessment of 21-128 primers on pregnant and non-pregnant 
plasma DNA   
Lanes marked PP1-PP3 show PCR products for 21-128 primers after digestion with 
Hpa II and Hha I; on plasma DNAs from pregnant women in their third trimester.  
Lanes marked NP1-NP3 show PCR products for 21-128 primers after digestion with 
Hpa II and Hha I; from plasma DNAs from non-pregnant women.  The lane marked 
PL is a placental DNA positive control and the lane marked N is a non-template 
negative control.  MW denotes the 100bp DNA ladder (Invitrogen, UK).  There is a 
product in all of the samples therefore the 21-128 marker is non-specific for fetal 
DNA. 
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Figure 8.4:  Assessment of LM18-58A primers on pregnant and non-pregnant 
plasma DNA 
Lanes marked PP1-PP3 show PCR products for LM18-58A primers after digestion 
with Hpa II and Hha I; on plasma DNAs from pregnant women in their third 
trimester.  Lanes marked NP1-NP3 show PCR products for LM18-58A primers after 
digestion with Hpa II and Hha I; from plasma DNAs from non-pregnant women.  
The lane marked PL is a placental DNA positive control and the lane marked N is a 
non-template negative control.  MW denotes the 100bp DNA ladder (Invitrogen, 
UK).  LM18-58A is shown to be fetal specific as there is product band in all three 
pregnant samples PP1-PP3 and no band in any of three non-pregnant samples. 
 
8.5 Additional testing of the most promising candidate epigenetic 
biomarkers on plasma DNA  
 
CEBs 21-107, 22-09 and LM18-58A all seemed to be specific for fetal DNA in the 
maternal circulation, showing distinctive products when used to amplify DNA 
extracted from the plasma of pregnant women, compared with a distinct lack of 
amplification when used to amplify DNA extracted from non-pregnant women 
(figures 8.4) (data for 21-107 and 22-09 is not shown due to low resolution of 
reproduced images).  This indicated that these putative markers were suitable for 
further testing on plasma DNA samples and could potentially be used in non-
invasive prenatal diagnosis of fetal aneuploidies.  To that end additional plasma 
samples were assessed using these CEBs (figure 8.5).  In the first instance the total 
amount of cell free plasma DNA was assessed by the use of BETA GLOBIN to 
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amplify DNA extracted from the plasma of six samples collected from pregnant 
women and six samples collected from non-pregnant women (figure 8.5 A). 
 
However, of the three CEBs tested, none have been found to be specific for cell-free 
fetal DNA.  All three markers 21-107 (figure 8.5 B), 22-09 (figure 8.5 C) and LM18-
58A (figure 8.5 D) each amplified DNA in all of the pregnant and non-pregnant 
samples tested. 
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Figure 8.5:  Further testing of candidate epigenetic biomarkers with pregnant 
plasma DNA versus non-pregnant plasma DNA 
The total cell-free plasma DNA is assessed using beta globin primers in (A); the total 
amount of in pregnant samples (PP1-PP6) is approximately equal to that of non-
pregnant plasma DNA samples (NP1-NP6).  The PCR products for 21-107 (B) are 
not specific to cff DNA; the PCR product is present in pregnant plasma DNA 
samples (PP1-PP6) is also present in approximately the same concentration as in the 
non-pregnant samples (NP1-NP-6). The PCR products for 22-09 (C) are not specific 
to cff DNA; the product present in pregnant plasma DNA samples (PP1-PP6) is also 
present in approximately the same concentration as in the non-pregnant samples 
(NP1-NP-6). The PCR products for LM18-58A (D) are not specific to cff DNA; the 
product present in pregnant plasma DNA samples (PP1-PP6) is also present in 
approximately the same concentration as in the non-pregnant samples (NP1-NP-6).  
MW denotes the 100 bp DNA ladder (Geneflow, UK). 
 
 
 
 
 
 
 
 
 
 
 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 BP
200 BP
300 BP
300 BP
400 BP
400 BP
200 BP
100 BP
300 BP
400 BP
200 BP
100 BP
300 BP
400 BP
200 BP
100 BP
M
W
N
P1
N
P1
N
P1
N
P1
N
P2
N
P3
PP
2
N
P4
PP
3
N
P5
N
P6
PP
1
PP
4
PP
5
PP
6
N
P2
N
P3
N
P4
N
P5
N
P6
PP
2
PP
3
PP
1
PP
4
PP
5
PP
6
M
W
M
W
N
P2
N
P3
N
P4
N
P5
N
P6
PP
2
PP
3
PP
1
PP
4
PP
5
PP
6
N
P2
N
P3
N
P4
N
P5
N
P6
PP
2
PP
3
PP
1
PP
4
PP
5
PP
6
M
W
50 BP
50 BP
50 BP
50 BP
A
B
C
D
 148 
8.6 Further characterisation of the A1 candidate epigenetic biomarker 
on the AIRE gene promoter; with pregnant plasma DNA. 
 
As one of the strongest CEBs the A1 region of the AIRE promoter was also assessed; 
by Real-Time PCR amplification of DNA extracted from plasma samples obtained 
from pregnant women 24 hours prior to elective delivery and 24 hours after delivery.  
The PCRs were carefully calibrated with peripheral blood leukocyte serial dilutions.  
All pregnancies were later verified to be male births.  The A1 CEB was compared to 
the SRY cff DNA biomarker, in order to assess it clearance after delivery.  The data 
show that SRY sequences are cleared rapidly from the maternal plasma after delivery 
(figure 8.6 A), whereas the unmethylated "fetal" fraction of the A1 DNA sequences 
are not cleared as rapidly from the maternal circulation, and are still detectable after 
delivery (figure 8.6 B). 
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Figure 8.6:  Detection of DNA sequences before and after delivery 
(A) Shows the SRY sequence is detected in the plasma DNA of pregnant women 
before delivery, the absolute quantification for the 6 samples assessed ranges from 
1867 pg/ml to 840 pg/ml.  24 hours after delivery SRY DNA sequences are not 
detected in any of the samples tested.  (B) Shows the unmethylated A1 cff DNA 
sequences detected as a fraction of total plasma DNA, before delivery and 24 hours 
post delivery; there is a trend towards clearance of A1 sequences after delivery 
although it is not as pronounced as the clearance of SRY sequences. 
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8.7 Discussion 
 
In order to assess all of the CEBs, primers were redesigned to give shorter amplicons 
between 70-150 bp in order to ensure maximum efficiency when amplifying the 
fragmented plasma DNA.  The 21-43 primers did not amplify a PCR product and the 
12-42 primers were non-specific (figure 8.1).  Primers for CEBs: 2-28, 1-16, 1-50, 
21-107, 18-CR, 21-58 were clearly differentially methylated between leukocyte and 
placenta DNA, whereas the 21-128 CEB was only partially differential (figure 8.1).  
CEBs 21-107, 18-CR, 21-58, 2-28, 1-16 and 1-50 were amenable to further testing 
on plasma DNA from pregnant women collected in the third trimester. 
 
Several CEBs were assessed using plasma DNA, extracted from whole blood 
obtained from pregnant women just prior to delivery, with a control group of plasma 
DNA collected from the whole blood of non-pregnant women. BETA GLOBIN was 
used to assess the total amount of cell-free DNA in each plasma sample (figure 8.2).  
The levels of total DNA were approximately equal between all samples, meaning 
that any differences detected would not be due to lower DNA concentrations in any 
of the samples. 
 
The CEB 21-107 was detected in pregnant plasma DNA and was not detected in the 
non-pregnant control plasma DNA (data not shown).  The presence of a product 
band indicated that there was a methylated sequence in the plasma of pregnant 
women which is not present in non-pregnant women.  21-107 appeared to be a 
promising CEB which required further validation with additional plasma samples.  
 
The CEB 21-128 was also tested with plasma DNA from pregnant women, this 
marker had been shown to be partially differential when using peripheral blood and 
placenta DNA (figure 8.1) and it was assumed that this would also be the case in 
plasma DNA, however 21-128 amplified DNA in both pregnant and non-pregnant 
DNA equally (figure 8.3), indicating that this CEB is not suitable for further 
characterisation, for use as a marker in non-invasive prenatal diagnosis. 
 
The CEB 22-09 was also assessed on plasma DNA from pregnant and non-pregnant 
women (data not shown), this CEB also showed a product in 3 pregnant samples but 
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not in the 3 non-pregnant samples.  These data showed that the 22-09 sequence is 
methylated in pregnant plasma DNA but not in non-pregnant DNA, which could 
mean that 22-09 is a suitable for further testing on plasma DNA samples. 
 
Analysis of the LM18-58A CEB showed a product present in the 3 pregnant samples 
and no product in the 3 non-pregnant samples, except for a very faint band in one 
sample (figure 8.4).  This meant that the sequence for LM18-58A is methylated in 
pregnant plasma DNA but unmethylated in non-pregnant plasma DNA, and is also 
suitable for further testing on plasma DNA samples. 
 
In the first round of testing with plasma DNA, the three CEBs tested appeared to 
work well and were selected for further testing, these were 21-107, 22-09 and LM18-
58A; other markers tested on the same plasma samples did not work so well, these 
were 21-128 (figure 8.3); 21-58 and 21-43 (data not shown).  These data indicated 
that 21-107, 22-09 and LM18-58A were markers for differentially methylated DNA 
and were apparently detecting cff DNA which is methylated in the pregnant plasma, 
as well as other CEBs which did not appear to function. 
 
As the number of samples tested was very small (n=3) further testing on plasma 
DNA was undertaken with a group of 6 pregnant samples and 6 non-pregnant 
samples of plasma DNA (figure 8.5).  The total DNA for each plasma DNA sample 
was assessed using beta globin (figure 8.5 A).  The CEBs 21-107, 22-09 and LM18-
58A were assessed using the same plasma DNA samples (figure 8.5 B, C and D 
respectively).  Each of the CEBs amplified a product in both the pregnant and non-
pregnant DNA samples.  This means that the markers are not consistent and cannot 
be used for as part of test for non-invasive prenatal diagnosis as they cannot 
accurately distinguish epigenetic differences between pregnant and non-pregnant 
plasma DNA samples. 
 
One reason why these CEBs may have worked in the first experiment may be due to 
inter-individual variation of methylation patterns; it could be that by chance the 3 
pregnancies selected were methylated in fetal fraction for all 3 markers but not in the 
additional 6 samples tested.  This is highly unlikely but a possibility none the less.  
Sample contamination is ruled out, as digestions were carried out using a digestion 
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in-tube protocol before PCR, therefore no PCR products could have contaminated 
any prior reactions as PCR products are unmethylated and would be cleaved by 
either Hpa II or Hha I. 
 
One CEB has shown some promise, the A1 region of the AIRE gene promoter (21-
A1).  21-A1 was tested on plasma DNA collected from pregnant women prior to 
delivery by elective surgery; and on plasma DNA collected from women 24 hours 
after delivery, as a control SRY was also assessed (figure 8.6).  All pregnancies were 
later confirmed as male-bearing pregnancies.  In all samples assessed the SRY 
sequence was present before delivery and rapidly cleared 24 hours after delivery 
(figure 8.6 A).  21-A1 sequences were detected before delivery and show a trend 
towards clearance 24 hours after delivery (figure 8.6 B). 
 
21-A1 may be a partial marker for fetal-specific DNA, and could potentially form 
part of a larger diagnostic test if more markers were discovered. Even if the markers 
discovered are not completely specific for cff DNA if there is a large enough panel 
they could form a diagnostic test for fetal aneuploidy as the power of any diagnostic 
test increases with the number of markers used. 
 
The difficulty in obtaining epigenetic markers for cff DNA using the model system 
is an important issue that should be addressed, and any future discovery of cff DNA 
markers should be done by analysis of first trimester plasma DNA from pregnant 
women, by combination of either MeDIP or methylation-specific restriction 
endonuclease analysis, with whole genome amplification and tiling microarray 
analysis.  This would lead to a more accurate and rapid detection of epigenetic 
biomarkers with a lower rate of marker failure upon validation. 
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9.1  Discussion  
 
Since the discovery of cell-free fetal DNA in the circulation of pregnant women (Lo 
et al, 1997) it has been a major goal to develop fetal-specific biomarkers for the 
detection of trisomy 21.  The main aim of this research project has been to discover 
epigenetic biomarkers for the detection of fetal DNA; with a view to developing 
non-invasive prenatal diagnosis of fetal aneuploidy, primarily for the detection of 
trisomy 21 but also for the detection of trisomy of chromosomes 18 (Edward 
syndrome) and 13 (Patau syndrome). 
 
The criteria for fetal DNA-specific epigenetic biomarkers are:  they must be 
differentially methylated in order to distinguish cell-free fetal DNA (cff DNA) from 
cell-free maternal DNA (cfm DNA); they must be independent of fetal sex; they 
must be detectable during pregnancy and cleared rapidly after delivery and they must 
be detectable during the first trimester of pregnancy. 
 
Over the last few years potential epigenetic DNA biomarkers have been discovered 
on chromosomes 18, 3 and 21 these markers: MASPIN, RASSF1A and PDE9A have 
been detected in the plasma DNA of pregnant women during the third trimester 
(Chim et al, 2005; Chan et al, 2006; Chim et al, 2008).  The discovery of these 
markers shows that it is possible to detect cff DNA molecules in the plasma of 
pregnant women without relying on the detection of paternally inherited sequences. 
 
However, these epigenetic biomarkers do not yet fulfil the criteria for use as 
biomarkers for non-invasive prenatal diagnosis (NIPD), as they have not been shown 
to accurately detect cff DNA in the plasma of pregnant women, during either the first 
or second trimesters. 
 
In addition to our discovery of candidate epigenetic biomarkers (CEBs) for fetal 
aneuploidy, some basic scientific questions are addressed here with regards to the 
presence and properties of cell-free plasma DNA (cfp DNA). 
 
The knowledge gained from studying the properties of cfp DNA is not only 
applicable to the field of NIPD; but also to the field of cancer diagnosis and 
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prognosis; as hypermethylation of tumour suppressor genes and in some cases the 
hypomethylation of oncogenes has been linked to the progression or recurrence of 
many forms of cancer including: hepatocellular carcinoma and oesophageal 
adenocarcinoma (Franco et al, 2008; Kawakami et al, 2000; Tischoff and Tannapfel, 
2008). 
 
One of the properties of cfp DNA which was previously undetermined is the relative 
abundance of methylated and unmethylated CpG DNA from single copy sequences 
in plasma.  Prior literature on the presence of CpG methylation in the circulation, 
states that unmethylated CpG DNA may act as a pathogen-associated molecular 
pattern (PAMP), and elicit an immunogenic response (Cornelie et al, 2004; 
Januchowski et al, 2004).  The implication of this may be that CpG unmethylated 
DNA may interact with immune responsive cells in the blood, which may lead to 
preferential clearance of unmethylated DNA from the circulation. 
 
Another publication suggests that the compact structure of heterochromatin may 
confer protection to CpG methylated DNA sequences and prevent the action of 
DNAases present in the blood (Herman, 2004), this may suggest that CpG 
methylated DNA is not cleared as rapidly as unmethylated DNA.  Taking these ideas 
together it is reasonable to hypothesise that methylated DNA sequences are over-
represented in plasma by comparison to unmethylated DNA sequences. 
 
In order to assess the abundance of methylated and unmethylated DNA in plasma a 
novel system was developed for the quantification of both types of DNA in the 
circulation.  We have developed our own protocol for bisulfite conversion of plasma 
DNA to enable successful bisulfite sequencing of plasma DNA without over-
conversion of methylated cytosines (see chapter 2).  Using the XL region of the 
GNAS1 imprinted locus it is possible to amplify both the methylated and 
unmethylated alleles, assessing both DNA types in an unbiased way.  Using GNAS1 
as a measure of both methylated and unmethylated DNA it has been possible to 
determine that CpG methylated and CpG unmethylated DNA sequences are present 
in equal abundance, circulating in the plasma of healthy individuals. 
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This conclusion is supported by the data obtained by the amplification of CpG 
methylated and CpG unmethylated DNA sequences from plasma DNA samples 
(table 4.1) these data show that CpG methylated DNA sequences and CpG 
unmethylated sequences do not differ strikingly, and are neither retained nor cleared 
in a preferential way. 
 
The implication of this data is that it is possible to develop epigenetic biomarkers 
using cfp DNA, without bias caused by an excess or absence of either CpG 
methylated or CpG unmethylated DNA.  These experiments should be repeated with 
the use of plasma DNA obtained from pregnant women, primarily from the first 
trimester and with the use of more imprinted loci, in order to determine if there are 
any caveats specific to pregnancy, which may alter the ratio of methylated to 
unmethylated DNA. 
 
An additional discovery emerging from this data is that imprinted loci which 
coincide with an SNP could be used as fetal-specific DNA biomarkers (figure 3.7). 
In addition genetic combination of a polymorphic locus and DNA methylation could 
be used to determine whether or not X chromosome inactivation in the placenta is 
parent-of-origin-specific in humans, as it is in the mouse (Okamoto et al, 2005) 
where the paternal X chromosome is inactivated in the trophoblasts of female fetuses. 
 
One important property of cfp DNA is the relative abundance of each sequence.  
Because cfp DNA is released into the circulation largely from cells undergoing 
apoptosis (Babochkina et al, 2005; Gavrieli et al, 1992, Kolialexi et al, 2004; 
Sekizawa et al, 2004), it may be possible that the DNA released is fragmented or 
damaged in such a way as to alter the abundance of specific sequences.  Previous 
work has shown that the relative abundance of repeat ALU sequences is greater than 
that of single gene sequences (Stroun et al, 2001).  However, here we address the 
separate issue of the relative abundances of single gene sequences compared with 
each other.  This is important as the development of a non-invasive prenatal 
diagnostic test may require the use of such techniques as relative chromosome 
dosage (RCD), which compares the relative abundance of DNA sequences on 
different chromosomes for the detection of trisomy. 
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The largest difference in sequence abundance detected was between MPH1 and 
Beta-Actin sequences, showing an average difference of 12.3 fold; even accounting 
for small discrepancies which may arise from pipetting errors or well-reading, which 
may occur during PCR, this level of variation in sequence abundance may mean that 
RCD is not a suitable technique for the quantification of cfp DNA; unless such 
differences are maintained between individuals.  By assessing individual sequences 
using real-time PCR, a closer analysis of cfp DNA has been achieved, building on 
knowledge obtained in the original study (Chan et al, 2005 b), increasing the 
understanding of the kinetics of cfp DNA. 
 
This experiment should also be repeated using plasma DNA collected from pregnant 
women during the first trimester, in order to establish the situation with regards to 
sequence abundance during pregnancy.  Also the relative abundance of cff DNA 
may also be affected by the routine acquisition of aneuploidy of cytotrophoblasts 
which invade the maternal circulation and are thought to contribute the majority of 
cff DNA to the circulation (Fisher et al, 1989; Librach et al, 1991; Weier et al, 2005).  
However, the relative abundance of fetal DNA sequences can only be assessed in 
this way once fetal-specific DNA markers have been developed. 
 
In agreement with the data presented by Old and Stallard (Old and Stallard, accepted 
for publication) the conclusions made here also support the idea that cfp DNA 
should be assessed by method of allelic ratio.  As the data show that the relative 
abundance of single copy gene sequences are not equal in cfp DNA. 
 
The model system of peripheral blood leukocyte DNA versus term placenta DNA 
can be used to successfully identify candidate epigenetic biomarkers (CEBs) (Old et 
al, 2007).  Out of a total of 366 DNA regions assessed ~3% were found to be 
differentially methylated between peripheral-blood leukocyte and term placenta 
DNA.  When searching for differentially methylated regions it does not appear to be 
the case that concerted methylation is exclusive to promoter regions, but may also be 
detected within intergenic and exogenic regions also. 
 
Using methylation-sensitive restriction endonuclease (MSRE) analysis a panel of 
CEBs has been identified (some presented Old et al, 2007) on chromosomes 21, 18, 
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12, 2 and 1 (see chapter 5).  In addition to MSRE analysis, methylated DNA 
immunoprecipitation (MeDIP) and combined bisulfite restriction analysis (COBRA) 
can also be used to identify CEBs (see chapters 6 and 7).  Tiling microarrays can be 
designed to give coverage of entire chromosomes, with the exception of the 
sequences which make up the gaps between oligonucleotides and regions for which 
it is not possible to synthesise oligonucleotides such as telomere repeats and CpG 
rich regions (Weber et al, 2005; Wilson et al, 2006).  Combined with either MeDIP 
or bisulfite sequencing, tiling microarrays can be used to generate chromosomal 
methylation maps, which can be used to identify differentially methylated regions. 
 
So far the development of epigenetic biomarkers has led to the development of one 
epigenetic biomarker which is partially specific for cff DNA; this is the 21-A1 
epigenetic biomarker, which shows a trend towards clearance from maternal plasma 
after delivery.  All other CEBs which have been successfully tested on peripheral 
blood leukocyte and term placenta DNA failed to be validated on pregnant samples; 
i.e. the placental methylation signature was detected in both pregnant and non-
pregnant samples. 
 
This data calls into question the validity of using the model system of peripheral 
blood leukocyte DNA versus term placenta DNA for the identification of epigenetic 
biomarkers for the detection of fetal aneuploidy.  The epigenetic biomarkers 
MASPIN, RASSF1A and PDE9A have yet to be successfully developed into a non-
invasive diagnostic test as yet, so far it has been demonstrated that the placental 
DNA methylation signatures of these markers are only detectable in the third 
trimester (Chim et al, 2005; Chan et al, 2006; Chim et al, 2008).  It would appear 
that term placenta DNA is a poor surrogate for the placental DNA circulating in 
plasma during the first and second trimesters, and that peripheral blood-leukocyte 
DNA is a poor substitute for maternal plasma DNA.  The most logical way of 
discovering epigenetic biomarkers for cff DNA, is to develop markers using first 
trimester plasma DNA from pregnant women. 
 
In the first instance first trimester plasma DNA should be used to confirm the 
properties of cfp DNA, such as the ratio of methylated to unmethylated DNA and the 
relative abundance of DNA sequences.  Once the general properties of cfp DNA 
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during pregnancy have been ascertained, the next step is to proceed with the 
discovery of epigenetic biomarkers. 
 
Pooled samples of first trimester plasma DNA could be either be treated by bisulfite 
conversion or MeDIP, and applied to tiling microarrays for chromosomes 21, 18 and 
13, which have the highest incidence of trisomies.  By using a whole chromosome 
tiling array, the efficiency of biomarker discovery is increased. 
 
If no reliable epigenetic biomarkers were discovered by this method, this experiment 
would finally end the search for fetal-specific DNA epigenetic biomarkers, for the 
use in non-invasive prenatal diagnosis of fetal aneuploidy, meaning that efforts 
should be redirected into either placental RNA biomarker discovery which so far is 
the most promising approach, or detection of fetal/pregnancy specific proteins in the 
maternal circulation, in order to improve current screening methods. 
 
However, if a suitable panel of reliable epigenetic biomarkers were discovered, they 
could be used to form a non-invasive prenatal diagnostic test, which would allow the 
safe detection of fetal aneuploidy and prevent the loss of pregnancies which are 
caused by the current invasive techniques.  Either way this experiment could provide 
vital information for the future of non-invasive prenatal diagnosis of fetal aneuploidy. 
 
It is possible that RNA biomarkers such as PLAC4 may provide suitable coverage of 
the population for trisomy detection, provided that a sufficient number of 
heterozygous SNPs can be found to provide informative markers across the 
population (Chan et al, 2006).  To date PLAC4 has been the most successful RNA 
fetal biomarker discovered, which may mean that other markers may not be as 
successful.  
9.2 Conclusions 
 
Methylated and unmethylated CpG DNA sequences are present in equal abundances, 
in the plasma of healthy individuals.  This discovery shows that there are no specific 
mechanisms in the blood, which may preferentially clear either methylated or 
unmethylated CpG DNA sequences.  This means that analysis of methylated cfp 
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DNA is not biased by an excess of either DNA type and could be exploited for the 
development of epigenetic biomarkers, for use with either NIPD or cancer diagnosis. 
 
Cfp DNA molecules which are derived from single-copy gene sequences are not 
present in equal abundance in the plasma of normal healthy individuals; this is an 
important factor to take into account when developing any diagnostic test.   
 
The model system developed by Chim and colleagues (Chim et al, 2005) is flawed; 
and has not been validated by any of the candidate epigenetic biomarkers discovered 
in this project; any future epigenetic biomarker discovery for the purpose of NIPD 
should be developed by a simple and direct assessment of first trimester plasma 
DNA. 
 
It is expected that the issue of rapid and accurate NIPD of fetal trisomy 21 will be 
solved in the coming years.  RNA testing has been reported by Sequenom (see 
chapter1).  However, it is likely that NIPD of trisomy 21 will ultimately be carried 
out with DNA biomarkers, as the direct assessment of DNA is the most likely source 
of fetal genetic material to give a direct quantitation of chromosome number. 
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